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Abstract 
Antibody production in the lungs is an essential defence mechanism against respiratory 
pathogens. However, little is known about the local activation of B cells in the lung.The 
production of BAFF and APRIL by airway epithelial cells could contribute to local 
recruitment, activation, class switch recombination and antibody production by B cells in the 
lung.  
In vitro, BEAS-2B cells were used to characterize BAFF and APRIL production simulated 
either by RSV infection or addition of cytokines. RSV and IFN-β significantly induced 
expression of BAFF mRNA and protein but not APRIL. BAFF mRNA reached significantly 
high levels at 12h and declined at 48h after either RSV infection or IFN-β stimulation. 
Western blot analysis of resting epithelial cells showed that membrane BAFF was expressed 
by resting cells. On RSV infection or IFN-β stimulation, expression of membrane BAFF 
increased at 12 and 24hours and disappeared at 48h, which suggests soluble BAFF was 
cleaved from the membrane and released into the culture supernatant by 48h, where it was 
measured by ELISA. When BEAS-2B cells were infected with RSV after pre-incubation 
with anti-IFN β, expression of BAFF was blocked, which indicates that airway epithelial 
cells can produce BAFF in an interferon dependent manner. BEAS-2B cells did not express 
CXCL12, CXL13, CCL19 or CCL21, which indicates there are other potential sources that 
express these chemokines during RSV infection rather than the airway epithelium. 
A murine model of RSV infection was used to examine expression of BAFF, APRIL and of 
the chemokines CXCL12, CXCL13, CCL19 and CCL21. Cytokine mRNA and RSV N gene 
expression were measured by Taqman PCR in lung tissue from control mice at day 0 and 
mice challenged with RSV (A2 strain) or control UV-treated RSV at days 1, 2, 4, 7, 8, 10, 
14 and 21 days after RSV infection by ELISA. RSV N RNA was significantly detected at 
day 1, 2 and 4 after RSV infection compared to UV RSV control. BAFF mRNA expression 
was increased significantly after RSV infection on day 1 ,7 and 8 in comparison to UV 
treated RSV control at the same time points. Equally, BAFF protein was also elevated 
significantly after RSV infection at days 1, 2, 4, 7 and 8 in comparison to UV- RSV control 
at the same time points. 
CXCL13 mRNA expression was increased significantly after RSV infection on day 1 and 7 
in comparison to UV-RSV control at the same time points. Moreover, CXCL13 protein was 
increased significantly after RSV infection at day 1, 2 and 7 in comparison to UV RSV 
control at the same time points. CXCL12, CCL19 and CCL21 mRNA and protein levels 
were not increased significantly after RSV infection, which may indicate they are not active 
during RSV infection. 
Examination of mouse lung sections showed strong positive staining of B cells (CD20) 
following RSV infection at day 1, 2, 4, 7 and 8 and FACS analysis B cells numbers were 
increased significantly at day 6 and 8 following RSV infection relative to UV-RSV control. 
 
RSV infection results in up-regulated BAFF and CXCL13 expression, consistent with a role 
for CXCL13 in recruiting B cells and BAFF in promoting airway B cell survival or 
differentiation. Collectively, these results suggest that the airway epithelial could help recruit 
and support B cell growth and development and Ab production in the lung.  
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CHAPTER 1: INTRODUCTION 
 
RSV is a common pathogen of the human respiratory tract. The work described in 
this thesis focuses on the response of the airway epithelium to RSV infection. 
Specifically, how the innate response of the epithelium to infection may influence 
induction of the adaptive immune response through production of B cell growth 
factors. Here the characteristics of RSV itself are first described, followed by a 
discussion of how this virus causes airway disease, particularly bronchiolitis, in 
infants. This is followed by an explanation of how the immune response is known to 
respond to RSV and of the role of two growth factors BAFF and APRIL in the 
immune system. Finally, the aims and objectives of this study, which include both an 
analysis of the human airway epithelial response to infection and experiments using 
a murine model of RSV infection to examine these responses, are presented. 
1.1. Respiratory syncytial virus (RSV) 
 
RSV was first described in 1956 in samples from the upper respiratory tract of a 
chimpanzee with an acute respiratory illness characterized by coughing, sneezing, 
and mucopurulent nasal discharge and named chimpanzee coryza agent (Blount, 
Morris & Savage 1956). Subsequently, in 1957, this virus was also isolated from an 
infant with acute lower respiratory tract disease (Chanock, Roizman & Myers 1957). 
Its name is derived from a characteristic cytopathic effect, the formation of 
multinucleated giant cells or syncytia observed in infected airway epithelial cell 
culture (Chanock, Roizman & Myers 1957; Prober & Sullender 1999). RSV is one of 
the paramyxoviridae, subfamily of pneumovirinae genus pneumovirus (Borchers et 
al. 2013; Collins & Graham 2008). RSV is divided into two serological groups, A 
and B, based on their antigenic and genetic characteristics (Anderson et al. 1985; 
Oliveira et al. 2008). It is the most common cause of acute respiratory tract infection 
in newborn infants and young children (Hall et al. 2009). RSV also causes upper and 
lower respiratory tract infection in elderly or immunocompromised people (Falsey et 
al. 2005; Falsey & Walsh 2005). 
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1.1.2. Epidemiology   
 
In temperate regions RSV outbreaks occur in late autumn or at the beginning of 
winter and typically peak between mid-December and early February. In tropical 
regions RSV infection occurs during the rainy season and can peak twice in spring 
and autumn (Borchers et al. 2013). Duration of the RSV epidemic varies from one 
year to another (Figure 1.1), but on average the duration of the outbreak is 22 weeks 
(Bricks 2001). Humans are the only host for RSV and viral infection is highly 
contagious and can transfer from person to person either by contact directly with 
contaminated secretions, droplets or fomites or through self-inoculation of eyes and 
nose (Collins & Graham 2008). Self-inoculation with contaminated hands is 
considered to be source of infection as the virus can survive in contaminated hands 
for more than half hour and on the surface of contaminated objects, for several hours 
(Bricks 2001). 
Several factors are thought to contribute to the pathogenesis of RSV infection. The 
age of infants at the start of the RSV infection is a high risk factor, infants < 3-6 
months are more susceptible to RSV infection. Other risk factors include smoking by 
family members in the household, a previous stay in hospital, daycare attendance 
both of which might enhance the risk of exposure and developing an infection with 
RSV (van Drunen Littel-van den Hurk & Watkiss 2012). Viral load correlates with 
the risk of developing severe infection and has been associated with the severity of 
RSV disease (DeVincenzo et al. 2010). Other risk factors that may increase the risk 
of developing RSV infection relate to the host, such as the premature infant, chronic 
lung disease of prematurity, incomplete development or damage to the airway, 
immunodeficiency, immunosuppression or old age that could extend viral 
replication, male gender, low birth weight, multiple births and low titre of RSV-
specific maternal antibodies (Groothuis, Hoopes & Jessie 2011; van Drunen Littel-
van den Hurk & Watkiss 2012). 
RSV is also a major cause of morbidity and mortality in elderly people and 
immunocompromised patients (Falsey et al. 2005). Worldwide, RSV infects 34 
million people and causes 200,000 deaths yearly (Nair et al. 2011). Although RSV 
has a single serotype, primary infection results in moderate levels of antibody that do 
provide lasting protection, reinfection can occur throughout life again (Glezen et al. 
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1986; Trento et al. 2006). So far there is no safe and effective vaccine available 
against RSV (Jorquera, Oakley & Tripp 2013). However, during each epidemic 
season infants at high risk of developing bronchiolitis, such as premature infants and 
those with congenital heart disease can receive a prophylactic treatment Palivizumab 
(Synagis), which is a humanized monoclonal antibody that can neutralize RSV. 
Treatment with this antibody reduces RSV incidents up to 55% (Cardenas, Auais & 
Piedimonte 2005). Globally, morbidity and mortality due to cases of RSV in infants, 
the immunocompromised, and elderly continue to increase. Thus, better 
understanding of the mechanism of RSV pathogenesis and methods of prevention are 
required (van Drunen Littel-van den Hurk & Watkiss 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The seasonal and yearly variation of RSV bronchiolitis. Taken from (Agency HP. 
Laboratory reports received by HPA Colindale of infections due to respiratory syncytial 
virus, England and Wales 2013). 
 
 
 
 
Figure 1.1. Laboratory reports of RSV infection from 1991 to 2013, 4 weekly in 
England and Wales 
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1.1.3. RSV structure 
 
 
The genome of RSV is a non–segmented single stranded negative sense RNA (15.2 
kb) (Domachowske & Rosenberg 1999) (Figure 1.2). The genome is located in the 
helical nucleocapsid and encodes for 11 proteins, including both structural and non-
structural proteins. The virus is enveloped with a lipid bilayer derived from the host 
plasma membrane. RSV has three surface viral glycoproteins, attachment protein G, 
fusion protein F, and the small hydrophobic or SH protein. G glycoprotein facilitates 
RSV attachment to the infected cell (Teng, Whitehead & Collins 2001). RSV F 
protein mediates fusion between the virus and the host plasma membrane of the cell 
(Gonzalez-Reyes et al. 2001). Unlike the F and G proteins, the role of the SH protein 
in RSV replication and pathogenesis is not fully understood. However, it has been 
shown that SH protein can act to inhibit production of the inflammatory cytokine 
TNF-α and this may lead to enhanced viral replication in vivo (Li et al. 2011). 
The Nucleocapsid is surrounded by the M protein situated in the inner layer of the 
lipid bilayer and which has been found to play a key role in the assembly of the viral 
particles (Lay et al. 2013). The RSV nucleocapsid has a helix shape and is 
surrounded by four nucleocapsid proteins, including (N), (P), (M2-1), and (L) (Lay 
et al. 2013). RSV (N) protein and (P) protein are essential for transcriptional activity 
(Hacking & Hull 2002). The (L) protein initiates viral transcription on infection after 
which replication proceeds (Fearns & Collins 1999; Oshansky et al. 2009). The M2-
1 is a transcription elongation factor, whereas M2-2 regulates viral transcription 
(Hacking & Hull 2002). Non-structural proteins including NS1 and NS2 are 
involved in altering the host response to infection by interrupting Interferon 
signaling (anti-alpha and anti –beta activity) (Spann, Tran & Collins 2005).  
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In (A) - electron micrograph of RSV at the cell membrane of an infected cell. In (B )- a 
cartoon diagram  shows the mains parts of RSV, the nucleocapsid is surrounded by M, 
matrix protein and an envelope containing host cell membrane and viral glycoproteins: G, 
attachment glycoprotein; F, fusion glycoprotein; and SH, small hydrophobic. In (C) the 
genome of RSV is non-segmented RNA, negative sense, (strain A2), 15.2 kb, which is 
associated with viral polymerase proteins and contained within a helical nucleocapsid 
composed of: N, nucleoprotein; P, phosphoprotein; L, large RNA-dependent-RNA-
polymerase; M2-1; M2-2; NS1, non-structural protein-1; and NS2, non-structural protein-2. 
Taken and modified from (Electron micrograph of respiratory syncytial virus (RSV) virion at 
a cell membrane  2014; Collins & Graham 2008; Lay et al. 2013).  
 
 
 
 
 
 
 
 
Figure 1.2. Structure and genome organization of RSV 
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1.1.4. Pathogenesis of RSV 
 
After inhalation RSV replicates in the nasopharynx with an incubation period of 4-5 
days. This may be followed by spread to the lower respiratory tract over the next 
days that leads to the development of bronchiolitis, characterized by air trapping, 
increased airway resistance , mucus production and wheezing (Collins & Graham 
2008; Hall 2001; McNamara & Smyth 2002). RSV Infection is primarily restricted 
to airway epithelial cells (Johnson et al. 2006; Welliver et al. 2007), lower airway 
type 1 pneumocytes and ciliated cells of the small bronchioles near the alveoli are 
reported to be the main sites of RSV infection. Additionally, non-ciliated epithelium 
cells, intraepithelial DCs and possibly alveolar macrophages can be infected with 
RSV (Johnson et al. 2006). 
Infiltration of inflammatory immune cells, such as neutrophils and macrophages that 
can contribute to pulmonary inflammation, is observed during infection (Aherne et 
al. 1970; Lay et al. 2013; Welliver et al. 2007). Although RSV infection of 
respiratory epithelium causes airway damage, the relative contributions of virus-
induced inflammation and the host immune response, each of which may contribute 
to RSV-induced disease severity, remains unclear (Varga & Braciale 2013). 
Neutrophil cells are one of the major inflammatory cells present in the airways 
during RSV bronchiolitis (Everard et al. 1994; McNamara & Smyth 2002). In RSV 
infection of the infant, neutrophils were found to represent a median of 93% and 76 
% in the upper and lower airway, respectively (Everard et al. 1994; McNamara & 
Smyth 2002). Moreover, in RSV infection neutrophil chemotaxis is thought to be 
dependent on the production of the chemokine IL-8 by airway epithelial cells and 
macrophages. These findings suggest that neutrophils may contribute to the 
pathological changes that occur during RSV bronchiolitis (McNamara & Smyth 
2002; Wang & Forsyth 2000). 
Alveolar macrophages are present in the lower respiratory tract; these cells have 
been reported to be a significant source of pro-inflammatory cytokines such as TNF-
α, IL-6 and IL-8 after RSV infection (Becker, Quay & Soukup 1991; Oshansky et al. 
2009). Depletion of macrophages in BALB/c mice prior to RSV infection 
significantly inhibited the early production of inflammatory cytokines and resulted in 
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increased virus titres in the lung (Oshansky et al. 2009; Pribul et al. 2008), which 
suggests that macrophages may play a more important role during the earliest time 
points after RSV infection. Moreover, depletion of alveolar macrophages in BALB/c 
and NZB mice prior to RSV infection resulted in airway occlusion, which suggests 
that alveolar macrophages contribute to the control of RSV disease and act to reduce 
disease severity (Oshansky et al. 2009; Reed et al. 2008).  
Eosinophils may be involved in the pathogenesis of RSV. RSV infected respiratory 
epithelial cells show expression of eosinophil chemo-attractants including RANTES 
and MIP-1α (Becker & Soukup 1999; Harrison et al. 1999). Furthermore, children 
who were vaccinated with a formalin-inactivated RSV formulation (FI-RSV) and 
who died upon subsequent RSV infection (Kapikian et al. 1969; Kim et al. 1969) 
showed at post mortem analysis extensive infiltration of Eosinophils cells into the 
lung, possibly due to the activation of a Th2 response against RSV (Connors et al. 
1994; Moghaddam et al. 2006; Waris et al. 1996). This suggests that these cells may 
contribute to RSV disease. However, their precise role in RSV disease remains 
unclear and needs to be fully characterized (Rosenberg, Dyer & Domachowske 
2009). 
 
NK cells are cells of the innate immune system which have a key role in clearance of 
virus-infected cells through their natural cytotoxicity. NK cells can recognize 
infected cells that express low levels of MHC class one (Kärre 2002). However, 
viruses can escape from recognition by the NK cells through increased expression of 
MHC class one (Kärre 2002). Furthermore, it has been found that RSV infection of 
BALB/c mice induced severe lung injury and promoted activation and accumulation 
of lung NK cells at the early stage (peaked at day 3) that produced significant 
amounts of IFN-γ secretion, which was responsible for acute lung injury (Li et al. 
2012). Depletion of NK cells  prior to RSV infection resulted in attenuated lung 
immune injury and reduced infiltration of inflammatory cells and reduced secretion 
of IFN-γ into the BALF, which suggests that NK cells are involved in the lung 
immune injury at the early stage of RSV infection through IFN-γ secretion (Li et al. 
2012).  
 
DCs are APCs that may be considered to link innate and adaptive immune responses. 
Found in both lymphoid and non-lymphoid tissues, their main function is to take up 
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antigens and present them to T cells in the context of MHC class I or class II 
molecules (Trombetta & Mellman 2005). Upon activation, DCs undergo maturation 
that results in increased phagocytic capacity, surface peptide-major 
histocompatibility complexes and up-regulated expression of co-stimulatory 
molecules such as CD80 and CD86 (Trombetta & Mellman 2005). 
Efficient immunity against viruses is promoted by DCs, that prime antigen-specific 
helper and cytotoxic T cells. Therefore, impaired DC function and prevention of the 
induction of T cell immunity could be an advantage of RSV to induce disease 
(González et al. 2008). 
To evaluate whether RSV infection can enhance the capacity of DCs to activate 
naïve T cells,  RSV-infected murine DCs were used to stimulate naïve T cells in 
vitro (González et al. 2008). T cell activation was examined by measuring IL-2 
secretion in response to increasing numbers of control or RSV-infected DCs. T cells 
stimulated with RSV-pulsed DCs resulted in a strong inhibition of IL-2 secretion as 
compared with T cells stimulated with unpulsed or UV-RSV-pulsed DCs, that 
secreted significant levels of IL-2. In addition, in the presence of RSV neutralizing 
antibodies, RSV failed to inhibit the capacity of DCs to stimulate T cells. RSV has 
impaired T cell activation by murine DCs directly through elimination of 
immunological synapse assembly (González et al. 2008). Taken together this showed 
that RSV is responsible for the observed inhibition of DC function and T cell 
activation and therefore RSV infection of DCs could contribute to RSV pathogenesis 
by reducing T cell-mediated virus clearance. Furthermore, direct contact of T cells 
with RSV F protein has been shown to inhibit T-cell activation (Schlender et al. 
2002). Thus, it could be possible that RSV-infected DCs expressing F protein may 
also inhibit T-cell activation by the same mechanism. 
 
 
 
 
 
 
 
 
33 
 
1.1.5. The host immune response to RSV 
 
1.1.5.1. Innate immune response 
 
Innate immunity represents the first line of host defence against foreign organisms. It 
attracts effector molecules and cells to the site of the infection through the release of 
cytokines. It is characterized by rapid response and lacks immunological memory. 
 
1.1.5.1.1. Airway epithelial cells 
 
The human lung is exposed to a wide range of inhaled microbes and therefore the 
airway epithelium cells are  at the direct interface of the human body with the 
inhaled environment and represent a primary site for entry of microorganisms. The 
epithelium forms a physicochemical barrier complemented by the mucociliary 
escalator mechanism of ciliated cells, mucus production by secretory goblet cells that 
act as the first line of defence against inhaled microbes (Bals & Hiemstra 2004; 
Mukherjee & Lukacs 2013). The mucus layer of the airway epithelium is covered 
with a wide range of peptides, proteins, and organic molecules, including IFNs, 
lactoferrin (LF), β-defensins (BDs), and nitric oxide (NO) that act as antimicrobial 
host defence molecules (Figure 1.3) and thus airway epithelium regulates both innate 
and adaptive immune responses, through production of antiviral substances and 
production of cytokines and chemokines which recruit and activate immune cells in 
the submucosa (Vareille et al. 2011). LF is member of the transferrin gene family 
and has been shown to act as antiviral by preventing RSV entry to host cells through 
interaction with RSV fusion protein (Sano et al. 2003). In addition, BDs such as 
hBD-2 and hBD-3 can inhibit viral replication by interfering with T cells, monocytes 
and immature DCs, either through inducing cytokine production by epithelial cells or 
directly binding to certain viruses (Schutte & McCray 2002; Vareille et al. 2011). 
NO has also an important role in the antiviral defence of the airway epithelium 
through inhibition of viral replication. For example, it has been shown that increased 
parainfluenza virus 3 replication in CF patients is due to lack of NOS-2 response 
(Zheng et al. 2003).  
Notable factors known to be expressed by respiratory epithelial cells that have been 
shown to play key role in host immune defence and regulation of immune response 
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in the lung include surfactant proteins (SP), including SP-A and SP-D  (LeVine & 
Whitsett 2001). These proteins can also act as opsonins during RSV infection 
(Welliver 2008), SP-A can bind with RSV G and F proteins and improves the 
antigen uptake of RSV by HEp-2 cells (Ghildyal et al. 1999; Hickling et al. 2000). 
In addition, it has been found that SP-D binds with RSV G protein and can inhibit 
RSV infection in vivo and in vitro (Hickling et al. 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
The airway epithelium can regulate both innate and adaptive immune responses by 
production of antiviral substances such as IFNs, lactoferrin, β-defensins, and nitric 
oxide in the mucus layer, as well as production of cytokines and chemokines that 
recruit and activate immune cells response in the submucosa. In addition, 
mucociliary escalator mechanism of ciliated cells and tight junctions (TJs) provided 
mechanical, biological, and chemical protection. Taken from (Vareille et al. 2011). 
 
 
 
 
 
 
Figure 1.3. Anti-viral defences of the airway epithelium to respiratory viruses 
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1.1.5.1.2. Recognition of RSV by Toll-Like Receptors (TLRs)  
 
 
TLRs are PRRs expressed by innate immune cells, which recognize PAMPs 
associated with groups of pathogens (Kumar, Kawai & Akira 2009). Airway 
epithelial cells can recognize RSV F protein by TLR4 (Figure 1.4) expressed on the 
cell surface (Kurt-Jones et al. 2000). The outcome of this interaction leads to NF-kB 
activation and promotes secretion of cytokines including IL-8, IL-10, IL-6 and IFN-β 
(Kurt-Jones et al. 2000; Tulic et al. 2007). RSV can also be recognized by 
intracellular TLR3 on respiratory epithelial cells (Rudd et al. 2006). TLR3 can 
recognize viral products during replication, such as dsRNA. It has been found that 
after RSV infection mice lacking TLR3 increase production of Th2 cytokines, as 
well as mucus in the lung in comparison to wild-type mice (Rudd et al. 2006). This 
suggests that TLR3 or signaling from TLR3 may play a key role in regulating the 
immune environment in the lung, as well as induce expression of IFN-β.   
 
 
 
 
 
 
 
 
 
 
 
Activation of TLR4 with RSV F glycoprotein in a TRIF or MyD88-dependent signaling 
pathway prompts production of type I interferon or proinflammatory cytokines. Endosomal 
TLR3 can detect dsRNA that is generated during replication of RSV and then induces 
production of type I interferon or proinflammatory cytokines in a TRIF-dependent signaling 
pathway. Taken and modified from (Kim & Lee 2014). 
Figure 1.4. Recognition of RSV by TLRs 
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1.1.5.1.3. Cytokines during RSV infection 
 
Cytokines are typically secreted regulatory proteins (~5–20 kDa) produced by 
different cells in response to immune stimuli which enable the cells to communicate 
with each other. They can act in a paracrine or autocrine manner. Cytokines have 
important regulatory functions in cell behaviour, including proliferation, 
differentiation, function and migration. IFNs , TNF, and chemokines are examples of 
cytokines (Wood 2011). 
 
1.1.5.1.3.1. Interferon type 1 
 
There are two major types of IFN, type I and type II. Type I include IFN-α and IFN-
β, type II include IFN-γ. Most cell types, including macrophages, fibroblasts, 
lymphocytes, endothelial cells and epithelial cells, produce IFN-α and IFN-β (Wood 
2011), whereas IFN-γ is mainly produced by lymphocyte cells, including NK cells, 
TH1 cells and CD8, as well as activated monocytes (Katze, He & Gale 2002; 
Yamaguchi et al. 2005). IFN-α and IFN-β have an ability to inhibit viral replication 
in infected cells. It has been shown that deficient IFN-β production may contribute to 
infection due to the failure of infected host cells to mediate early apoptosis and 
increased virus replication (Vareille et al. 2011; Wark et al. 2005). In addition, 
secretion of Type-1 interferon has several functions (Figure 1.5). First, it can limit 
the spread of viral infection to the neighbouring cells through induction of the cell-
intrinsic antimicrobial states in the infected cells. Second, modulation of the innate 
immune responses either by promoting antigen presentation and natural killer cell 
functions or restraining pro-inflammatory pathways and cytokine production. Third, 
initiate the adaptive immune system though supporting the development of high-
affinity antigen-specific T and B cell responses and immunological memory 
(Ivashkiv & Donlin 2014; Trinchieri 2010). 
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Early virus detection can be mediated though PRRs that identify PAMP expressed on 
various pathogens. Infected cells produce type I interferons. Innate immune cells, such as 
macrophages and DCs, produce type I IFNs. Cells such as plasmacytoid DCs (pDCs) 
produce large quantities of IFNα. Non-immune cells, such as fibroblasts and epithelial cells 
predominantly produce IFNβ. In infected and neighbouring cells, type I IFNs activates 
expression of IFN-stimulated genes (ISGs), which lead to initiate an intracellular 
antimicrobial status that limits the spread of infectious agents. Innate immune cells also 
respond to type I IFNs by enhancing antigen presentation and the production of cytokines 
and chemokines. Adaptive immunity is also influenced by type I IFNs: for example, type I 
IFNs can increase antibody production by B cells and amplify the effector function of T 
cells. Taken from (Ivashkiv & Donlin 2014). 
 
 
Figure 1.5. Role of Type I interferon in controlling innate and adaptive immunity 
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1.1.5.1.3.2. Chemokines  
 
Chemokines are a family of small chemotactic cytokines, their name is derived from 
their main function which is to induce chemotaxis of immune cells and normal tissue 
maintenance of the secondary lymphoid tissue. Structurally, chemokines are 
classified into four subfamilies, CXC, CC, CX3C and XC, according to the positions 
of conserved cysteine residues that form disulphide bonds. Based on their function, 
they can be further subdivided into two groups, inflammatory chemokines and 
homeostatic chemokines. Inflammatory chemokines are produced by immune cells 
and other cells such as epithelial cells during infection and can induce the migration 
of leukocytes to the site of infection. These chemokines examples include CXCL8, 
CCL2, CCL3, CCL4, CCL5, CCL11, and CXCL10 (Fernandez & Lolis 2002). 
Homeostatic chemokines (section 1.4) direct the trafficking of lymphocytes to 
lymphoid tissues under non inflammatory conditions and are also involved in 
immune surveillance and act for example to localize T or B cells with antigen in the 
lymphatic system  (Fernandez & Lolis 2002). These chemokines examples include 
CXCL12, CXCL13, CCL19 and CCL21. 
In vitro, it has been shown that RSV infection of human respiratory epithelial cells 
and alveolar macrophages induced chemokine expression including IL-8, CCL3, 
CCL4 and CCL5 (Fiedler, Wernke-Dollries & Stark 1995; Jaovisidha et al. 1999; 
Mellow et al. 2004; Thomas et al. 1998). 
In vivo, RSV infection in BALB/c mice results in chemokine expression including 
CXCL2, CXCL10, CCL5, CCL11, CCL4, CCL3, CCL2, CCL1 and lymphotactin 
(Haeberle et al. 2001). Furthermore, it has been shown that during severe RSV 
infection in infants chemokines expressed include, CXCL10, CXCL8, CCL2 and 
CCL3 in the lower respiratory tract. Thus, these chemokines may contribute to the 
pathogenesis of RSV disease through directing migration of leucocytes, including 
neutrophils into the lungs (McNamara et al. 2005). 
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1.1.5.2. Adaptive immune response 
 
Adaptive immunity represents the second line of host defence against pathogens. It is 
very highly specific, takes a longer time to develop and provides effective response 
against pathogens. In contrast to innate immunity, it develops immunological 
memory cells. Adaptive immunity consists of two types, including cell-mediated 
immunity and humoral immunity.  
1.1.5.2.1. Cell-mediated immunity 
 
The cellular immune response has an important role in controlling viral infection, in 
particular CD8 T cells which are essential in the host defence against viral infection. 
CD8 T cells can recognize viral peptides in the context of MHC class I molecules. 
After viral recognition, CD8 T cells mediate death of the infected cell by inducing 
apoptosis. Multiple pathways involved including released cytotoxic proteins 
including the granzymes and perforin (Janeway 2001). The granzymes can induce 
apoptosis, and perforin forms holes in the target-cell membrane through which the 
granzymes can enter the infected cells. Furthermore, apoptosis can also be induced 
by a membrane-bound molecule, FasL, which is expressed by CD8 T cells and binds 
to Fas expressed by target cells. Moreover, CD8 T cells also produce cytokines such 
as IFN-γ, TNF-α, and TNF-β, which further contribute to host defence. IFN-γ can act 
as an inhibitor of viral replication and can also induce increased expression of MHC 
class I, as well as macrophage activation. In addition, TNF-α or TNF-β can synergize 
with IFN-γ in macrophage activation, and in killing infected cells through their 
interaction with TNFR-I (Janeway 2001; Zajac & Harrington 2008). 
CD4 T cells also known as helper T cells can recognize viral peptides in the context 
of MHC class II molecules expressed by the antigen presenting cells. Recognition 
leads to production of a wide range of cytokines. Based on cytokine production, CD4 
T cells can be divided into distinct subsets, including Th1, Th2, and T-regs and 
recently Th17. Th1 cells are characterized by the production of IFN-γ. Th2 cells 
produce cytokines including IL-4, IL-5, and IL-13. Th17 cells are characterized by 
the production of cytokines including IL-17, IL-21 and IL-22 (Ouyang, Kolls & 
Zheng 2008). 
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T-regs cells are characterized by expression of the transcription factor Foxp3 and 
production of the suppressive cytokines including IL-10 and TGF-β (Rosendahl 
Huber et al. 2014; Zajac & Harrington 2008).  
 
Children with defective T-cell responses show reduced RSV clearance, which 
suggests an important role for the adaptive cellular immune response against RSV 
(Fishaut, Tubergen & McIntosh 1980). Histological analysis of infants with fatal 
cases of RSV showed few CD4 and CD8 T cells in the lung (Welliver et al. 2007). 
However, another study has detected virus-specific CD8 T cells in the bronchial 
alveolar lavage and peripheral blood of infants after RSV infection (Heidema et al. 
2007). 
It has been reported that BALB/c mice which lack CD8 T cells have delayed viral 
clearance, demonstrating the importance of CD8 T cells in clearance during primary 
RSV infection (Graham et al. 1991b). Furthermore, RSV infection of BALB/c mice 
showed that 30–50 % of specific CD8 T-cell response in the lungs that recognize an 
immunodominant M282–90 epitope of RSV which mediates viral clearance (Chang & 
Braciale 2002). 
To find out the effector mechanism involved in RSV clearance by specific CD8 
cells, RSV-specific memory CD8 T cells deficient in IFN-γ were transferred to naive 
recipient mice and following subsequent RSV infection these cells failed to provide 
protection, which suggests the role of IFN-γ produced by RSV-specific CD8 T cells 
is essential for secondary responses to RSV (Ostler, Davidson & Ehl 2002). Another 
mechanism for target cell apoptosis is mediated by FasL that is expressed by 
activated T cells and binds to Fas on target cells. In addition, it has been reported that 
FasL-deficient mice show delay in the viral clearance in comparison to wild-type 
controls which is suggests the important of FasL in RSV clearance during acute 
infection (Rutigliano & Graham 2004). Taken together, these observations indicate 
the importance of CD8 T cells in the control and elimination of RSV during acute 
infection.  
RSV disease is characterized by wheeze, increased mucus production and airway 
hyperreactivity, features shared with asthma, which is characterized by induction of 
Th2 immune responses that produce cytokines including IL-4, IL-5 and IL-13 and, 
therefore, Th2 responses have been implicated in contributing to the pathogenesis of 
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RSV during severe infection. Furthermore, the roles of Th2 cytokines including IL-
4, IL-5 and IL-13 in the pathogenesis of RSV disease in humans remain 
controversial. Studies have demonstrated the association between the levels of Th2 
cytokines and the severity of RSV disease in young children (Legg et al. 2003; 
Roman et al. 1997). On the other hand, other reports did not observe any correlation 
between the levels of Th2 cytokines and the severity of RSV disease (Brandenburg 
et al. 2000; Garofalo et al. 2001). Thus, it could be possible that both of Th1/Th2 
cells contribute to the various manifestations of RSV disease. RSV infected BALB/c 
mice showed that IL-13 production is associated with increased mucus production 
(Tekkanat et al. 2001). RSV infection is most common in infants under 6 months of 
age when the human immune system is believed to be more Th2 dominant (Varga & 
Braciale 2013).  
It has been shown that DCs isolated from human cord blood produce low levels of 
IL-12, which is important for differentiation of CD4 T cells into Th1 or IFN-γ 
secreting cells. Therefore, it could be possible that the Th2 response observed in 
children during RSV infection may be as a result of functional differences in 
neonatal-derived DCs that lead to insufficient signals provided by DCs to naïve T 
cells (Hunt et al. 1994). Flow cytometric analysis of DCs isolated from infant cord 
blood showed significant low levels of intercellular adhesion molecule-1 (ICAM-1; 
CD54) and (MHC) class I and class II than those on adult blood DCs. Therefore cord 
blood DCs may not deliver sufficient signals to activate T cells as a result of their 
low cell surface expression of MHC and cell adhesion molecules (Hunt et al. 1994). 
However, work in mice showed that age influences RSV infection. Mice infected 
with RSV at early age (e.g 5 days ) develop disease and when they are re-challenged 
again at 8 weeks old they develop Th2 response cytokines ,whereas if the mice were 
infected for the first time at 4 weeks with RSV and re-infected again at 8 weeks they 
will develop Th1 response (Openshaw 2013). Moreover, it has been shown that 
Th17 cells also may contribute to RSV-induced disease severity (Kallal et al. 2010). 
RSV-infected infants has been shown to induce significant levels of IL-17A protein 
in tracheal aspirate samples and neutralization of IL-17A in mice leads to a 
significant decline in mucus production after severe RSV infection. Therefore, IL-17 
may play an essential role in RSV-induced disease (Mukherjee et al. 2011). Mice 
deficient in T-regs prior to RSV infection have delayed viral clearance as well as 
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enhanced disease severity (Fulton, Meyerholz & Varga 2010). This suggests that T-
reg cells have an important role in regulation of viral clearance during RSV infection 
and reduce the level of disease. 
1.1.5.2.2. Humoral immunity 
 
Antibodies play an important role in preventing re-infection with viruses either by 
directly neutralizing or enhancing the opsonization of extracellular viral particles. 
RSV specific neutralizing antibodies bind to (G) and (F) proteins (Varga & Braciale 
2013). Mice infected with RSV initially produce virus specific serum IgM followed 
by IgG (IgG2a) and RSV-specific IgA is present in their BAL fluid (Borchers et al. 
2013; Kamphuis et al. 2012; Singleton et al. 2003). 
It has been shown that viral clearance is not altered in BALB/c mice deficient in B 
cells, but severe lung inflammation, increased viral replication and clinical illnesses 
are more noticeable compared to animals with a complete B cell compartment after 
re-infection with RSV (Graham et al. 1991a),which suggests that viral clearance is 
mediated by the T cells response during the primary infection. 
In young children it has been shown that following acute RSV infection both levels 
of IgA and IgG antibodies titres rapidly declined. However, in adults lower nasal 
IgA titres were associated with elevated risk of RSV infection (Walsh & Falsey 
2004). In addition, following one year of natural RSV infection 75% of adults 
showed decrease in serum neutralizing anti-RSV F and anti-RSV G IgG titres 
compared to uninfected subjects, who remained stable overtime (Falsey, Singh & 
Walsh 2006). Therefore, this decrease is more likely to allow re-infection with RSV, 
as increased susceptibility to RSV infection has been associated with lower serum 
neutralizing antibody titre in the elderly (Falsey & Walsh 1998). Furthermore, it has 
been shown that maternal antibodies can interact with the immaturity of the immune 
system and this can lead to reduced antibody responses induced by severe RSV 
infection (Kasel et al. 1987; Murphy et al. 1986). It has been reported that 50-70% of 
children less than six months of age had RSV specific neutralizing antibodies that 
can be detected following RSV infection (Brandenburg et al. 1997; Murphy et al. 
1986). In addition, it has been found that antibodies produced against RSV have low 
avidity which may raise the susceptibility of infants and allow re-infection 
(Meurman, Waris & Hedman 1992). 
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Moreover, histological tissue of infants who died following severe RSV infection 
showed prominent presence of B cells and near absence of CD3+ T cells, which 
suggests that B cell activation in the lungs during severe infection could be T cell-
independent (Borchers et al. 2013; Reed et al. 2009). However, equally it could be 
possible that those children died because they did not make a proper T cell response.  
1.1.6. Modulation of host response by RSV 
 
The RSV nonstructural proteins , including NS1 and NS2 have been reported to 
inhibit type I IFN production (Ramaswamy et al. 2006). Reduced IFN production 
may enhance viral replication, as well as reduce chemokine production that also 
could affect the inflammatory response. Thus, this can negatively affect the CD8 T-
cells response since CD8 T cell require type 1 IFNs to become activated (Kotelkin et 
al. 2006; Varga & Braciale 2013). Therefore, suppression of the type I IFNs 
response by viral protein such as NS2 may reduce production of factors important 
for the activation of CD8 T cells, such as decreased expression of MHC class I 
molecules whose expression is up-regulated by type 1 IFNs as well as CXCR3 which  
is regulated by IFN-α /β in CD8, and it is critical for the efficient CD8+ T-cell 
activation (Ogasawara et al. 2002). Furthermore, suppression of the IFN response by 
the NS2 protein may enhance death of RSV-specific CD8, as incubation of activated 
CD8
+
 and CD4 with type I IFNs lead to a strong inhibition of their death (Kotelkin et 
al. 2006; Marrack, Kappler & Mitchell 1999; Varga & Braciale 2013). 
The RSV G protein can be found in two forms: a membrane anchored and a soluble 
secreted form. The soluble form can bind neutralizing antibodies blocking 
neutralization and opsonization of the virus by antibody acting as an immune decoy 
for the whole virus. RSV G protein also has structural homology to the CX3C 
chemokine fractalkine, and once secreted can modify the local inflammatory 
environment in the lung by varying the infiltrating inflammatory cells that express 
fractalkine receptor CX3CR1, such as neutrophils and NK cells, which then may 
show impaired chemotaxis (Tripp et al. 2001). Consistent with this, it has been 
reported that mice infected with RSV G protein resulted in inhibited trafficking of 
NK cells and dendritic cells into lung compared with mice challenged with RSV 
lacking of G protein (Harcourt et al. 2006; Varga & Braciale 2013). 
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1.2. Tumor necrosis factor Family (TNF) 
 
TNF cytokine family members control many aspects of the immune system 
including lymphocyte activation, differentiation and apoptosis (Treml et al. 2009). 
TNF family members are type II transmembrane proteins that can form membrane-
bound or released as soluble molecules. The BLyS family of proteins including both 
BAFF and APRIL are comparatively new additions to the TNF cytokine superfamily 
(Treml et al. 2009). The B-cell activating factor or BAFF was identified 
independently by different groups. Schneider et al. discovered it by sequence 
homology with the members of the TNF superfamily (Schneider et al. 1999) and 
subsequently named this molecule BLyS due to its ability to induce B lymphocyte 
proliferation and immunoglobulin production (Moore et al. 1999). Other names for 
BAFF include THANK (Mukhopadhyay et al. 1999), TALL-1 (Shu, Hu & Johnson 
1999), and TNFSF13B (Gross et al. 2000). APRIL, also known as TRDL-1α, TALL-
2, or TNFSF13 (Kelly et al. 2000), was recognized as a close structural homologue 
of BAFF (Hahne et al. 1998). 
1.2.1. BAFF 
 
1.2.1.1. BAFF gene 
 
The human BAFF gene located on chromosome 13q33.3  has 6 exons and 5 introns 
(39 kb). In mouse, the gene is on chromosome 8 A1.1 and comprises of 7 exons and 
6 introns (31 kb) (Lahiri et al. 2012). The genomic organization is shown in (Figure 
1.6), where the alternative splicing points in associated transcripts are shown, and the 
name of the resulting protein form indicated.  
 
 
 
 
Exons are shown as boxes and introns (thin line) are illustrated. Points for alternative 
splicing are presented, and the name of the predicted protein is indicated. Taken from 
(Lahiri et al. 2012). 
Figure 1.6. Genomic organization of BAFF in humans (A) and mice (B) 
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1.2.1.2. BAFF transcripts 
 
There are various forms of BAFF transcript, including ΨBAFF, ΔBAFF and 
Δ4BAFF (Figure 1.7). Ψ BAFF is a long transcript only identified in humans, 
formed as a result of incomplete splicing of intron sequences. This isoform seems 
not able to make BAFF protein. ΔBAFF is identified in both humans and mice. This 
form lacks exon 3 in humans or exon 5 in mice. The corresponding protein of 
ΔBAFF has not been detected yet. ΔBAFF is associated with heteromultimers and 
the soluble form of these molecules binds poorly to receptors relative to 
homomultimers of BAFF. Therefore, ΔBAFF may suppress BAFF function by 
competitive co-association and limiting BAFF homotrimerization (Lahiri et al. 
2012). ΔBAFF and BAFF have different effects on B cell survival and marginal zone 
B cell numbers. Analysis of ΔBAFF in transgenic mice showed a decreased number 
of B cells and T cells relative to BAFF (Gavin et al. 2005; Lahiri et al. 2012). 
Furthermore, the functional characteristics and patterns of expression for ΔBAFF 
and Δ4BAFF proteins have not yet been fully defined. The points for alternative 
splicing and the name of the resulting protein are indicated (Figure 1.6) (Lahiri et al. 
2012).   
 
 
 
 
 
 
 
 
 
 
 
 
 
The number of base pairs (bp) in the open reading frame (ORF) is shown next to each BAFF 
transcripts, including ΨBAFF, ΔBAFF and Δ4BAFF. Taken from (Lahiri et al. 2012). 
 
 
 
 
 
 
Figure 1.7. Diagram illustration of BAFF transcripts in humans (A) and mice (B) 
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1.2.1.3. BAFF protein  
 
Human and mouse BAFF are type II transmembrane proteins (Figure 1.8). Type II 
membrane proteins have their C-terminus (COOH) exposed to the extracellular and 
have their N-terminus (NH3) on the cytoplasmic side of the cell, while type I 
membrane proteins have their N-terminus (NH3) exposed to the extracellular and the 
C-terminus (COOH) portion exposed on the cytoplasmic side. Human BAFF protein 
contains 285 amino acids (aa) (31.2 kDa), mouse BAFF 309 aa (34.2 kDa). The 
soluble form results from cleavage of the membrane bound form. In human BAFF 
the transmembrane domain is encoded by exon 1 (from L
47
 to Y
67
) and in mouse 
from L
48
 to Y
68
). Also, the cleavage site of membrane BAFF where soluble BAFF 
cleavage is encoded by exon 2 after (R
133
) and for mouse after (R
126
). Moreover, for 
humans the C-terminal domain is encoded by exons (3, 4, 5, and 6), while in mouse 
(4, 5, 6, and 7). This domain is known as the TNF homology domain (THD), which 
has an essential role in the organization of protein structure (Lahiri et al. 2012). 
Initially, BAFF is expressed on the cell membrane and can be cleaved by a furin-
convertase enzyme and then released as soluble molecule.  Soluble Human BAFF 
contains 152 aa (17.2 kDa) (from A
134
 to L
285
) and 183 aa (from A
127
 to L
309
) (20.6 
kDa) in mice. The main difference between human and mouse BAFF is the exon 3, 
which in mice has no matched counterpart to that in humans (Lahiri et al. 2012).  
 
 
 
 
 
 
 
Coloured boxes represents exons. The hatched areas represent the transmembrane region. 
The vertical arrow indicates the cleavage site for furin and the horizontal arrow illustrates 
the THD. The number of (aa) and expected molecular weight in kilo Daltons (kDa) for each 
BAFF protein are also described. Taken from (Lahiri et al. 2012). 
Figure 1.8. Diagram illustration of BAFF protein in humans (A) and mice (B) 
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The biological form of BAFF is a trimers (Zhukovsky et al. 2004). This structure 
consists of layered aromatic residues from three monomers (Figure 1.9). The FLAP 
region of BAFF is termed due to its shape (Liu et al. 2002). It allows trimer–trimer 
interaction leading to a virus-like assembly of soluble trimmers as an oligomer 
consisting of 60 monomers or 20-trimers connected to each other by hydrogen and 
hydrophobic bonds. Indeed, it has been shown that the pH of the environment plays 
an important role in forming and deforming of different forms of BAFF, including 
monomers, trimers and oligomers. At pH = 6.0, BAFF is present in a trimeric form. 
At pH = 6.5, the ratio oligomers/trimers ratio is 1:2 and 1:1 at pH = 7.0. At pH = 7.4,  
the oligomeric form is predominant (Lahiri et al. 2012). Furthermore, BAFF-60 mer 
can bind to its receptors (Liu et al. 2002). While this form has been described only in 
mice, it remains unclear if it can be or cannot be detected in humans (Vincent et al. 
2013). Therefore, it could be possible that interaction of BAFF 60-mer with its 
receptors may act to increase BAFF signalling at a local site and concentrate BAFF 
on the cell surface more than the BAFF 3 mer does. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAFF monomer (A). BAFF trimer and FLAP region implicated in 60-mer formation (B). 
BAFF 60-mer (C). In (D) BAFF trimer and BAFF-R monomer in surface representation, 
before and after binding. One BAFF trimer can bind three receptors, each contacting a 
single monomer within the BAFF trimer. Taken from (Bossen & Schneider 2006). 
 
Figure 1.9. Structure of BAFF 
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1.2.1.4. Expression of BAFF 
 
BAFF is mainly expressed by PBMCs, low levels of BAFF in tissues including 
spleen and lymph nodes have been detected. The major immune cells that expressed 
BAFF are monocytes, macrophages, dendritic cells, neutrophils and activated T cells 
(Mackay & Ambrose 2003). Moreover, expression of BAFF by B-CLL cells has 
been demonstrated (Daridon et al. 2007; Kern et al. 2004). Other cells such as 
stromal cells from the BM, FDC, synoviocytes, astrocytes, and epithelial cells of the 
salivary glands have been shown to express BAFF. BAFF expression is regulated by 
cytokines. Stimulation of monocytes with IFN-α, IFN-γ, IL-10 or CD40L has been 
shown to increase the expression of membrane BAFF. It has been shown that 
stimulation of neutrophils with G-CSF and IFN-γ leads to increased secretion of 
BAFF (Scapini et al. 2003). However, neutrophils do not express BAFF on their 
surfaces. This secretion of BAFF has been blocked by targeting the furin like 
convertase responsible for cleavage of the membrane form by a specific inhibitor. 
This suggests that when produced by neutrophils BAFF is processed intracellularly 
and subsequently secreted by these cells and not cleaved from the membrane. 
Therefore, the mechanism of BAFF cleavage via the furin protease can occur either 
intracellularly, at least in neutrophils, or at the cell surface (Lahiri et al. 2012).  
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1.2.2. APRIL 
 
1.2.2.1. APRIL gene  
 
The human APRIL gene is located on chromosome17 (17p13). Seven transcript 
variants of APRIL have been identified, including APRIL-α [NM_003808.3] which 
is composed of 6 exons, APRIL-β [NM_172087.2] that is characterized by the 
deletion of exon 3 and the resulting form of APRIL is quite similar to ΔBAFF , 
APRIL-γ [NM_172088.2] has seven exons, APRIL-δ [NM_001198622] is 
characterized by loss of exon 2 and two nucleotides, APRIL-ε [EF_211088.1] has 
only exon1, APRIL- η [NM_001198624.1] is missing the initial exon 2 as well as the 
full exon 1 which is replaced by 2 exons of 84 and 239 bp and APRIL-ζ 
[NM_001198623.1], where the initial exon 2 is missing and the resulting exon 2 
contains only 42 bp, as indicated in (Figure 1.10) (Lahiri et al. 2012). The molecular 
significance of these multiple alternate spliced forms has yet to be defined. The 
major form studied at the protein level is formed from the full length transcript 
derived from all six exons and shown first in Figure 1.10 
 
 
 
 
 
 
 
 
Exons are represented by grey boxes. The thin line corresponds to introns. Taken from 
(Lahiri et al. 2012). 
 
 
 
 
 
Figure 1.10. Genomic organisation of APRIL transcripts 
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1.2.2.2. APRIL protein 
 
At the protein level both human and murine APRIL molecules (Figure 1.11) share 
about 85% similarity (Hymowitz et al. 2005). APRIL is synthesized as type II 
transmembrane protein (molecular weight 27 kDa). APRIL is expressed by several 
cells such as dendritic cells, monocytes, neutrophils, macrophages, and activated T 
cells (Huard et al. 2008; Mackay & Ambrose 2003; Stein et al. 2002). In addition, 
non-immune cells such as epithelial cells can express it (Kato et al. 2006). Moreover, 
APRIL is expressed by tumour cells such as CLL (Haiat et al. 2006). In contrast to 
BAFF, APRIL does not have a cell surface membrane bound form and is processed 
and cleaved in the Golgi apparatus by a furin-convertase enzyme before reaching the 
cell surface (Daridon, Youinou & Pers 2008) and results in secreted or soluble 
APRIL (molecular weight 14 kDa) (Dillon et al. 2006; Lopez-Fraga et al. 2001). 
Unlike BAFF, APRIL does not from 60-mer complexes (Bossen & Schneider 2006), 
but can combine with BAFF and to form heterotrimers, which are either formed at 
the cell surface or inside cells (Golgi apparatus), and increased expression of these 
heterotrimers complexes has been suggested to occur in autoimmune diseases, 
although any pathogenic role has yet to be defined (Roschke et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
APRIL monomer (A). APRIL trimer (B). An APRIL trimer can bind three receptors, each 
contacting a single monomer within the APRIL trimer. Taken from (Bossen & Schneider 
2006). 
Figure 1.11. Structure of APRIL 
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1.2.3. BAFF and APRIL Receptors 
The interaction of BAFF/APRIL with their receptors is both specific and redundant 
(Figure 1.12). BAFF and APRIL both bind with each of two receptors expressed by 
B cells, transmembrane activator and calcium modulator and cyclophylin ligand 
interactor (TACI) and B-cell maturation antigen (BCMA). BAFF binds TACI with 
higher affinity than it does BCMA, while APRIL interacts with BCMA with higher 
affinity than TACI. In addition, BAFF also interacts with a third receptor known as 
B cell-activating factor receptor (BAFF-R). APRIL interacts with heparan sulphate 
proteoglycans (HSPGs),which form part of the extracellular matrix and are 
expressed by many cell types including B cells (Mackay & Leung 2006). It has been 
thought that engagement of APRIL with HSPGs enhances APRIL signalling at a 
local site and concentrates APRIL on the cell surface (Vincent et al. 2013). BAFF 
and APRIL receptors are mainly expressed on B cells, however their expressions are 
different from cell to cell (table 1.1). Indeed, BAFF-R is expressed by all peripheral 
B cells subsets including immature and mature B-cell subsets, marginal zone (MZ), 
germinal center (GC), follicular ,transitional type-1 (T1), transitional type-2 (T2) and 
some plasmacytoid B cells  and TACI is expressed by stimulated follicular and MZ 
B cells, while BCMA is expressed by activated memory and plasmacytoid B cells 
(Schneider 2010).   
 
 
 
 
 
 
BAFF can be expressed as a membrane-bound or released into a soluble cytokine after cleavage at a 
furin protease site. In contrast to BAFF, soluble APRIL is cleaved intracellularly. BAFF only has 
weak affinity for BCMA. BAFF-R is important for survival and maturation of immature B cells. TACI 
is critical for T-cell-independent responses of B cells, negative regulation of the size of the B-cell 
compartment and class-switch recombination. BCMA enhances plasma-cell survival. Taken and 
modified from (Vincent et al. 2013).  
Figure 1.12. Interaction of BAFF and APRIL with their receptors 
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Table 1.1. Types of cells expressing BAFF/APRIL and their receptors. Taken and modified 
from (Vincent et al. 2013). 
 
Cell type Ligands Receptors 
Astrocytes (human primay cells) BAFF  
Microglia (rat primary cells) BAFF BAFF-R, TACI 
Immature B cells (human and mouse)  BAFF-R 
Mature B cells (human and mouse) APRIL, 
BAFF 
BAFF-R, TACI 
Bone marrow plasma cells (human and mouse)  BCMA 
Myeloid precursor cells (human) APRIL  
Activated T cells (human) APRIL, 
BAFF 
BAFF-R 
NK cells (human blood cells) BAFF  
pDC (human and mouse) BAFF  
Neutrophils, Monocytes, Macrophages and 
Dendritic cells (human and mouse) 
APRIL, 
BAFF 
 
Intestinal epithelial cells (human) BAFF  
Adipocytes (human and mouse) APRIL, 
BAFF 
BAFF-R, BCMA, 
TACI 
Skin keratinocytes (human) APRIL, 
BAFF 
BAFF-R, BCMA, 
TACI 
Adipose-derived stem cells (human) APRIL, 
BAFF 
BAFF-R, BCMA, 
TACI 
BM CD14
+
 cells and osteoclasts  (human ) APRIL, 
BAFF 
 
Primary CNS lymphoma cells (human)  BAFF-R, BCMA, 
TACI 
CLL stromal microvascular endothelial cells 
(MVECs) (human) 
APRIL, 
BAFF 
 
CLL cells (human and mouse) BAFF 
APRIL 
BAFF-R, BCMA, 
TACI 
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1.2.4. Functions of BAFF and APRIL 
  
  1.2.4.1. B cell survival 
 
For many years, it has been thought that functional BCR signals were sufficient for 
B cell survival (Mackay et al. 2010). However, the discovery of BAFF and APRIL 
changed this view (Figure 1.13).  
It has been revealed that mice deficient in BAFF or BAFF-R have a significantly 
lower number of peripheral B cell compared to control (Mackay & Schneider 
2009) and in mice or patients challenged with anti-BAFF this leads to the loss of 
mature B cells (Dall'Era & Wofsy 2010; Vora et al. 2003). This suggests that 
BAFF mediates an important role in B cell development or maintenance of B cell 
numbers. 
In vitro, it has been reported that APRIL can stimulate proliferation of primary B 
cells purified from the spleen of normal mice and in in vivo, the administration to 
mice of APRIL daily for 5 days (1mg/kg) resulted in an increase in the size of the 
spleen and accumulation and increased numbers of splenic B cell (Yu et al. 2000). 
However, a study in APRIL deficient mice showed normal B cells development 
and normal proliferation in vitro (Castigli et al. 2004). Taken together, this 
suggests that APRIL may be less important to some extent in B cell development at 
the early stages and the possible role of APRIL in maintaining long lived plasma B 
cell survival through interaction with BCMA (Treml et al. 2009). 
BAFF can maintain the survival of murine and human B cells at various phases of 
development and differentiation. BAFF sustains B cell survival by altering 
expression of pro- and anti-apoptotic molecules. In vitro, it has been found that 
expression of the anti-apoptotic genes including bcl-xL, Mcl-1, Al and bcl-2 
increased upon exposure of murine B cell to BAFF (Do et al. 2000; Hsu et al. 
2002; O'Connor et al. 2004), whereas the pro-apoptotic molecules including Bak, 
Blk and Bim were reduced (Amanna et al. 2001; Craxton et al. 2005; Do et al. 
2000; Lesley et al. 2004). This indicates that BAFF supports the survival of B cells 
by modifying the balance between pro-survival and pro-apoptotic molecules 
(Tangye et al. 2006).  
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B cells at the early stage (TR; Transitional, FO; Follicular, MZ; Marginal zone) express 
BAFF-r and TACI, but only BAFF is required for their normal development. Changes of 
receptor expression are taken place upon antigen stimulation. Thus, T cell dependent stimuli 
is mediated by BAFF-r expression that resulted in germinal center reactions, whereas T cell 
independent stimuli is mediated by TACI expression which is resulting in production of  
short-lived plasma cells. BCMA is expressed on Long-lived bone marrow plasma cells that 
require APRIL for their normal survival. Memory cells express TACI, but are independent of 
BAFF and APRIL. Taken from (Treml et al. 2009). 
     
 
 
 
 
 
 
 
 
 
 
Figure 1.13. Expression of BAFF and APRIL receptors and cytokine dependence 
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1.2.4.2. Class switch recombination (CSR) 
 
 
CSR is a genetic process where during antigen driven responses B cells can switch 
expression of the heavy chain for IgM to produce new class or isotype of antibody 
such as IgG, IgE and IgA (Chaudhuri & Alt 2004). CSR requires two signals. The 
first one normally comes by T-cell cytokines including (IL-4, IL-10, IL-13 and TGF-
β), and the second signal is mediated by interaction of CD40 on B cells (Stavnezer & 
Amemiya 2004). BAFF has been recognized to play a role as a second signal for 
CSR in the absence of T cells or CD40-dependent signalling (Litinskiy et al. 2002; 
Mackay, Silveira & Brink 2007).  
BAFF
 
influences this process by engagement with TACI and BAFF-R to enhancing 
class switching to IgG, IgA or IgE antibodies (Castigli et al. 2005b; Kato et al. 2009; 
Stavnezer & Amemiya 2004). Although CSR is generally restricted to lymphoid 
organs, it has been reported that local immunoglobulin CSR and IgE production also 
take place in the nasal and airway mucosa of patients who had allergic asthma and 
allergic rhinitis, in addition to in the oesophageal mucosa of patients with 
eosinophilic oesophagitis (Kato et al. 2009; Vicario et al. 2010).
 
Furthermore, it has been shown in vitro that BAFF and APRIL are able to induce 
CSR in murine B cells also (Castigli et al. 2004; Castigli et al. 2005b). Stimulation 
of murine B cells with BAFF or APRIL resulted in production of IgA and IgG1, but 
for production of IgE, the IL-4 was required in addition to BAFF or APRIL (Castigli 
et al. 2004; Castigli et al. 2005b). Furthermore, in mice lacking TACI (–/–TACI 
mice) both APRIL and BAFF fail to induce IgA secretion by B cells in contrast to 
mice with B cells expressing a non-functional BAFF-R or which lacked BCMA. 
This demonstrates the importance of TACI in inducing CSR at least to IgA in 
response to BAFF or APRIL (Castigli et al. 2004; Castigli et al. 2005b). TACI is 
required for APRIL-induced production of IgA by human B cells, but not IgG, while 
BAFF-R contributes to BAFF-mediated CSR to both IgG and IgA by human B cells. 
It has been shown that human B cells with mutations in TACI also fail to secrete IgA 
in response to APRIL or BAFF, which suggests an important role for TACI in CSR 
to IgA (Castigli et al. 2005a; Tangye & Fulcher 2010). 
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1.2.4.3. T-Cell activation 
 
T-cell production and response to BAFF and APRIL can be considered a 
controversial issue. BAFF and APRIL were initially suggested to be expressed by 
activated T cells (Lavie et al. 2004). However, other studies were unable to fully 
confirm this observation and show significant production of BAFF and APRIL 
(Mackay & Leung 2006). Moreover, TWE-PRIL is a transmembrane protein that 
consists of a part of the APRIL sequence and the TWEAK gene (Kolfschoten et al. 
2003), and it has been shown to be expressed on resting and activated primary T 
cells, which may make detection of APRIL difficult (Mackay & Leung 2006). In 
addition, expression of BAFF and APRIL receptors (BAFF-R, TACI and BCMA) 
remains not fully identified. BAFF-R and TACI have been detected on activated T 
cells (Lavie et al. 2008; Wang et al. 2001). However, BCMA is not expressed on T 
cells. It has been reported that BAFF can act as a co-stimulator of T cell activation. 
Stimulation of human or murine T cells with anti-CD3 mAb in the presence of 
exogenous BAFF has increased proliferation and cytokine production (Huard et al. 
2004; Huard et al. 2001; Ng et al. 2004). Furthermore, in vitro  it has been reported 
that BAFF may also be able to improve response of CD4
+
, CD8+, naïve and effector 
T cells (Huard et al. 2001; Tangye et al. 2006). In addition, APRIL can also act as 
co- factor when T cells were stimulated with anti-CD3, and the exactly role of BAFF 
and APRIL in T cells function and survival remains to be investigated (Mackay & 
Leung 2006).    
1.3. Role of BAFF and APRIL in diseases  
 
1.3.1. Infectious diseases  
 
BAFF can be induced in response to viral infection including hepatitis C virus, 
human immunodeficiency virus (HIV) RSV and H1N1 influenza (McNamara et al. 
2013; Rodriguez et al. 2003; Toubi et al. 2006). Moreover, studies in vitro showed 
that cell lines, including Human umbilical vein endothelial cells (ECs), HL-60 cells 
and Human erythroleukemia K562 cells infected with Dengue virus, Epstein–Barr 
virus (EBV), Sendai virus and reovirus-1, respectively, also induce expression of 
BAFF (Dalrymple & Mackow 2012; He et al. 2003; Ittah et al. 2011). Furthermore, 
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APRIL was expressed following RSV infection in humans (Reed et al. 2009). 
However, in our recent study focusing on airway epithelial cell expression both in 
vitro and in vivo we did not detect significant up-regulation of APRIL after RSV 
infection in humans (McNamara et al. 2013). Several studies have reported that up-
regulation of BAFF following viral infection is IFN-β dependent (McNamara et al. 
2013; Nardelli et al. 2001). 
Treatment with type 1 interferon can induce BAFF expression by myeloid cells and 
epithelial cells. Furthermore, infection of salivary gland epithelial or stimulation with 
dsRNA, induced BAFF expression (Ittah et al. 2009; Ittah et al. 2011). In addition, 
IFN-β expression is also strongly induced by virus infection or dsRNA stimulation 
of airway epithelial cells (Guillot et al. 2005; Ronni et al. 1997). BAFF induction by 
viral infection is a general phenomenon, but the types of viruses and the mechanisms 
depend on the cell type (Ittah et al. 2011). BAFF secretion as a result of infection is 
thought to play an important role in local immune responses (Ittah et al. 2011). 
Mice infected with influenza virus for 35 days and later treated for 2 weeks with 
TACI-Fc that neutralizes both BAFF and APRIL resulted in reduced percentage and 
total number of antibody secreting cells (ASCs), including virus-specific ASCs, in 
lungs and bone marrow (BM). This was associated with a significant reduction in 
antiviral serum IgG, as well as virus-specific IgG and IgA in the BAL (Wolf et al. 
2011). However, mice treated with anti-BAFF antibody after 36 days of Influenza 
infection showed no change in protective antiviral antibody titres IgG and IgA in 
serum or BAL. CD19
+
 B cells were significantly reduced in spleen, lung-draining 
medLN, and lungs. These observations suggested that blockade of BAFF and 
APRIL, but not BAFF alone, reduces ASC survival in response to influenza virus 
infection (Wolf et al. 2011). Furthermore, it has been shown that TACI has a 
significant impact on antiviral Ab responses, TACI deficient mice and WT mice 
were infected with influenza virus for 0, 8, 18, 32, 33, 60 and 90 days. At the early 
time of infection there was no difference between TACI deficient and WT strains in 
the antibody production, IgM peaked at 15 days to 30 days (Wolf et al. 2011). 
However, after 30 days of infection, virus-specific IgG titres in the serum declined 
significantly in TACI deficient mice in comparison to control, which indicates TACI 
is required for maintenance of antiviral IgG in the serum. Furthermore, as in the 
serum, there was no difference in virus-specific IgM in the BAL from WT and 
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deficient mice on day 8. However, by day 32 virus-specific IgG and IgA were 2- and 
10-fold reduced in BAL of TACI deficient mice, respectively. In addition, the 
concentration of total IgG in BAL was not different, while total IgA was reduced in 
TACI deficient mice (Wolf et al. 2011). 
To further understand the mechanism behind this process APRIL alone could be 
blocked and see if the survival of B cells will be affected or not since the study 
above targeted BAFF and APRIL or BAFF alone but not APRIL alone.  
Moreover, BAFF has been reported to be expressed in response to parasite infections 
including diseases such as Malaria. In vivo, it has been found that malarial infections 
result in decreased BAFF expression by DCs, which can lead to decrease ability of 
these DCs to support memory B-cell differentiation of ASCs in addition to the 
survival of ASCs (Liu et al. 2012), and by over-expressing BAFF, malarial-specific 
antibody secreting cell numbers were increased and mice were protected from 
infection (Liu et al. 2012). Taken together, these observations underline the 
importance of BAFF and APRIL in providing appropriate long lasting protective 
responses to infections and therefore increase our understanding of these cytokines 
during RSV infection and may help us to find out why there is not an effective long 
lived antibody to RSV.  
1.3.2. Cancer  
 
B-CLL is characterized by the slow accumulation in patients of small mature B cells 
expressing CD5, CD19, CD23 and CD20 markers on their surface. This 
accumulation results from deficient apoptosis (Haiat et al. 2006). In vitro, it has been 
shown that B cells die as result of a lack of essential growth factors in the culture 
medium  (Haiat et al. 2006). This rate of B-CLL cell death in vitro can be modulated 
by cytokines such as BAFF (Haiat et al. 2006). Recently, it has been reported that 
BAFF and APRIL can be expressed by B-CLL cells and are able to protect the 
leukaemic cells against spontaneous and drug-induced apoptosis via autocrine and/or 
paracrine pathways. This suggests that BAFF and APRIL may be involved in the 
pathogenesis of B-CLL (Bojarska-Junak et al. 2009; Haiat et al. 2006). Furthermore, 
it has been shown that BAFF and APRIL produced by stromal cells such as MVECS 
enhanced cancer cell survival upon engagement of CD40 on MVECs by CD40L 
aberrantly expressed on the surface of CLL cells (Cols et al. 2012). Thus, as BAFF 
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and APRIL have key roles in B cell survival this may contribute to expanding the 
CCL disease especially in patients who are suffering associated infection. 
1.3.3. Autoimmune disease 
 
BAFF and APRIL play a central role in the pathogenesis of several autoimmune 
diseases. BAFF overproduction is often a characteristic of autoimmune diseases, 
such as systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, and 
rheumatoid arthritis (Lied & Berstad 2011). In addition, it has been shown that 
patients with systemic lupus erythematosus have higher concentration of APRIL in 
the serum that seems to correlate with the titre of anti-DNA antibodies (Koyama et 
al. 2005). Furthermore, it has been reported that blockade of APRIL in NZB mice 
developing lupus spontaneously was associated with reduction of the concentration 
of auto-antibodies against double-stranded DNA (Huard et al. 2012). Moreover, 
BAFF and APRIL could enhance autoimmune disease such as RA through 
maintaining the germinal centre - like structure, either by support of the survival of 
auto-reactive B cells or inducing them to undergo class-switching that results in 
pathogenic autoantibodies (Tangye & Fulcher 2010). 
1.4. Role of homeostatic chemokines in viral infection and iBALT 
formation 
 
Homeostatic chemokines are commonly expressed in secondary lymphoid organs 
such as spleen, where they control placement of lymphocytes and DCs (Cyster 
1999). Chemokines CXCL13, CCL19, CCL21 and CXCL12 are each homeostatic 
chemokines that are believed to influence lymphoid tissue structure (Zlotnik, 
Burkhardt & Homey 2011). 
CXCL13 is ligand for CXCR5, whereas CCL19 and CCL21 are ligands for CCR7. 
CXCL12 is the ligand for CXCR4 (Bleul et al. 1996; Zlotnik, Morales & Hedrick 
1999). CXCL12 is another B cell chemoattractant. CXCL13 chemokine is expressed 
in B cell follicles and can attract naive B cells that express CXCR5 (Gunn et al. 
1998), DCs and activated CXCR5
+
 T cells (Ansel et al. 1999). CXCL13 is also 
expressed by HEVs, small subsets of normal CD4
+
 and CD8+ T cells, and skin-
derived migratory dendritic cells (Forster et al. 1994; Saeki et al. 2000; Wang et al. 
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2007; Wu & Hwang 2002; Yu et al. 2002), and helps to recruit CXCR5-expressing 
cells into lymphoid organs (Ebisuno et al. 2003). 
In contrast to CXCL13, CCL21 and CCL19 are expressed in the T cell zones of the 
secondary lymphoid organs and they attract naïve T cells that express CCR7 and 
activated CCR7+ve APC to enter the T cells area. CCR7 is present on activated B 
cells, naive and central memory T cells, and dendritic cells. Both CCL21 and CCL19 
chemokines strongly recruit subsets of T cells, B cells and mature dendritic cells into 
secondary lymphatic organs (Luther et al. 2000; Ngo, Lucy Tang & Cyster 1998). 
CCL21 is also expressed on HEVs and involved in recruitment of T cells from blood 
into lymph nodes (Gunn et al. 1999). Thus, homeostatic chemokines play an 
essential role in organizing and maintaining the B and T cell areas of secondary 
lymphoid organs and contribute to shape the architecture of the secondary lymphoid 
organs in addition to initiating the interaction of lymphocytes and APCs (Rangel-
Moreno et al. 2005). 
Moreover, recent studies have found that homeostatic chemokines, including 
CXCL13, CCL19, and CCL21 are expressed in non-lymphoid tissues, such as lungs, 
after inflammation or infection and can trigger lymphocytes to the side of infection 
during local immune responses. For example, after influenza infection CXCL13, 
CCL19, and CCL21 are expressed in the lung including within areas containing B 
and T cells, and similar to ectopic lymphoid follicles. Accumulation of B and T cells 
in these areas can be termed iBALT (Figure1.14) (Moyron-Quiroz et al. 2004; 
Rangel-Moreno et al. 2007). The iBALT may be formed to initiate and provide an 
immune response independently from the lymph node.  
Within the airway iBALT can be found in areas around the bronchioles and nearby 
arteries and has been established to be induced in response to different respiratory 
stimuli such as exposure of neonatal mice to inhaled LPS (Rangel-Moreno et al. 
2011), toll-like receptor ligands (Luhrmann, Tschernig & Pabst 2002), small proteins 
(Wiley et al. 2009) and cigarette smoke (van der Strate et al. 2006). Exposure of the 
lungs to non-replicative virus-like particles (VLPs) also induces the formation of 
iBALT (Richert et al. 2013; Wiley et al. 2009).
 
Local expression of CXCL13 and CCL21 may contribute to the organization of 
ectopic lymphoid tissues which are frequently correlated with chronic diseases, such 
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as rheumatoid arthritis. It has been reported that expressions of ectopic lymphoid 
tissues promote local immune responses. However, they might also promote or allow 
activation of abnormal T and B cell responses which could lead to autoimmunity or 
amplification of chronic inflammation as a result of incorrect organization or 
structure (Aloisi & Pujol-Borrell 2006; Kato et al. 2013).  
 
 
 
 
 
 
 
 
 
 
 
Upon antigen recognition by PRRs (such as TLRs) expressed on epithelial cells or DCs, this 
leads to immediate early activation that eventually contributes to development of iBALT. The 
formation of iBALT depends on complex interactions between activated DCs, stromal cells 
and adhesion molecules on HEVs, results in release of chemokines and cytokines that recruit 
of T and B cells to the site which are often organized into distinct zones. FDCs are located 
in B-cell area where they present antigen and co-stimulatory signals to the B cells. Tregs in 
the draining mediastinal lymph node can attenuate formation of iBALT , however, the 
mechanism remains unknown, but it could be is possible that Tregs may not fully inhibit 
cells activation and therefore exit from lumph node and  migrate to the lungs to initiate 
iBALT formation. Taken from (Foo & Phipps 2010). 
 
 
Figure 1.14. Potential mechanism of formation of  iBALT during infection 
62 
 
1.5. Aim of thesis 
 
The main aim of the work described in this thesis was to investigate the ability of 
airway epithelial cells to support protective immune responses, particularly B 
lymphocyte responses during RSV infection both in vitro and in vivo. 
BEAS-2B cells, a cultured airway epithelial cell line, were used to characterize 
expression of BAFF and APRIL, following both RSV infection and cytokine 
stimulation in vitro. The forms of BAFF which epithelial cells can express after RSV 
infection and the mechanisms that regulating expression BAFF were also examined. 
Further aims were to determine if BAFF derived from RSV infected epithelial cells 
has functional activity influencing B cell survival, and if epithelial cells have the 
ability to additionally support the adaptive immune response by expression of 
homeostatic chemokines, including, CXCL13, CCL19, CCL21 and CXCL12. This 
work is described in chapter three. 
To further understand the airway B cell response to RSV infection a murine model of 
human RSV infection was used to evaluate expression of BAFF and APRIL. In 
addition, to investigate which forms of BAFF are expressed in murine lungs after 
RSV infection. Further aims were to examine RSV and BAFF localization in murine 
lung sections. These experiments are described in chapter four. 
Furthermore, local expression of the lymphoid chemokines, including CXCL12, 
CXCL13, CCL19 and CCL21 which could influence B and T cellrecruitment in to 
the airway were studied in this model of RSV infection. This work is described in 
chapter five. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1: Growth of the Human airway epithelial cell line, BEAS-2B  
 
2.1.1. Preparation of medium 
 
Airway epithelial BEAS-2B cells were grown in DMEM media (SIGMA, at#D6546, 
UK) supplemented with 10% FBS (cat#F7524, SIGMA, UK) and L-Glutamine–
Penicillin–Streptomycin solution (cat# G6784, SIGMA, UK). 
 
2.1.2. Culture of BEAS-2B cells 
 
BEAS-2B cells were used in experiments to model the activity of normal human 
epithelial cells. BEAS-2B cells are derived from human bronchial epithelium
 
transformed by an adenovirus 12-SV40 hybrid virus. Firstly, all external surfaces of 
supplement vials and medium bottles were decontaminated with 70% ethanol. 
Cryovials tubes of BEAS-2B cells were removed from store in liquid nitrogen and 
immediately placed at 37°C in a water bath until around 80% thawed. Cells were 
pipetted into a sterile universal tube followed by addition of 5ml of warm complete 
DMEM medium to avoid osmotic shock. Afterwards, cells were centrifuged at 400g 
for 10 minutes, the supernatant discarded and pellet re-suspended in 15 ml volume 
DMEM. Cells were grown in T75 tissue-culture flasks containing complete DMEM 
medium and incubated at 37°C in an atmosphere including 5% CO2 and 95% air. 
After 24h of culture, cells were examined under the light microscope to ensure that 
they were attached and the culture media was changed to remove dead cells and 
replenish nutrients. 
 2.1.3. Subculturing of BEAS-2B cells 
 
Cells were subcultured when 70-80% confluent (Figure 2.1). Culture medium was 
removed and cells washed twice with 5mL sterile phosphate buffered saline PBS 
(SIGMA, cat#P3813) or complete DMEM medium. 2.5 ml of Trypsin/EDTA 
solution 1:10 (SIGMA, cat# T3924) was then added to T75 flask and the flask placed 
directly into incubator at 37C˚, 5% CO2 for 2 minutes. Microscopically, cells were 
examined to ensure that most of them had ‘rounded up’ and detached from the flask 
surface. Next, 6 ml of complete DMEM medium was added and cells aspirated by 
gently pipetting. Cells were centrifuged at 400g for 10 minutes, the supernatant 
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discarded and the pellet re-suspended in 5 ml complete DMEM medium. The total 
number of cells was counted using a haemocytometer. Depending on how many cells 
were needed, cells were diluted with complete DMEM medium and pipetted into 12-
well plates (2.5 ×10
5 
cells /ml) or T75 flask (2.5 ×10
6
 cells /ml). Subsequently, cells 
were placed in incubator at 37C˚, 5% CO2 for 24h and media was changed. Cells 
were grown until confluent again. 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAES-2B cells were grown at 1× 10
6
 cells/ml in T 25 flask contained complete DMEM for 3 
days. Magnification (40x).  
 
 
2.1.4. Freezing of BEAS-2B cells 
 
Culture medium was removed and cells washed twice with sterile PBS. Cells were 
dissociated with trypsin, placed in 5-10 ml media and transferred into sterile 
centrifuge tube and centrifuged at 400g for 10 minutes, the supernatant discarded 
and the pellet re-suspended in 1 ml complete DMEM. Next, cells were counted and 
viability estimated by trypan blue (SIGMA, Cat# T6146) exclusion. Viability should 
be over 90% to ensure cells are healthy enough for freezing. Cells were then 
centrifuged again at 400g for 5 minutes and medium removed. Subsequently, they 
were re-suspend in cell freezing medium (SIGMA, cat# C6164) at a concentration of 
1x10
6
 cells per ml, cells mixed and aliquots of 1 ml placed into storage cryovials. 
Cells were transferred immediately to -20°C for one hour, followed by -80°C 
overnight before long term storage in liquid nitrogen. 
 
 
 
 
Figure 2.1. Light microscope image of BEAS-2B cells confluent 80% 
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2.1.5. Stimulation of BEAS-2B cells with cytokines  
 
1.5 × 10
4
 BEAS-2B cells /ml were seeded with DMEM complete medium in 12-well 
plates. Cells at 70%  confluence, were treated with cytokines (200ng/ml) including 
IFN-α (PEPROTECH, cat#300-02A), IFN-β (PEPROTECH, cat#300-02BC), IL- β 
(PEPROTECH, cat#200-01B) dsRNA (Invivogen,cat#tlrl-pic) and  LPS (SIGMA, 
cat#L2630) for 0, 3, 6, 12, 24 and 48h. Supernatants and RNA were collected and 
analyzed for protein and mRNA expression respectively. 
 
2.1.6. Concentration of supernatants 
 
BEAS-2B cells were plated at 1x10
6
 cells per ml in T25 flask until about 80% 
confluent. DMEM media was removed and cells washed twice with media free from 
serum and antibiotics. 2.5ml supplement free media were added to flask. BEAS-2B 
cells were infected with RSV at a multiplicity of infection (MOI= 1 PFU/cell), and 
non-infected cells used as control. Cells were rocked gently for two hours at 37°C. 
2.5 ml complete DMEM media were added and incubated at 37°C for 48h. The 
supernatant of BEAS-2B cells was concentrated using Centriplus YM-10 filter 
(Millipore).  
2.1.7. Neutralization of IFN-β 
 
In order to determine if BAFF expression was directly induced by RSV infection or 
if it was indirectly dependent on interferon β production by RSV infected cells, 
BAFF expression in BAES-2B cells was compared in the presence or absence of an 
anti-interferon β-neutralising antibody (eBioscience, UK, cat# 16-9978, 
concentration =1 mg/ml ). 5 μl of anti-interferon β-neutralising antibody (20 μg/mL) 
was added into BEAS-2B cells cultured into 96-well plate at 2 x 10
4
 cells/ml. 
Expression of mRNA BAFF was measured by RT-PCR after 12h of RSV infection. 
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2.1. 8. Inhibition of furin convertase 
In order to determine if the mechanism of BAFF cleavage is furin like protease 
dependent BEAS-2B cells were infected with RSV at MOI =1 and incubated with 
(50 or 100 μM) furin convertase inhibitor (chloromethylketone) (Enzo, cat# Alx-
260-022-M001) added at time 6h after RSV infection for 24h or 48h. To further 
understand the mechanism of BAFF cleavage, BEAS-2B cells infected with RSV or 
stimulated with IFN-β were incubated with Brefeldin A (1:100) (eBioscience, 
cat#00-4506-51) after RSV infection of 6hours for 24 and 48h. 
2.2: Isolation of Human lymphocytes 
Human lymphocyte cells were prepared from the peripheral blood of healthy 
laboratory donors after obtaining informed consent and with the approval of the 
Liverpool Research Ethics Committee (LREC 2K/175). Lymphocytes were isolated 
from the peripheral blood by firstly adding an equal volume of Ficoll-Paque 
PREMIUM (GE Healthcare Life Sciences, UK, cat# 17-5442-02) to 20 ml blood 
followed by centrifugation, 400g for 30min at room temperature. The centrifuge was 
run with the brake off in order to achieve better separation. This method relies on 
density gradient for separation. After centrifugation, two layers were formed, the 
interface layer (containing lymphocytes) was collected and cells washed twice with 
sterile PBS contain 0.02% BSA. Cells were re-suspended in 1ml of RPMI complete 
medium (RPMI-1640, SIGMA, cat# R8758) plus 0.02% BSA and purified cells 
counted (normally 2.5×10
7
 cells /in 20 ml blood). 
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2.2.1. Purification of Human B cells 
 
Human peripheral bloods were obtained from healthy donors. The PBMC were 
isolated using Ficoll separation method. From the lymphocyte layers, B cells were 
purified using human B cell enrichment kit (STEMCELL, cat#19054). Briefly, 
lymphocytes were suspended at a concentration of 5×10
7 
cells/ml in 2ml of RPMI 
media and transferred into a polystyrene tube (BD Bioscinences, cat#352057). 2ml 
of the human B cells enrichment kit was added to the cells and incubated at room 
temperature for 10 minutes. After that, 2 ml of magnetic particles were added to cell 
suspension and incubated at room temperature for 5 minutes. Then, 3ml of RPMI 
media was added to the cell suspension and the cell suspension tube placed into 
magnet for 5 minutes. After that, desired cells were poured off into new tube, 
whereas unwanted cells remain bound in the original tube by the magnetic field. B 
cells were re-suspended in PBS containing 0.02% BSA to block non-specific 
antibody binding and stained with B cells marker anti-CD19 (Cat#560993, BD 
Pharmingen
TM)
 for 30 min in the dark at 4°C. Then B cells were gated and analyzed 
with a BD FACS (BD Biosciences).The purity of the B cells was assessed by FACS 
to be >99% (Figure 2.2). 
 
 
                                                                                  
 
  
   CD 19   before purification (36.6 %)                                          CD19 after purification (99.9 %) 
 
B cells were isolated and stained with anti-CD19 and the purity assessed by FACS. In (A) 
dot blot and histogram represent CD19 from
 
normal B cells before purification .In (B) dot 
blot and histogram represent expression of CD19
 
normal B cells after purification. In (A) 
the percentage of CD19 cells before purification was (36.6) and in (B) after purification was 
(99.9) .The purity was >99.9%. 
 
 
A B 
Figure 2.2. Isolation and  purification of human B cells from the peripheral blood 
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2.2.2. Measurement of Cell Number by haemocytometer 
 
10 µl of a re-suspended cell pellet was mixed with 10 µl trypan blue to count the 
viable cells that are not stained and dead cells which can be stained with it. A 
volume of 10 µl of mixed cells suspension was added into the haemocytometer slide. 
Then, cells were counted in each of the four large quarters multiplied by 2 and 
divided by 4 and multiplied by 10
5 
and the total cell number calculated taking into 
account the volume. 
2. 3: Animals 
 
2.3.1. Experiment design  
 
All experiments involving animals were carried out by Prof Jurgen Schwatze and 
Miss Amanda McFarlane working at Queens Medical Research Institute at the 
University of Edinburgh. All studies were conducted in accordance with Home 
office procedures for animal experimentation and Prof Schwarze holds ethical 
committee approval for the studies at the University of Edinburgh. BALB/c mice 
were maintained under specific-pathogen-free conditions. All mice were 8 weeks of 
age and anesthetized and then infected intranasally (i.n.) with RSV A2 (2×10
6 
PFU 
in 0.1ml) or UV treated RSV or PBS. 
Kindly, three groups of RSV mice were provided for the experiments. The first set of 
experiments includes day 0, 1, 2, 4 and 7 days. The second group consists of day 0, 
1, 2, 4, 6 ,7 and 8 days and the third group includes day 0, 1, 2, 4, 7, 10, 14, 21days. 
At day 0 mice were given PBS and for each day on which samples were collected, 
three mice were infected with RSV, whereas three mouse where infected with RSV 
which had been inactivated by UV treatment as a further control. 
After collection, lungs were divided into 3 parts, left upper lobe to study protein, left 
lower lobe for mRNA preparation and the whole right lungs to study the frozen 
sections.  
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2.3.2. Measurement of the total protein concentration (BCA) 
2.3.2.1. Principle 
 
Bicinchoninic acid assay is a colorometric assay used for determining the total 
concentration of protein in a sample (range from 0-2000 µg/mL). The total protein 
concentration is shown by a colour change of the sample solution from green to 
purple in proportion to protein concentration, which can then be measured using a 
plate reader. The principle of this method relies on two reactions. The protein present 
in the sample reduces from Cu+2 to Cu+1, and it then can react with bicinchoninic 
acid forming purple-coloured products and the optical density measured. 
 
2.3.2.2. Preparation of protein standard 
A seven point standard curve using 2-fold serial dilutions in sterile distilled water 
was prepared and a high standard of 2000 µg/mL and blank well applied as control 
(Thermo scientific, cat#23209). 
 
2.3.2.3. Preparation of reagent solution 
 
The working reagent was made up to 1:50 dilution, 1 parts B (blue/green) (Thermo 
scientific, cat#1859078) and 50 part A (colourless) (Thermo scientific, cat#23221). 
 
2.3.2.4. Preparation of plate 
 
25µL of each standard or unknown sample was pipetted in duplicate into a 
microplate well. Samples were diluted in sterile distilled water (23l water+ 2l 
sample = 1:12.5 dilution). Subsequently, 200µL of reagent solution was added to 
each well. The plate was mixed thoroughly on a plate shaker for 30 seconds then 
covered and incubated at 37°C for 30 minutes before cooling to room temperature. 
The absorbance was measured at 540 nm on a plate reader. 
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2.3.2.5. Calculation 
 
                                     
                          
                                  
   
2.4. RNA Extraction and Isolation  
 
2.4.1. RNeasy Mini kit 
Extraction of RNA should be done under clean and sterile conditions. Total RNA 
was extracted from BEAS-2B or mouse lung (Left Lower Lope) using RNeasy Mini 
kit according to the manufacturer’s instructions (QIAGEN, cat#74104). This product 
combines the selective binding properties of a silica-based membrane with the speed 
of microspin technology. A specialized high-salt buffer system allows up to 100 μg 
of RNA longer than 200 bases to bind to the RNeasy silica membrane. To enhance 
RNA extraction, β-mercaptoethanol (SIGMA, cat# 60-24-2) was added to the lysing 
buffer RLT (100 µl+9990 µl) which contains the denaturant guanidine-thiocyanate. 
This inactivates RNases to ensure purification of intact RNA. Briefly, 500µl of lysis 
buffer RLT was added into each well of 12–well plate that had about 2.5×105 cells. 
Cells were mixed well and transferred into autoclaved eppendorf tubes. Next, 300µl 
of 70 % sterile ethanol was added to the homogenised lysate in each tube, mixed and 
placed into RNeasy Mini column. This aimed to provide appropriate binding 
conditions. Tubes were centrifuged at full speed for 15 sec. After that, collection 
tubes were discarded and 700 µl of wash buffer RWI was added and centrifuged at 
full speed for 15 sec. Subsequently, cells were washed twice with 500 µl of RPE for 
15 sec and for two minutes. Next, the collection tubes were removed and replaced 
with new tubes. RNeasy Mini columns were centrifuged at full speed for two 
minutes. Finally, 50 µl of free DNAse /RNAse free water were added into each tube 
for one minute at room temperature. The total RNA was collected by centrifuging 
the Mini column into sterile eppendrof tubes. In order to determine the yield and 
concentration of RNA the concentration of total RNA was measured by NaNoDrop 
(Biotech International). 
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2. 4.2. Reverse Transcription 
 
The cDNA single-strand was synthesized with SuperScript II reverse transcriptase 
and random primers (A&B applied biosystem, cat#4368814). The following 
components were added to each 10 µl of RNA for each sample to be reverse 
transcribed: 
 
1.10X RT Buffer (2 µl) 
2. 25X dNTP Mix (100mM) (2 µl) 
3. 10X RT Random Primers (2 µl) 
4. Free RNA/DNA water (3µl) 
5. MultiscribeTM Reverse Transcriptase (1µl) 
 
Samples were then left in a water bath at 37°C for one hour. Once synthesized the 
cDNA was stored at -20
o
C until further required for PCR and then diluted with 
nuclease-free water, depending on how much cDNA was needed (typically 80µl of 
free DNA RNA water was added into each sample). 
 
 
2.4. 3. Real-Time Polymerase Chain Reaction (RT-PCR) 
 
 
TaqMan real-time RT-PCR was performed using an Applied Biosystems 7500 
Sequence Detection System in 25µl reactions. The TaqMan® probes (Table 2.1) 
were added into TaqMan® gene expression master mix (Applied Biosystems, 
cat#4369016), which contains the DNA polymerase. 13.75µl of probes mixed with 
master mix were pipetted into each well of 96-well plate. Samples of cDNA 
(11.25µl) were added into each well to give a final volume of 25µl. Each sample was 
prepared in duplicate. The plate was sealed with a cover and gently centrifuged for 
10 seconds. Finally, PCR plate was placed into the PCR machine for 2-3 hours 
according to the number of cycles entered. 
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2.4.4. Principle of PCR 
 
The main aim of this technique is to amplify specific target of DNA. PCR involves 
three essential steps including:  
1.    Denaturing: At 95C, dsDNA is separated to yield single stranded DNA. 
2. Annealing: At 40C- 65C, primers bind the single target DNA 
3. Extending: At 72C , DNA polymerase extends the primers  
The RT-PCR is standard PCR with the advantage of detecting the amount of DNA 
formed at the early phases of the reaction. 
There are three phases (Figure 2.3) in total throughout the PCR amplification: 
1. Exponential: The product at this phase has exactly doubling of products at every 
cycle and the efficiency of this reaction is 100%. During this phase the Real-Time 
PCR quantifies the amplicons. 
2. Linear: reaction’s components reduce due to being consumed during the reaction 
3. Plateau: Reaction stops and no more products are being made. 
The threshold cycle (Ct) is the point between an amplification curve and the 
threshold line, where fluorescent signal is detected. This line is set during the 
exponential phase. Once the sample reaches this level, the cycle number is quantified 
and measure of the concentration of target in the PCR reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. RT-PCR amplification curve of data analysed 
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TaqMan® probes Human Murine 
MRPL32 Hs00388301_m1 Mm00503378_m1 
APRIL Hs00182565_m1 Mm03809849_s1 
BAFF Hs00198106_m1 Mm00446347_m1 
CXCL13 Hs00757930_m1 Mm00444533_m1 
CCL19 Hs00171149_m1 Mm00839967_g1 
CCL21 Hs00989654_g1 Mm03646971_gh 
CXCL12 Hs00930455_a1  
RSV  N 30 µl RSVn+10 µl RSV R + 10 µl RSV F +50 µl clean 
water. 
 
Three primers, RSVAF (forward) 1µM, RSVAR 
(reverse) 1µM and RSVN-TAQ (10uM), were obtained 
individually and prepared. RSVAF and RSVAR primers 
were mixed together with Nuclease-free water in a 1 in 
10 dilution. RSVN-TAQ was diluted 1 in 10 separately, 
with Nuclease-free water. (Dewhurst-Maridor et al. 
2004)
 
Table 2.1.TaqMan® Gene Expression Assay Product Number (Life technologies). 
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2.4.4.1 Analysing RT-PCR Data 
 
The following steps were used to analyse the RT-PCR data: 
1) All Ct values of the samples were averaged  
2)  The Ct value of samples for each probes were corrected to the house keeping 
gene L32  
For example: The L32 expression - BAFF. This produced a Ct value relative 
to L32 expression. 
3) Corrected to relative control by taking the Ct value produced in step 2 minus 
the cycle value for the relative control (non-stimulated cells).  
4) Fold expression in comparison to L32. This can be calculated by 2 to the power 
of n, where n = value determined in step 2. This calculation converts the value from 
a Ct number to the fold difference. This particular calculation is because every 
cycle is a 2 times increase during the exponential phase.    
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2.5. Enzyme-Linked ImmunoSorbant Assay (ELISA) 
2.5.1. Principle  
The main purpose of using an ELISA method is to determine if a particular protein is 
present or not in the sample of interest and if so, how much by its concentration. 
This method can be done in two ways termed direct and indirect Sandwich ELISA. 
This method has been used to find out protein concentration in BEAS-2B cells 
culture supernatant and homogenised mouse lung tissue. 
2.5.2. Plate Preparation 
 
The capture Antibody was diluted to the working concentration in PBS without 
carrier protein and 96- well plate coated with 100 µl per well of the diluted antibody. 
Plates were sealed and incubated overnight at room temperature. Then, the plate was 
washed with the wash buffer (0.05% Tween-20 in PBS (400 µl) by use the auto 
washer (ELx50 Microplate Strip Washer-Bio-Tek) for total of three times and 
ensured that removing any remaining wash buffer by aspirating or by inverting the 
plate and blotting it against clean paper towels. Plate was blocked with Reagent 
Diluent, 1% BSA (SIGMA, cat#A7030) in PBS, by adding 300 µl for one hour at 
room temperature and the plate washed three times with wash buffer. 
 
 
2.5.3. Sample preparation  
 
Human BAFF and chemokines including CXCL13, CCL19 and CCL21 were 
measured in the culture supernatants of BEAS-2B cells. In mouse lung the left upper 
lobe was homogenised in 2 ml of PBS+ protease inhibitors. BAFF, CXCL12, 
CXCL13, CCL19 and CCL21 were measured in the homogenised tissue supernatants 
(Table 2.2) 
 
 
 
 
 
76 
 
 
Human Lower limit of 
detection (pg/ml) 
Murine  Lower limit of 
detection (pg/ml) 
BAFF (R&D Systems, 
cat#DBLYSOB) 
 
5 
BAFF 
(cat#MBLYS0, 
R&D Systems) 
 
47 
CXCL13 (R&D 
Systems#DY801) 
 
16 
CXCL13 (R&D 
Systems,cat#DY
470) 
 
16 
CCL19  (R&D 
Systems cat#DY361) 
 
16 
CCL19 
(cat#DY440, 
R&D Systems) 
 
16 
CCL21 (R&D Systems 
,cat#DY366) 
 
31.25 
CCL21 
(cat#DY457, 
R&D Systems) 
 
16 
 
 
  
CXCL12 (cat#) 
DY460 
 
47 
                              Table 2.2: Human and murine ELISA number of product. 
 
 
2.5.4. Preparation of standard 
 
A seven point standard curve using 2-fold serial dilutions in Reagent Diluent was 
prepared. A high standard of 1000 pg/ml is recommended for mouse CXCL13, 
CCL19 and CCL21, whereas 3000 pg/ml was recommended for CXCL12. For the 
human cytokine ELISA assays a high standard of 1000 pg/ml is recommended for 
CXCL 13 and CCL19, whereas 4000 pg/ml was recommended for CCL21. The 
standard curve was calculated using a computer programme (KC Junior) generating 
a four parameter logistic (4-PL) curve-fit. 
 
 
2.5.5. Assay Procedure 
 
A total volume of 100µl/sample or standards in Reagent Diluent per well was added 
to the plate, previously coated with capture antibody and blocked with BSA. Then, 
the plate was covered with an adhesive strip and incubated for 2 hours at room 
temperature. The plate was then washed three times with the wash buffer (0.05 % 
tween 20 in PBS). After that, 100µl of the detection antibody diluted in Reagent 
Diluent (1% BSA in PBS) were added per well and the plate incubated for two hours 
at room temperature. Then, the plate was washed three times with the wash buffer. 
Next, 100 µl of the working dilution of Streptavidin-HRP diluted in reagent diluent 
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(1:200) was added to each well and incubated for 20 minutes at room temperature 
without light.. Plates were then washed three times with the wash buffer. 100 µl of 
substrate solution (TMB Substrate solution, Thermo scientific, cat# N301 Solution) was 
added to each well and incubated for 20 minutes at room temperature in dark 
condition and monitored the development of the colour. 50 µl of Stop Solution 
(H2SO4) was added to each well (the colour changes from blue to yellow). The 
optical density (OD) of each well was determined using a microplate reader (BioTek 
ELx800 Absorbance Microplate Readers) set to 450 nm. KC Junior software was 
used to find out the concentration. 
2. 6. RSV A2 preparation  
The main aim of preparation of RSV is to ensure that we have enough stock to 
achieve infection. The following steps described the propagation of RSV A2 in the 
laboratory. 
2. 6.1. RSV propagation 
 
Hep2 cells were seeded in a T75 flask at 30,000 cells/cm2 in a total volume of 15ml 
of DMEM plus 10% FCS, and grown for 24h at 37°C in 5% until 50% confluent. 
Media removed and cells washed twice with sterile PBS. RSV A2 stock was placed 
in 4ml of FCS-free medium and added to Hep-2 monolayers cells. To ensure 
infection over the whole flask they were rocked gently for two hours at 37C. Then, 
11ml of media was added and the flask left overnight in the incubator. After 24hours, 
11 ml of media was removed and replaced with DMEM plus (2% FCS total). Cells 
were assessed daily for cytopathic effect (e.g. dead cells floating, until the cytopathic 
effect reached approximately 50%, typically 48h. The monolayer was then harvested 
using a cell scraper, and centrifuged at 400g for 5 minutes in precooled centrifuge at 
4°C and lysed on ice by use of 1-2ml syringe and needle (25 gauge). Aliquots were 
snap frozen and stored at −80°C. 
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2. 6.2. RSV Plaque assay 
 
RSV titre was determined using a modified plaque-forming unit assay. Briefly, the 
virus was serially diluted and added to A549 cell monolayers containing about 2 x 
10
4
 cells/ml grown in 96-well plates (total volume 50 μl). The cells were incubated 
for 24h before being fixed in methanol and stained with an anti-RSV biotinylated 
antibody goat anti-RSV, AbD Serotec (Oxford, cat #7950-0104, UK) labelled using 
an extravidin peroxidise colour development substrate (Sigma Fast-Red, Sigma-
Aldrich). Plaques were visualized using light microscopy and counted (Figure 2.4). 
Plaque forming units (PFU) were calculated as: number of plaques/ml × dilution 
factor × 20 (for 50 μl culture volume).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
’Plaque’ of RSV +ve cells (dark brown) as indicated by arrows were formed after staining 
with an anti-RSV biotinylated antibody goat anti-RSV, labelled using an extravidin 
peroxidise colour development substrate. 
 
 
 
 
 
Figure 2.4. Light microscopy image of A549 cells after RSV infection 
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2. 7. RSV infection of BEAS-2B cells 
 
BEAS-2B cells were grown in 12 wells plates until about 80% confluent. DMEM 
media was removed and cells washed twice with media free from serum and 
antibiotics. 250µl supplied free media were added to each well. Confluent monolayer 
cultures of BEAS-2B cells were infected with RSV at a multiplicity of infection 
(MOI= 0.025, 0.25, 1 and 2.5 PFU/cell), and non -infected cells used as control. 
Then cells rocked gently for two hours at 37ºC. 250 µl complete DMEM media was 
added and incubated at 37ºC at different time points, including 0, 3, 6, 12, 24, 48h.  
2. 8. Immunofluorescence staining assay 
 
2. 8. 1. Coated glass microscopy slides with ploy-l-lysine  
 
Microscopy slides were coated with poly-L-lysine (Sigma, UK cat#P8920) diluted in 
distilled water (1:10) for 5 minutes. Slides were then air dried at room temperature 
overnight. This aids in the adhesion of tissue sections to slides.   
2. 8.2. Preparation and cutting of tissue for frozen sections (Cryostat) 
Mouse tissues, lungs and spleen, were embedded into frozen media immediately 
after extraction and stored at -80 C. This media was used to keep the tissue fresh and 
well structured. An area of around 1 square centimeter of each specimen was cut 
using a scalpel and placed onto a metal tissue disc which was then secured in a 
cryostat chuck. Frozen tissue support media (Bright, UK, and cat #53581-1) was 
rapidly added and samples cooled at –20 to –30°C for 20minutes. Subsequently, the 
frozen tissue block was attached to the cryostat. The tissue block allowed to 
equilibrate to the cryostat temperature (-20°C) before cutting sections. Sections were 
cut at 10 microns thick and picked up onto coated slides. During cutting sections the 
surface temperature of tissue might change, and can be cooled using cryospray 
(Bright, UK, cat#57713-1) to enhance the efficiency of cutting. Tissue sections were 
air dried at room temperature for 20 minutes until sections are firmly adhered to the 
slide. After that, tissues were fixed with pre-cooled acetone 100 % (4°C) for 10 
minutes, before air dying for 20 min at room temperature. Slides were stored at -
80°C for further use. 
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2. 8.3. Immunostaining of frozen tissue sections 
  
Slides were rehydrated in PBS for 3 min. Non-specific binding of antibodies was 
blocked with blocking buffer (5 % Milk in PBS), and sections incubated in a 
humidified chamber at room temperature for 1h, then washed twice with PBS 
plus1% Tween 20 for 2 changes, 5 min each. Following that, tissue sections were 
incubated with appropriately diluted primary antibody in blocking buffer (Table 2.3), 
and incubated in a humidified chamber for 1h at room temperature. Subsequently, 
sections were washed twice with PBS plus1% Tween 20 for 2 changes, 5 min each. 
Tissue sections were incubated with appropriately diluted secondary antibody in 
blocking buffer (Table 2.3) and incubated in a humidified chamber for 1h at room 
temperature. Then, sections were washed twice with PBS plus1% Tween 20 for 2 
changes, 5 min each. DAPI stain (1:10000 in PBS) (SIGMA, cat#D8417) was added 
for 3 minutes. Slides were rinsed with PBS plus Tween 20 for 5 min, followed by 
adding one drop of mounting media (R&D, UK, and cat #NL996); afterwards slides 
were covered with a coverslip and sealed with one drop of nail varnish. Eventually, 
tissue sections were examined under the confocal microscope (LEICA DM 2500).  
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Primary antibodies and their Isotypes Secondary antibodies 
Rat anti-BAFF -FITC(Abcam ,ca#16082) (1 mg /ml) used 
at 1:50 
Isotype: Rat IgM, kappa monoclonal [RTK2118] (FITC) 
(Abcam, -cat#ab35774) (0.5 mg/ml ) used at 1:25  
   
Direct labelling  
Rat  monoclonal to CD20 [AISB12] 
(Abcam,cat#ab171203) 
 ( 1 mg/ml) used at 1:100 
Isotype:Rat IgG2A  (R&D cat#MAB006) (0.5 mg /ml) 
 used at 1:50 
Donkey anti-Rat   1 mg /ml  used at (1:200) 
R&D (cat#NL013) 
Rat anti-CD3 MAb (Clone 17A2), IgG2B 
 (R&D ,cat # MAB4841) (0.5mg /ml)  used at 1:50 
Isotype: Rat IgG2B Isotype Control (Clone 141945), Rat 
IgG2B  
R&D (Cat # MAB0061)(0.5mg /ml)  used at 1:50 
 
Goat Anti-Rat IgG NL493 Affinity Purified PAb 
R&D (Cat # NL015)  1 mg /ml  used at (1:200) 
Anti–mouse CXCL13 (R&D ,cat#AF470) (0.2 mg/ml) used 
at 1:15 
Isotype: Normal Goat IgG Control, Goat IgG ( 1 mg/ml) 
 (R&D ,cat# AB-108-C)  
Donkey anti- goat R&D (cat#NL001) 1 mg /ml  
used at (1:200) 
 
Goat anti- RSV  (Abcam ,cat#ab20745)  (4 mg/ml) used 
at 1:100 
Isotype: Normal Goat IgG Control, Goat IgG 
(R&D, cat# AB-108-C) (1 mg /ml)  used at  (1:30) 
Donkey anti- goat R&D (cat#NL001) 1 mg /ml  
used at (1:200) 
 
Table 2.3. List of primary and secondary antibodies with their isotype controls used in 
Immunofluorescence Staining. 
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2. 9. MTT assay  
The MTT assay is a colorimetric assay used to assess cell viability. MTT is a yellow 
tetrazolium salt which is reduced to purple formazan by mitochondrial activity of 
living cells.
 
The formazan crystals are then solubilized, and the concentration 
determined by optical density which reflects the cell viability. For the analysis of the 
biological activity of secreted BAFF by the epithelial cells, BEAS-2B cells were 
cultured in complete DMEM medium and then infected with RSV A2 at MOI 1 for 
48h. The supernatant was concentrated using centriplus YM-10 (Millipore, 
cat#43040). Purified B cells were cultured at a density of 2 × 10
5
 cells/100 μl/well of 
a 96-well flat-bottom microtitre plate in RPMI 1640 (SIGMA,cat#R5886) 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. 
Media alone, B cells, B cells plus 10 ng/ml rBAFF (R&D, cat# 2149-BF-010) and B 
cells plus 1: 20 of concentrated supernatant of epithelial cells infected with RSV for 
48h and incubated for 5 days. To detect intracellular enzyme activity, 20 μl of MTT 
reagent (SIGMA, cat#Tox1) was added for the last 4 h of incubation. After 4h, 100 
μl of detergent reagent (SIGMA, cat#Tox1) was added to all wells. Cells were mixed 
very well and the plate placed in microtitre plate reader. Absorbance at 540nm was 
measured. All the samples were done in triplicate by taking the average of three 
readings.  
2. 10. Western blot analysis 
Western blot was used to determine the molecular weight of the specific protein of 
interest such as BAFF, and to also to investigate the forms, including membrane 
bound and soluble that airway epithelial cells can express following RSV infection 
both in vitro and in vivo. Briefly, a mixture of proteins is separated based on their 
molecular weight. The proteins are separated through gel electrophoresis and then 
transferred into a membrane, where a band for each protein can be detected after 
incubated with specific antibodies to the protein of interest, which also can be 
visualized by developing the film.  
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2. 10.1. Sample preparation  
 
BEAS-2B cells were plated into 24-well plate 2.5×10
6 
 cells/ml. Media was removed 
and the cells were disrupted by cell scraper. Cells were washed with PBS, the pellet 
lysed with SDS buffer containing 10% DTT and protease inhibitors (1:100). Mouse 
lung tissues were homogenised and then lysed in 100 µl of SDS plus 10 µl of 10% 
DTT and 2 µl of protease inhibiters. 
 
2. 10.2. Gel electrophoresis 
BEAS-2B cells and mouse lungs tissue were denatured by boiling for 3min at 100°C. 
Thereafter, samples and ladder (Biorad, UK, cat#161-0373) (10µl) were loaded into 
the gel placed in the electrophoresis apparatus containing the running buffer. Proteins 
were always separated using 12% precast gel (Bio-Rad .UK, Cat#456-1046) at voltage 
140 (Bio-Rad power supply, 1000/500) for 1h. 
 
2. 10.3. Transfer blot 
Proteins were transferred onto nitrocellulose membranes (Biorad, UK, cat#170-
4156) by using a transfer system (trans-blot turbo, Biorad, UK) for 7 minutes. 
Following transfer, the membranes were blocked with 5% skim milk in Tris-buffered 
saline with Tween 20 (TBST) for  half an hour and then washed with 1%TBST and 
incubated with the primary antibody rat anti BAFF (1:1000) (ab16081) for overnight 
at 4°C. Membranes were then washed for 30 minutes with 1% TBST and then 
incubated with HRP-conjugated secondary antibodies (1:20,000) (ab98373) for 1 
hour at room temperature. After that, the membrane was washed for 30 minutes 
with1%TBST. Then, the membrane was placed into cling film and incubated with 
ECL (GE healthcare, cat#RPN2232) for 5 minutes and then placed in the 
hypercassette. 
2. 10.4. Detection 
 
A dark room was used when developing the film. Briefly, the film (GE healthcare, 
UK, cat# 28-9068-35) was exposed to the membrane inside the hypercassette 
(Amersham Biosciences). Then, the film was placed into the developer, water and 
fixer respectively. 
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2. 10.5. Adding - actin 
 
- actin was used as control to see how much of protein was loaded into each lane. 
Membranes were blocked with 5% marvel for half hour and then incubated with 
appropriate diluted primary antibody in blocking buffer for one hour at room 
temperature. Next, membranes were washed with 1% TBST for 1 min, 3 min, 10 
min, 5 min, and 5 min. After that, the membrane was incubated with appropriately 
diluted secondary antibody in blocking buffer for one hour at room temperature 
(Table 2.4). Next, membranes were washed with 1% TBST for 1 min, 3 min, 10 min, 
5 min, and 5 min as the same method mentioned above. 
 
 Primary Ab Secondary Ab 
Human Anti-beta Actin 
(Abcam, cat#ab8226) used 
at (1:1000) 
Goat Anti-Mouse IgG HRP 
Affinity Purified PAb, Goat IgG 
(HAF007,R&D) used at (1:1000) 
Mouse Anti-Actin ,ab produced in 
rabbit (1:1000) 
(SIGMA,cat#A2668) 
Goat anti rabbit–HRP  (1:20,000) 
(SIGMA,A0545) 
Table 2.4. Human and mouse primary and secondary antibodies used for -actin. 
 
2. 11. Flow cytometery 
 
This technology measure emission of fluorochrome molecules to generate specific 
multi-parameter data from particles and cells as they flow in a fluid stream through a 
beam of light (laser). Fresh lung tissue from mice either RSV infected or challenged 
with UV treated RSV was disrupted mechanically and cells washed in PBS. Cells 
were stained using anti-B220 (ebiosciences, cat#48-0452-82) and anti-CD19 
antibodies (Biolegend, cat no 115522). B cells numbers were counted by BD FACS 
Calibur™. This work was kindly done by Dr A McFarlane in Edinburgh. 
2.12. List of reagents and solutions  
 
     TBS 10x (concentrated TBS) 
a. 20mM 24.228 g Tris 
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b. 150mM 87.66 g NaCl 
c. Mix up to 1000 ml distilled water. 
d. pH to 7.5 with conc HCl. 
    To prepare TBS-T x1 in 1 litre 
            100 ml of TBS 10x + 900 ml distilled water + 1ml Tween20 
     Bromophenol blue lysis buffer (SDS) 
a. 10% glycerol (10ml) 
b. 125mM TRIS buffer (pH 6.8) (12.5ml) 
c. 3% SDS (3ml of 10% SDS or 3g) 
d. 0.2% bromophenol blue (a few grains)                     
e. Make up to 90ml with distilled water 
     Phosphate buffered saline (PBS) 
One pack of phosphate buffered saline PBS (SIGMA, cat#P3813) was 
dissolved in (1) litre distilled water. The PBS was autoclaved if required 
sterile.  
     Running buffer 
a. Tris Base 3.03 g 
b. Glycine 14.4 g 
c. SDS 1g 
d. Make up to1 litre with distilled water 
2.13. Statistical Analysis 
 
In chapter three, data was expressed as mean ± SEM and one way ANOVA test 
followed with Bonferroni post-hoc test used to calculate the statistical significance. 
In chapter four and five, data was expressed as mean ± of standard deviation (SD) 
and the two way ANOVA followed with Bonferroni post-hoc test was used to 
calculate statistical significance. GraphPad Prism 5.0 software was used to find out 
the stats. P-values indicate significance. (* for p<0.05, ** for p<0.001 and *** for 
p<0.0001). The software (KC Junior) was used to find out the ELISA protein 
concentration. 
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CHAPTER 3. IN VITRO, INDUCTION OF BAFF AND APRIL EXPRESSION 
BY RSV INFECTION OR CYTOKINE STIMULATION IN CULTURED 
HUMAN AIRWAY EPITHELIAL BEAS-2B CELLS  
3.1 Aims 
 
BAFF expression both in BAL samples and by primary airway epithelial cells during 
acute human RSV infection has previously been demonstrated (McNamara et al. 
2013). To begin to understand the potential role of the airway epithelium to support a 
B cell response by production of BAFF and APRIL (chapter 1, sections 1.2.1 and 
1.2.2) airway epithelium cell line BEAS-2B was used. The works described in this 
chapter aimed to: 
1- Characterize expression of BAFF and APRIL by cultured BEAS-2B airway 
epithelial cells, stimulated either by RSV infection or cytokine.  
2- Examine what form or forms of BAFF epithelial cells express after RSV 
infection and the mechanisms regulating expression.  
3- Determine if BAFF derived from BEAS-2B cells has functional activity on B 
cell survival. 
4- Establish if epithelial cells have the potential to support adaptive immune 
responses by expression of homeostatic chemokines, including, CXCL13, 
CCL19, CCL21 and CXCL12 (chapter 1, section 1.4). 
3.2. Results 
 
3.2.1. RSV N gene RNA is detected after RSV infection of BEAS-2B cells 
 
BEAS-2B cells were grown on 12-well plates until 80% confluent. Cultures of 
BEAS-2B cells were infected with RSV at a multiplicity of infection (MOI) of 
0.025, 0.25 and 2.5 PFU/cell, with non-infected cells used as control for 12h. To 
confirm that BEAS-2B cells were infected with RSV, RNA was prepared and RSV 
N gene measured by RT-PCR (chapter 2, table 2.4). RSV N gene expression was 
measured by RT-PCR (table 3.1). There was no RSV N RNA in non-infected control 
cultures. However, after RSV infection (Figure 3.2.1), RSV N RNA was induced 
significantly at MOI=0.025 (fold expression relative to L32 = 0.05, P=0.02), MOI 
=0.25 (0.29, P=0.01) and MOI =2.5 (2.31, P=0.02) relative to L32 (Figure 3.1). RSV 
infection of BEAS-2B cells was increased by increase the viral load of MO1. 
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RNA relative to L32 in three separate experiments. 1) all L32 Ct values of the samples 
were averaged, 2) all RSV N probes Ct values were averaged, 3) the CT value of 
samples for RSV N probe were corrected to the house keeping gene L32. For example: 
The L32 expression – RSV N. This produced a Ct value relative to L32 expression, 4) 
Fold expression relative to L32 and this can be calculated by 2 to the power of n, where 
n = value determined in step 3 .This calculation converts the value from a Ct number to 
the fold difference. This particular calculation is because every cycle results in an 
increase in the amount of product two fold. Expression of RSV N RNA in BEAS-2B cells 
post RSV A2 (MOI=1) infection in three independent experiments (ND = not 
determined, Ct =cycle threshold, which is defined as the number of cycles required for 
the fluorescent signal to cross a threshold value).  
 
 
 
 
 
 
1. Average of 
L32 Ct value 
 
2. Average of 
RSV N Ct value 
 
3. L32-RSV N  
(n) 
 
4. Fold expression 
relative to L32(2 to 
the power of n) 
Experiment 1 
Control 21.99 ND ND ND 
RSV infection 
at 
0.025 
25.43 30.28 -4.85 0.03 
 
0.25 
24.50 26.08 -1.57 0.33 
2.5 22.11 21.24 0.87 1.83 
Experiment 2 
Control 22.18 ND ND ND 
RSV infection 
at 
0.025 
25.12 29.15 -4.03 0.06 
0.25 23.81 25.98 -2.17 0.22 
2.5 23.57 22.48 1.08 2.12 
Experiment 3 
Control 22.11 ND ND ND 
RSV infection 
at 
0.025 
24.22 28.34 -4.11 0.05 
0.25 25.42 27.22 -1.79 0.28 
2.5 22.64 21.07 1.57 2.97 
Table 3.1: Summary of steps used to calculate fold expression of RSV N from initial 
RT-PCR values 
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BEAS-2B cells were infected with RSV at different MOI (0.025, 0.25 and 2.5) for 12h (A-C). 
RSV N RNA was induced in a dose dependent manner at each dose. The expression of RSV N 
RNA was increased significantly with increased MOI. Values are shown as fold expression 
in comparison to L32. The average of three independent experiments is shown in (D). (ND = 
not determined). Mean with SEM are shown (one way ANOVA followed with Bonferroni 
post-hoc test, *P <0.05, n=3).  
 
 
 
 
 
A B 
C D 
Figure 3.1. Detection of RSV RNA in BEAS-2B cells by RT-PCR 
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3.2.2. Following RSV infection BEAS-2B cells express BAFF mRNA in time- 
dependent manner 
 
    The influence of RSV infection on expression of BAFF mRNA by cultured airway 
epithelial cells was examined. 80% confluent of BEAS-2B cells were infected with 
RSV (A2 strain) at a multiplicity of infection of 1 (MOI= 1 PFU/cell) at time points, 
including time 0 (non-infected),3, 6, 12, 24, and 48h as described in (chapter 2, 2.7). 
At the time points indicated after RSV infection cell supernatants were removed and 
stored. Cells were isolated and RNA prepared using Qiagen (chapter 2, 2.4). 
Interestingly, BAFF mRNA was expressed consistently in non-infected BEAS-2B 
cells (less than -5 cycles relative to L32) (table 3.2). After RSV infection, BAFF 
mRNA expression was increased significantly at 6h (Fold increase relative to control 
= 9.35, P= 0.06) 12h, (91.05, P=0.04), 24h (48, P= 0.03) and 48h, (5.197, P=0.02) in 
comparison to non-infected control (Figure 3.2). BAFF mRNA expression was 
highest at 12h after RSV infection and declining significantly by 48hours. 
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BEAS-2B cells were infected with RSV A2 at (MOI=1) and BAFF mRNA expression was 
measured in three separate experiments. 1) All L32 Ct values of the samples were averaged, 
2) all BAFF probes Ct values were averaged, 3) the CT value of samples for BAFF probe 
were corrected to the house keeping gene L32. For example: The L32 expression – BAFF. 
This produced a Ct value relative to L32 expression, 4) Corrected to relative control by taking 
the CT value produced in step 3 minus the cycle value for the relative control (unstimulated 
cells). 5) Fold expression relative to L32 and this can be calculated by 2 to the power of n, 
where n = value determined in step 4. This calculation converts the value from a ct number to 
the fold difference. This particular calculation is because every cycle is two fold. (ND = not 
determined, Ct =cycle threshold, which is defined as the number of cycles required for the 
fluorescent signal to cross the threshold).   
 
 
 
 
 
1. Average 
of L32 Ct 
value 
 
2. Average 
of BAFF Ct 
value 
 
3. L32-BAFF 
 
4. Corrected 
to relative 
control (n) 
 
5. Fold expression 
relative to control (2 
to the power of n) 
Experiment 1  
Control 24.35 29.85 -5.50 0 1 
RSV 
infection at 
3h 
24.10 28.29 -4.19 1.30 2.47 
 
6h 
24.21 27.48 -3.27 2.23 4.69 
12h 23.79 22.40 1.39 6.89 119.08 
24h 23.95 23.46 0.49 5.99 63.82 
48h 24.95 28.00 -3.05 2.45 5.47 
Experiment 2  
Control 26.59 34.96 -8.37 0 1 
RSV 
infection at 
3h 
25.08 34.91 -9.83 -1.46 0.36 
6h 26.25 31.08 -4.83 3.54 11.65 
12h 24.74 26.41 -1.67 6.69 103.86 
24h 26.38 29.12 -2.73 5.63 49.71 
48h 26.21 31.97 -5.76 2.61 6.11 
Experiment 3  
Control 27.49 34.37 -6.88 0 1 
RSV 
infection at 
3h 
26.26 34.77 -8.51 -1.62 0.32 
6h 26.76 30.10 -3.33 3.54 11.69 
12h 25.200 26.43 -1.23 5.64 50.20 
24h 28.07 30.02 -1.94 4.93 30.66 
48h 28.14 33.02 -4.88 2.00 4.003 
Table 3.2. Summary of steps used to calculate fold expression of BAFF mRNA from 
initial RT-PCR values 
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BEAS-2B cells were infected with RSV A2 infection (MOI=1) for 0, 3, 6, 12, 24 and 48h. 
BAFF mRNA was measured by RT-PCR in three independent experiments (A-C). BAFF 
mRNA expression was induced significantly in a time –dependent manner, including 3, 6, 12, 
24 and 48hours. Values are shown as fold expression in comparison to non-infected control. 
The average of three results is shown in (D). Mean with SEM are shown (one way ANOVA 
followed with Bonferroni post-hoc test, *P <0.05, n=3).  
 
 
 
 
 
C 
B A 
D 
Figure 3.2. RSV infection of BEAS-2B cells induced BAFF mRNA expression in 
time- dependent manner 
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3.2. 3. RSV infection of BEAS-2B cells results in increased BAFF mRNA 
expression in a dose –dependent manner 
 
To determine the relationship between the level of RSV infection, or MOI of RSV 
infection and BAFF expression, BEAS-2B cells where infected with increasing 
amounts of RSV A2 (Figure 3.3) MOIs of (0.025, 0.25 and 2.5) for 12h. After 
infection the supernatants were removed, RNA prepared from the cells and BAFF 
mRNA expression analysed by RT-PCR. 12h was previously shown to be the 
optimum time point for BAFF mRNA expression (Figure 3.2.2). BAFF expression 
was elevated significantly at an MOI of 0.025 (fold increase 5, P=0.01), MOI of 0.25 
(57, P=0, 01) and MOI of 2.5 (121, P=0.01) in comparison to non-infected control 
(1). BAFF mRNA expression was increased by increasing RSV load. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BEAS-2B cells were infected with various MOI of RSV A2 (0.025, 0.25 and 2.5) for 12h. 
BAFF mRNA expression was measured by RT-PCR. BAFF mRNA was significantly 
increased at each dose of MOI (A-C). Values are shown as fold expression in comparison to 
control. The average of three independent experiments is shown in (D). Mean with SEM are 
shown (one way ANOVA followed with Bonferroni post-hoc test, *P <0.05, n=3).  
A B 
C 
D 
Figure 3 3. RSV infection of BEAS-2B cells induced BAFF mRNA expression in dose- 
dependent manner  
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 3.2.4. RSV infection did not significantly up regulate APRIL mRNA expression  
 
In order to determine if APRIL (Figure 3.4) can be also expressed after RSV 
infection, BEAS-2B cells were infected with different concentrations of RSV (A2) 
(MOI =0.025, 0.25 and 2.5) for 12h, supernatants removed and RNA prepared using 
Qiagen as described in (chapter 2, 2.4). APRIL mRNA expression was analysed by 
RT-PCR. There was no significant increase in expression of APRIL mRNA after 
RSV infection at MOI =0.025 (fold increase 1.07, P=0.4), MOI=0.25 (1.5, P=0.4) 
and MOI=2.5=0.1) in comparison to non-infected control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BEAS-2B cells were infected with RSV at MOI (0.025, 0.25 and 2.5) for 12h. APRIL mRNA 
was measured by RT-PCR. There was no significant increase of APRIL mRNA after RSV 
infection (A-C). Values are shown as fold expression in comparison to time 0 control. The 
average of three independent experiments is shown in (D). Mean with SEM are shown (one 
way ANOVA followed with Bonferroni post-hoc test, *P <0.05, n=3).  
A B 
C 
D 
Figure 3.4. RSV infection of BEAS-2B cells did not significantly increase APRIL 
mRNA expression 
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3.2. 5. RSV infection of BEAS-2B results in increased BAFF protein expression 
in dose dependent manners 
 
To confirm epithelial production of BAFF protein and not only mRNA after RSV 
infection, BAFF protein concentration (Figure 3.5) was measured in cell culture 
supernatants using a specific BAFF ELISA (chapter 2, 2.5). Significant levels of 
soluble BAFF were detected in the culture supernatant after RSV infection with 
different MOI in a dose dependent manner. Production of BAFF protein was 
increased significantly at MOI =0.025 (mean=11, P=0.01), MOI=0.25 (28, P=0.002) 
and MOI=2.5 (42, P=0.02) in comparison to non-infected control. BAFF protein 
levels were increased by increased RSV MOI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BEAS-2B cells were infected with RSV A2 at MOI’s of (0.025, 0.25 and 2.5) for 48h. BEAS-
2B cells cultures supernatant were collected and BAFF protein measured using a specific 
Human BAFF ELISA. BAFF protein levels were increased significantly after RSV infection 
and increased at high MOI (A-C). The average values from these three independent 
experiments are shown in (D). The software (KC Junior software) was used to find out the 
BAFF protein concentration. Mean with SEM are shown (one way ANOVA followed with 
Bonferroni post-hoc test, *P <0.05, n=3).  
A B 
C D 
Figure 3.5. RSV infection of BEAS-2B results in increased BAFF protein expression in 
dose dependent manners 
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3.2.6. Effect of cytokines on the expression of BAFF in BEAS-2B cells 
 
To determine if pro-inflammatory cytokines (Figure 3.6) can induce APRIL or 
BAFF expression BEAS-2B cells were stimulated with the pro-inflammatory 
cytokines IFN-α, IFN-β and IL-1β and also LPS and dsRNA (200 ng /ml) for 12h. 
Among these stimuli, IFN- β was found to significantly induce BAFF mRNA 
expression (fold increase relative to control=177, P=0.01) in comparison to 
unstimulated control (1). Furthermore, there was no significant increase in 
expression of BAFF mRNA after stimulation of BAES-2B cells with IFN-α (18.13, 
P=0.2), IL-1 β (1.3, P=0.7), LPS (2.60, P=0.4), and dsRNA (2.66, P=0.3). 
 
 
 
 
 
 
 
                                                                              
 
 
 
 
 
 
BEAS-2B cells were stimulated with 200 ng/ml dsRNA, IL-1β, ng/ml, IFNα, LPS or IFN-β 
for 12h (A-C). BAFF mRNA was measured by RT-PCR. IFN-β was found to induce 
significant levels of BAFF mRNA. Values are shown as fold expression in comparison to 
control .In (D) results shown are average of three independent experiments. Mean with SEM 
are shown (one way ANOVA followed with Bonferroni post-hoc test, *P <0.05, n=3).  
 
C D 
Figure 3.6. Effect of cytokines on the expression of BAFF mRNA in BEAS-2B cells 
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3.2. 7. IFN-β stimulation of BEAS-2B cells induces BAFF mRNA expression in a 
dose dependent manner  
 
To determine if BAFF expression is increased in a dose dependent manner by IFN-β 
treatment, BEAS-2B cells were incubated with increasing concentrations of IFN-β, 
(1 ng/ml, 5 ng/ml, 10 ng/ml, 100 ng/ml and 200 ng/ml) for 12h. Significant increases 
in levels of BAFF mRNA (Figure 3.7) expression were observed. This increase 
occurred in a dose-dependent manner after stimulation of IFN-β at 1 ng/ml (fold 
increase relative to control= 68, P=0.04), 5 ng/ml (120, P=0.03), 10 ng/ml (150, 
P=0.007), 100 ng/ml (169, P=0.0009) and 200 ng/ml (182, P=0.01) in comparison to 
non-infected control (1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BEAS-2B cells were stimulated various concentrations of IFN-β (1 ng/ml, 5 ng/ml, 10 ng/ml, 
100 ng/ml and 200 ng /ml) for 12h. BAFF mRNA was measured by RT-PCR. BAFF mRNA 
was induced significantly in a dose dependent manner (A-C). Values are shown as fold 
expression relative to control. The average of three independent experiments (D). Mean with 
SEM are shown (one way ANOVA followed with Bonferroni post-hoc test, *P <0.05, n=3).  
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C D 
Figure 3.7. IFN-β stimulation of BEAS-2B cells induces BAFF mRNA expression in a 
dose dependant manner 
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3.2. 8.IFN-β induced BAFF mRNA expression in time –dependent manner 
 
To evaluate the influence of IFN-β stimulation on expression of BAFF mRNA by 
cultured airway epithelial cells BEAS-2B cells were incubated with 200 ng/ml of 
IFN-β, for varying times (Figure 3.8). This concentration was shown previously to 
induce the highest level of BAFF expression for different times (0, 3, 6, 12, 24, 48h). 
IFN β stimulation significantly induced BAFF mRNA expression in time dependent 
manner at 3h (fold increase relative to control=45, P=0.03), 6h (179, P=0.02) and 
48h (6, P=0.04). The expression of BAFF mRNA reached high levels at 12h (245, 
P=0.01). Afterwards, BAFF mRNA was decreased significantly at 24h (30, P=0.007) 
and reached lower levels at 48h (6, P=0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. IFN-β induced BAFF mRNA expression in time–dependent manner 
BEAS-2B cells were stimulated with IFN-β 200 ng/ml for (0, 3, 6, 12, 24 and 48h). BAFF 
mRNA was measured by RT-PCR. BAFF mRNA was increased significantly in time 
dependent manner. BAFF mRNA reached high levels at 12h after IFN β stimulation (A- C). 
Values are shown as fold expression relative to control. The average of three independent 
experiments (D). Mean with SEM are shown (one way ANOVA followed with Bonferroni 
post-hoc test, *P <0.05, n=3).  
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3.2.9. IFN-β induced BAFF protein expression in dose–dependent manner 
 
To confirm epithelial production of BAFF protein and not only mRNA, BEAS-2B 
cells were stimulated with IFN-β at concentrations of 1 ng/ml, 5 ng/ml, 10 ng/ml, 
100 ng/ml and 200 ng/ml for 48h. Significant levels of BAFF protein (Figure 3.9) 
were detected in the culture supernatant. Production of BAFF protein was increased 
significantly by stimulation with IFN-β at a concentration of 1 ng/ml (mean 127, 
P=0.0009), 5 ng/ml (172, P=0.003), 10 ng/ml (219, P=0.0009), 100 ng/ml (204, 
P=0.001) and 200 ng/ml (233, P=0.002) in comparison to non-stimulated control (0).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BEAS-2B cells were stimulated with various concentrations of IFN-β (1 ng/ml, 5 ng/ml, 10 
ng/ml, 100 ng/ml and 200 ng/ml) for 48h. BAFF protein was measured in the culture 
supernatants by specific human BAFF ELISA (A-C). BAFF protein concentrations were 
increased significantly in dose dependent manner. The average of three independent 
experiments (D). Mean with SEM are shown (one way ANOVA followed with Bonferroni 
post-hoc test, *P <0.05, n=3).  
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Figure 3.9. IFN-β induced BAFF protein expression in dose dependent manner 
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3.2.10. RSV infection of cultured BEAS-2B cells induces BAFF expression by an 
IFN-β dependent mechanism 
 
In order to determine if BAFF expression was directly induced by RSV infection or 
if it was indirectly dependent on interferon β production by RSV infected cells, 
BAFF expression in BEAS-2B cells was compared in the presence or absence of an 
anti-interferon β-neutralising antibody. 5 μl of anti-IFN-β (20 μg/mL, chapter 2, 
2.1.7) was added into BEAS-2B cells cultured into 96-well plate at 2 x 10
4
 cells/ml. 
BAFF mRNA expression (Figure 3.10.1) was induced significantly after RSV 
infection at 12h (fold increase relative to control= 21, P=0.04) relative to control.  
Moreover, BAFF protein (Figure 3.10.2) was induced significantly after RSV 
infection at 48h (mean 20, P= 0.003) in comparison to control (0). However, 
treatment with neutralising anti-interferon β antibody inhibited production of BAFF 
mRNA (8.80, P=0.04) and protein expression (mean 13, P=0.04). These results 
indicate that BAFF produced initially following RSV infection, at the very least, is 
dependent on interferon β production. 
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BEAS-2B cells were infected with RSV at (MOI =1) for 12h. Matched samples contained 
addition of a neutralizing anti-human IFN β antibody (A-C). RSV infection of BEAS-2B cells 
induced significant BAFF mRNA at 12h and after added anti-IFN β antibody, BAFF mRNA 
was decreased significantly. Values are shown as fold expression in comparison to control. 
In (D) results shown are average of three independent experiments. Mean with SEM are 
shown (one way ANOVA followed with Bonferroni post-hoc test, *P <0.05, n=3).  
 
  
 
A B 
C D 
Figure 3. 10.1: BAFF mRNA expression following RSV infection is dependent on IFN β 
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BEAS-2B cells were infected with RSV at (MOI =1) for 48h. Matched samples also 
contained a neutralizing anti-human IFN-β antibody. RSV infection of BEAS-2B cells 
induced significant BAFF protein at 48h and after added anti-IFN β antibody, BAFF protein 
was decreased significantly. In (D) results shown are average of three independent 
experiments. Mean with SEM are shown (one way ANOVA followed with Bonferroni post-
hoc test, *P <0.05, n=3).  
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Figure 3. 10.2. BAFF protein expression following RSV infection is dependent on IFN-β 
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3.2.11. Cell surface expression of BAFF after RSV infection in BEAS-2B cells 
 
To examine what form of BAFF (chapter 1, section 1.2.1.3) airway epithelial cells 
express after RSV infection, BEAS-2B cells were plated into a 24-well plate at 
8×10
3 
 cells/well and infected with RSV at MOI=1 for 12, 24 and 48h. Then, cells 
were extracted by cell scraper, washed with PBS and centrifuged at 400 g/ for 10 
minutes, the pellet was lysed with (SDS) buffer containing 10% DTT and protease 
inhibitors (1:100) and analysed by western blot (chapter 2, 2.10). Interestingly, non-
infected epithelial cells expressed membrane BAFF (31kD) (Figure 3.11.A). 
However, after RSV infection membrane BAFF was expressed at 12hours and 
slightly less in 24hours. At 48hours after RSV infection supernatants were collected 
and BAFF protein measured by specific human BAFF ELISA. BAFF protein (17 
kD) was expressed significantly (mean =29, P=0.002) in comparison to control after 
RSV infection (Figure 3.11.B). 
 
  
Membrane BAFF (31 kD)  
 
 Soluble BAFF (17 kD)    
 
 
                                                                                 
 
BEAS-2B cells were infected with RSV at MOI=1 for 12 and 24h (A). Western blot was run 
under reduced conditions. Non -treated BEAS-2B cells expressed membrane BAFF (31kD). 
The RSV infected BEAS-2B cells expressed membrane BAFF (31 kD). Β-actin control was 
used to ensure all the samples were loaded equally. Human recombinant BAFF (rBAFF) 
was used as positive control for soluble BAFF (17 kD). Ladder was used to determine the 
molecular weight of BAFF. In (B) soluble BAFF (17 kD) was detected at 48h int the culture 
supernatant of BEAS-2B cells after RSV infection by using specific human BAFF ELISA 
(paired t test, n=3). 
β-Actin 
Ladder   rBAFF   Control     12h        24h A B 
Figure 3.11. Western blot of analysis of BAFF expression by BEAS-2B cells after 
RSV infection 
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3. 2.12.Mechanism of BAFF cleavage 
 
BAFF can be found into two forms, a membrane bound and a soluble molecule. It 
has been reported that soluble BAFF is derived from the membrane-bound BAFF by 
cleavage with a putative furin family protease or derived from intracellular 
processing of the longer form by the same enzyme (Nardelli et al. 2001; Scapini et 
al. 2003). 
Thus, I hypothesized that if production of soluble BAFF during RSV infection was 
furin dependent, inhibition of furin convertase enzyme would result in increased 
expression of membrane bound BAFF.  
To test this hypothesis and determine if soluble BAFF release relies on furin 
cleavage, BEAS-B cells were infected with RSV at MOI =1 and incubated with 50 
or 100 μM of the furin convertase inhibitor chloromethylketone 6hours after RSV 
infection and samples collected at 24 and 48h (Figure 3.12). 
Non-infected BEAS-2B cells expressed membrane BAFF at 24h and 48h. Moreover, 
RSV induced membrane BAFF expression at 24h and disappeared at 48h. Targeting 
furin convertase enzyme did not increase the expression of membrane BAFF at 24h 
and 48h. However, at high concentration of furin convertase inhibitor 100 Mm 
membrane BAFF expressions was reduced. This could be as a result of toxicity.  
Furthermore, Brefeldin A is known to inhibit protein secretion by cells. Thus, adding 
Brefeldin A to the RSV infected BEAS-2B cells should not alter BAFF production if 
it is cleaved from the cell surface by a furin convertase. Expression of membrane 
BAFF was not affected by Brefeldin A at 24 and 48h (Figure 3.12).  
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BEAS-2B cells were infected with RSV at MOI=1 for 24h and 48h. BEAS-2B cells were 
incubated with Brefeldin A (BA 1:100) and furin convertase inhibitor (FI) (50 μM, 100 
μM). Non-infected cells expressed membrane BAFF. RSV induced expression of membrane 
BAFF after 24h and disappears at 48h. Targeting furin did not increase the expression of 
membrane BAFF at 24h and 48h. However, at high concentration of FI 100 μM membrane 
BAFF expression was reduced. There was no clear effect of BA on the expression of 
membrane BAFF at 24h after RSV infection, which suggests that BAFF cleaved form the cell 
surface. β actin control was used to ensure all the samples were loaded equally. Human 
recombinant BAFF (rBAFF) was used as positive control for soluble BAFF (17 kD).  
 
 
 
 
 
 
 
 
 
 
rBAFF   Control   RSV       BA       FI 50    FI 100   Control    RSV    BA      FI 50      FI 100 
24h 48h 
 Soluble BAFF (17 kd) 
Membrane BAFF (31 kd) 
β-Actin 
Figure 3.12. Effect of Brefeldin A (BA) and furin convertase inhibitor (FI) on the 
expression of BAFF following RSV infection 
105 
 
3.2.13. Immunofluorescent localization of BAFF expression in cultured BEAS-
2B cells 
 
3.2.13.1. IFN-β induces BAFF expression in BEAS-2B cells  
 
To further confirm BAFF expression, BEAS-2B cells were treated with different 
concentrations of IFN-β, including 1ng/ml, 10 ng/ml and 100 ng/ml for 24h and 
nonstimulated cells used as control. BAFF has been stained with specific 
monoclonal antibody anti-BAFF FITC (green). Of note, un-stimulated BEAS-2B 
cells expressed BAFF (Figure 3.13.1.A) and BAFF was localized around cells as 
indicated by arrow. This further confirmed that non stimulated cells express BAFF 
(Figures 3.11 and 3.12). However, after IFN-β stimulation there was strong positive 
staining of BAFF that could be soluble BAFF bound to the extra cellular matrix 
around cells and nearby (Figure 3.13.1.B-D), and no comparable staining was 
noticed with the isotype control.  
 
 
 
 
 
 
 
 
 
               A-Un-stimulated         B- 1 ng/ml               C- 10 ng/ml                   D- 100 ng /ml 
 
BEAS-2B cells were stimulated with different concentrations of IFN-β (1ng/ml, 10 ng/ml and 
100 ng/ml) for 24h. In (A) un-stimulated BEAS-2B cells expressed BAFF (green) as 
indicated by arrow. In (B-D) there was strong positive staining of BAFF (green) after IFN-β 
stimulation. Isotype control was applied in each test and no comparable staining was 
noticed with the isotype control. Cell nuclei shown in blue (DAPI). Images A–D were 
originally obtained using confocal microscopy at 40x magnification.  
 
Isotype  
DAPI/BAFF 
Figure 3.13.1. Localization of BAFF in BEAS-2B cells stimulated with IFN-β 
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3.2.13. 2. RSV infection of BEAS-2B cells induced BAFF expression 
 
To evaluate expression of BAFF in BEAS-2B cells after RSV infection both BAFF 
and RSV were visualized by immunofluorescence staining. BEAS-2B cells were 
infected with RSV at (MOI =1) for 24h. BAFF (green) was expressed in non-
infected BEAS-2B cells (Figure 3.13.2. A). However, after RSV infection, there was 
strong positive staining of BAFF (Figure 3.2.13.2.B), and RSV (red) was detected in 
cytoplasm of infected cells (Figure 3.13.2.C), and no comparable staining was 
noticed with the isotype control. 
 
                 
                 
                   
                 
 
 
 
            
                
             
             
          
        
 
 
BEAS-2B cells were infected with RSV at (MO1=1) for 24h. In (A) non infected BEAS-2B 
cells showed positive staining of BAFF (green). In (B) there was strong positive staining of 
BAFF (green) after RSV infection. In (C) RSV was detected in the cytoplasm of infected cells 
(red). In (D) RSV (red) and BAFF (green) were detected after RSV infections. All the isotype 
controls were applied in each test. Cell nuclei shown in blue (DAPI). Images (A–D) were 
originally obtained using confocal microscopy at 40x and 400x magnification.  
Isotype control (DAPI)         DAPI /BAFF 40x               BAFF   400x 
A 
B 
C 
D  merge 
Figure 3.13.2. Localization of BAFF in BEAS-2B cells following RSV infection 
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3.2.14. The functional activity of BAFF secreted by RSV infected BEAS-2B on 
the survival of B cells 
To determine if BAFF derived from RSV infected epithelial cells was able to support 
B cell survival, purified human B cells (chapter 2, section 2.2.1) were cultured with 
or without addition of concentrated supernatant from RSV infected or non-infected 
BEAS-2B cells for 5 days and B cell survival measured by MTT assay (Chapter 2.9). 
For stimulation, culture supernatants were collected from BEAS-2B cells infected 
for 48hours with RSV, and from cultures without RSV infection and concentrated 
(Chapter 2.1.6). Comparison was made between B cells incubated alone, with 
addition of recombinant BAFF as a positive control, or with concentrated 
supernatants from BEAS-2B cells, either non infected or infected with RSV. Human 
recombinant BAFF (10 ng/ml) significantly enhanced B cell survival compared with 
media alone (mean OD=0.18, P=0.006) (Figure 3.14). Furthermore, RSV 
concentrated supernatant significantly increased B cell survival in comparison to 
RSV non- infected control (mean 16, P=0.04), which significantly suppressed B cell 
survival (0.09, P=0.03).  
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Purified Human B cells were incubated alone with media, stimulated with 10 ng/ml rBAFF, 
or concentrated supernatants from RSV infected and non-infected of BEAS-2B collected at 
48h, for 5 days. Each sample was triplicated with taken the average (A-C). The average of 
three independent experiments is shown in (D). The O.D. absorbance was 540 nm. B cell 
survival was measured by MTT assay. Mean with SEM are shown (one way ANOVA 
followed with Bonferroni post-hoc test, *P <0.05, n=3).  
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D 
Figure 3.14. Effect of epithelial cells secreted BAFF on the cell survival of B cells 
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3.2.15. RSV infection of BEAS-2B cells induce expression CCL21 mRNA, but 
not CXCL12, CXCL13 and CCL19  
 
To further understand the ability of epithelial cells to support the adaptive immune 
response by recruitment of B cell responses, expression of chemokines, CXCL12, 
CXCL13, CCL19 and CCl21 (Chapter 1.4) by BEAS-2B cells following RSV 
infection was studiedFigure. BEAS-2B cells were infected at an MOI of 1 for 3, 6, 
12, 24 and 48 and 72 h. After infection supernatant was collected and RNA prepared 
from the cells using Qiagen as described in the (chapter 2, 2.4). There was no mRNA 
or protein expression for CXCL12, CXCl13, CCL19 and CCL21 after RSV 
infection.  
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3.3. Discussion  
 
3.3.1. Determination of RSV infection in BEAS-2B cells 
 
The main targets of RSV infection are bronchial and bronchiolar epithelial cells, 
especially those that are ciliated (Johnson et al. 2007). To confirm that BEAS-2B 
cells were infected and determine the level of RSV infection for 12h, RSV N RNA 
was measured by RT-PCR. There was no expression of RSV N RNA in non-infected 
control cells. However, after RSV infection, RSV N RNA was induced significantly 
at MOI=0.025, 0. 25 and 2.5 (Figure 3.1). RSV A2 titre obtained in the PCR analysis 
of BEAS-2B cells was increased by increasing the virus dose and BEAS-2B cells 
showed permissive replication and response to RSV infection.  
In vitro, the most common models for the study of airway epithelial cells responses 
to RSV infection are immortalized respiratory epithelial cell lines such as BEAS-2B 
cells. However, their response to RSV infection is different from primary airway 
epithelial cells and might not accurately reflect the actual immune response to RSV 
infection by primary cells. These variations include different kinetics of viral 
replication, decreased cytotoxic responses and reduced production of pro-
inflammatory cytokines (Fonceca et al. 2012). 
Measuring RSV infection by RT-PCR has several advantages over the plaque assay 
method (Chapter 2.6.2). RT-PCR is more sensitive, specific, rapid and allows 
quantification of RSV replication. However, RT-PCR only measures N gene RNA, 
whereas for plaque assay the whole infective plaque forming unit of virus is 
measured.   
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3.3.2. RSV infection of BEAS-2B cells significantly induced expression of BAFF 
mRNA and protein but not APRIL 
 
Non-infected BEAS-2B cells consistently expressed low levels of BAFF mRNA 
(less than 5 cycles relative to L32 control, (Table 3.2). In contrast, after RSV 
infection, BAFF mRNA expression was increased significantly at 6h after RSV 
infection in comparison to non-infected control (FFigure 3.2). BAFF mRNA reached 
highest levels after 12h and declined significantly at 48h, which suggested that 
BAFF protein is released at this time point where it has been measured in the culture 
supernatant (FFigure 3.5). 
Furthermore, BAFF mRNA (Figure 3.3) and protein (Figure 3.5) expression were 
elevated significantly at different MOIs of RSV in comparison to non-infected 
control. These results demonstrated that RSV infection of airway epithelial cells 
induces significant expression of both BAFF mRNA and BAFF protein and their 
expression are increased at higher RSV MOIs, this could be as a result of increased 
production of IFN-β following RSV infection.  
APRIL mRNA expression but not protein was also measured by RT-PCR. By 
contrast to BAFF, there was no significant increase of APRIL mRNA after RSV 
infection or at different MOI in comparison to non-infected control (Figure 3.4). Due 
to the lack of any measurable increase in APRIL mRNA expression and the low 
sensitivity of commercially available APRIL ELISA assays which have minimal 
detection levels of around 400 pg/ml, APRIL protein expression was not studied 
further in these experiments.   
Furthermore, BAL samples taken from infants with severe RSV infection in 
comparison to control infants did not show increased expression of APRIL protein, 
although APRIL mRNA was constitutively expressed at levels five times higher than 
BAFF in primary epithelial brushings from healthy control children (McNamara et 
al. 2013). However, APRIL protein ( 1518±635 pg/ml) has previously been detected 
in nasopharyngeal secretion samples from surviving infants with acute bronchiolitis 
and detected in the lower respiratory tract in an immunohistochemical analysis of  
lung tissue from infants who died of acute RSV  (Reed et al. 2009). Thus, it could be 
possible that the source of APRIL in vivo is not epithelial cells or the time at which 
samples have been collected is not appropriate to allow detection of APRIL mRNA. 
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Moreover, expression of APRIL in vivo needs to be confirmed and it has been 
addressed further in chapter 4.   
 
 
3.3.3. Do dsRNA and LPS induced BAFF mRNA expression? 
To mimic viral and bacterial infection, BEAS-2B cells were treated with TLR 
ligands including, LPS (TLR4) and dsRNA (TLR3, and mimic of viral RNA) (200 
ng/ml) for 12h. There was no significant increased expression of BAFF mRNA 
(Figure 3.6). However, BAFF production by BEAS-2B cells stimulated with dsRNA 
has been reported (Kato et al. 2006). Thus, it could be possible that BAFF was not 
induced in high levels due to the low concentration of dsRNA used (200 ng/ml), as it 
was  used at up to 25 μg/ml (Kato et al. 2006). Moreover, epithelial cells express 
TLR4 and more response to LPS had been expected (Schulz et al. 2002). However, 
there was no significant increase of BAFF mRNA by BEAS-2B cells stimulated with 
LPS (200 ng/ml). Thus it could be possible that BAFF expression also requires a 
high LPS concentration but this data suggests that LPS is not a strong inducer of 
BAFF expression. 
3.3.4. What other cytokines can induce expression of BAFF and APRIL in 
BEAS-2B cells? 
 
To determine if other pro-inflammatory cytokines can induce APRIL or BAFF 
expression, BEAS-2B cells were stimulated with the cytokines IFN-α, IL-1β and 
IFN-β (200 ng/ml) for 12h (Figure 3.6). Among these stimuli, only IFN-β (200 
ng/ml) was found to significantly induce the highest level of BAFF mRNA 
expression (fold increase relative to control= 177, P=0.01) in comparison to non-
stimulated control after 12h of stimulation.   
This finding correlates with another study that found IFN-β strongly induced BAFF 
expression by BEAS-2B cells 6h after stimulation (Kato et al. 2006). Furthermore, 
IFN-β stimulation of BEAS-2B cells also significantly induced BAFF mRNA 
expression in a time dependent manner (Figure 3.8). The expression of mRNA 
BAFF reached high levels at 12h (245, P=0.01). Afterwards, BAFF mRNA was 
decreased significantly at 24h (30, P=0.007) and reached low levels at 48h (6, 
P=0.01) (Figure 3.2.8). BAFF mRNA expression was increased by increasing the 
concentration of IFN-β (Figure 3.7).  
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To confirm epithelial production of BAFF protein and not only mRNA, BEAS-2B 
cells were stimulated with various concentration of IFN-β for 48h. Significant levels 
of BAFF protein were detected in the culture supernatant (Figure 3. 9). 
 
Furthermore, concentrations of IFN-β as low as 1 ng/ml induced BAFF expression. 
The response of BAFF mRNA to IFN-β was more rapid than the response to other 
stimulus, which indicates that IFN-β is a potent and rapid stimulator of BAFF 
mRNA and protein expression in airway epithelial cells. In addition, BAFF mRNA 
and protein expression increased by increasing the concentration of IFN-β, which 
suggests that the level of interferon is a key regulator of BAFF expression following 
RSV infection.  
 
 
3.3. 5. RSV infection of cultured BEAS-2B cells induces BAFF expression by an 
Interferon β dependent mechanism 
 
To examine the mechanism of BAFF production after RSV infection and investigate 
if BAFF expression was directly induced by RSV infection, or if it was indirectly 
dependent on interferon β production by RSV infected cells, BEAS-2B cells were 
incubated with or without neutralizing anti-interferon β antibody and infected with 
RSV for 12h. BAFF mRNA was induced significantly after RSV infection (fold 
increase relative to control= 21, P=0.04). However, treatment with neutralising anti-
interferon β antibody inhibited BAFF mRNA expression (fold decrease relative to 
not treated= 8.8, P=0.04) (Figure 3.10.1). 
Moreover, to confirm that not only mRNA was inhibited but also BAFF protein 
(3.10.2), it was measured after treatment with neutralising anti-interferon β antibody 
and significantly inhibited BAFF protein expression (mean 13 pg/ml, P=0.04). These 
results indicate that early BAFF produced following RSV infection, at the very least, 
is dependent on interferon β production. Furthermore, these finding are supported by 
those of others using similar studies (Kato et al. 2006; McNamara et al. 2013). 
However, it has been reported that RSV protein, including NS1 and NS2 can inhibit 
Type 1interferon production during infection (Spann et al. 2004; Spann, Tran & 
Collins 2005). RSV can inhibit Type 1interferon which then affect the interferon 
expression and likely RSV can inhibit BAFF expression.  
114 
 
3.3.6. What form of BAFF do BEAS-2B cells express after RSV infection and 
BAFF cleavage? 
 
BAFF can be found in two main forms (Chapter 1.2.1.3), membrane bound or 
soluble. It has been reported that soluble BAFF is derived from the membrane-bound 
BAFF by cleavage with a putative furin family protease or derived from intracellular 
processing of the longer form by the same enzyme (Nardelli et al. 2001; Scapini et 
al. 2003). Therefore, to investigate what molecular weight or form of BAFF is 
expressed in BEAS-2B cells after RSV infection, BEAS-2B cells were infected with 
RSV for 12h and 24h and analyzed by Western blot. Interestingly, resting epithelial 
cells expressed membrane bound BAFF (31kD). In this regard, low levels of BAFF 
mRNA were also observed in non-infected epithelial cells (table 3.2), which 
suggested that resting epithelial cells express BAFF under normal conditions. 
However, after RSV infection membrane BAFF was expressed at 12h and slightly 
less at 24h (Figure 3.11 and Figure 3.12). After 48h of RSV infection soluble BAFF 
protein was measured by specific human BAFF ELISA. BAFF protein was induced 
significantly (mean =28 pg/ml, P=0.002) compared to non-infected control BEAS-
2B cells. Thus, it could be possible that at later time point (48h) soluble BAFF (17 
kD) was cleaved from the membrane and released in the culture supernatant (Figure 
3. 1; 3.9 and 3.11.B).  
Soluble BAFF has been reported to form homotrimers or a capsid-like assembly of 
20 trimers a 60-mer (Chapter 1.2.1.3). It is not possible from western blots such as 
these to determine which type of soluble BAFF has been detected in the culture 
supernatant of BEAS-2B cells after 48h. Expression of membrane BAFF was further 
confirmed by the immunofluorescence staining (Figures 3.13.1 and Figure3.13.2), 
BAFF was expressed in non-infected BEAS-2B cells and after RSV infection there 
was strong positive staining of BAFF.  
 
Thus, to understand the mechanism of BAFF cleavage after RSV infection in airway 
epithelial cells, I hypothesised that resting epithelial cells expressed membrane 
BAFF (Figure 3.15.A) and upon RSV infection and IFN-β stimulation, soluble 
BAFF is cleaved from the membrane and released. Thus, inhibition of furin or furin 
like convertases may lead to increased membrane BAFF expression and reduce or 
block soluble BAFF formation (Figure 3.15.B). In addition, to ensure that soluble 
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BAFF was cleaved from the cell surface and not intracellularly, Brefeldin A was 
used as an inhibitor of classical protein secretion by cells (Figure 3,15.C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resting epithelial cells express membrane bound BAFF. Release is dependent on furin 
cleavage (A). Inhibition of furin convertase should reduce or block soluble BAFF production 
(B). To ensure that soluble BAFF produced as results of cleaved from the membrane bound 
upon RSV infection Brefeldin A was used as an inhibitor of classical protein secretion (C).  
 
RSV infected BEAS-2B cells were analysed with Western blot (Figure 3.12) and 
there was no increased expression of membrane BAFF as expected after targeting of 
furin convertase by chloromethylketone. However, at high concentration of this 
Furin inhibitor (100 μm) membrane BAFF was inhibited. This could be explained as 
a result of toxicity. It has been shown that induction of soluble BAFF by dsRNA was 
completely suppressed by targeting the furin convertase like enzyme using a specific 
furin convertase inhibitor which suggests that the mechanism of production of 
soluble BAFF in airway epithelial cells may be similar to that found in myeloid cells 
(Kato et al. 2006; Scapini et al. 2003). Taken together, this suggests that there is 
another pathway of cleavage of BAFF in addition to the known one or it could be 
possible that the experiment did not work because the furin inhibitor was not 
sufficiently active.  
Figure 3.15. Proposed mechanism of BAFF cleavage during RSV infection 
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In addition, there was no effect of Brefeldin A at the level of expression of 
membrane BAFF which confirmed that soluble BAFF is only cleaved form the cell 
surface and not intracellularly as APRIL has been reported to be (Lopez-Fraga et al. 
2001).  
 
3.3.7. Does BAFF produced by RSV infected BEAS-2B cells support B cell 
survival? 
 
It has been reported that BAFF directly promotes proliferation, cell survival, CSR, 
and Ig production in B cells through a CD40-independent and T cell-independent 
pathway (Castigli et al. 2005; Litinskiy et al. 2002; Mackay et al. 2003; Moore et al. 
1999) (Chapter 1.2.4.2). To determine if BAFF derived from RSV infected epithelial 
cells was able to induce B cell survival, purified human B cells (Chapter 2.2.1) were 
cultured with or without concentrated supernatant from RSV infected or non-infected 
cells and with recombinant human BAFF (10 ng/ml). Recombinant Human BAFF 
significantly enhanced B cell survival compared with media alone (mean=0.18, 
P=0.006). Furthermore, RSV concentrated supernatant significantly increased B cell 
survival in comparison to RSV control (mean 16, P=0.04).  
These results suggest that after RSV infection epithelial cell-derived BAFF is active 
and could promote B cell survival (Figure 3.14). These findings correlate with those 
of a study that looked at the biological activity of BAFF derived from epithelia cells 
stimulated with IFN-β and has showed this could support B cell survival (Kato et al. 
2006). These experiments indicate that supernatants from RSV infected BEAS-2B 
cells can support B cell survival and they contain BAFF, a cytokine known to 
promote B cell survival. However to further confirm if BAFF alone and/or other 
factors present in these preparations actually mediated B cell survival then the BAFF 
should be neutralized or its receptors blocked and B cell survival examined.  
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3.3.8. Expression of CXCL12, CXCL13, CCl19 and CCL21 in BEAS-2B cells 
following RSV infection 
 
To determine if BEAS-2B cells have a potential role in support of adaptive immune 
responses through production of lymphoid chemokines, including CXCL12, 
CXCL13, CCL19 and CCl21 (chapter 1, 1.4), that could influence lymphocytes B 
and T cells trafficking during RSV infection, BEAS-2B cells were infected with 
RSV at MOI of 1 for 3, 6, 12, 24, 48 and 72h. No mRNA or protein expression for 
CXCL12, CXCL13, CCL19 and CCL21 were detected after RSV infectionFigure, 
which suggests that the signals could come from other sources and not airway 
epithelial cells. 
3.4. Summary  
 
RSV infection and IFN-β stimulation of BEAS-2B cells induced expression both of 
BAFF mRNA and protein. BAFF mRNA expression reached the highest levels at 
12h and declined at 48h, where BAFF protein was released and measured in the 
culture supernatant. BAFF mRNA expression following RSV infection is via IFN-β 
dependent pathway. IFN-β is a potent and rapid stimulator of BAFF expression in 
airway epithelial cells. Western blot analysis demonstrated that non-infected BEAS-
2B cells expressed membrane BAFF (31kD).Thus, it could be possible that after 
RSV infection soluble BAFF (17kD) was cleaved from the membrane and released 
into the culture supernatant. Inhibition of Furin convertase did not alter BAFF 
expression, which could suggest another way of cleavage rather than the known way. 
In addition, adding Brefeldin A did not change the pattern of BAFF, and this showed 
that soluble BAFF is cleaved form the cell surface. Overall, these results 
demonstrated the importance of the epithelium to maintain B cells response and 
survival in the airway through production of the key B cell survival factor BAFF. 
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CHAPTER 4: EXPRESSION OF BAFF AND APRIL CYTOKINES IN A 
MURINE MODEL OF HUMAN RESPIRATORY SYNCYTIAL VIRUS 
INFECTION 
4.1. Aims 
BAFF expression both in BAL samples and by primary airway epithelial cells during 
acute human RSV infection has previously been demonstrated (McNamara et al. 
2013). The experiments described in chapter 3 additionally demonstrate BAFF 
mRNA and protein were expressed by BEAS-2B cultured airway epithelial cells 
following RSV infection. Murine models of human RSV infection have been used 
extensively to study RSV infection (Openshaw 2013). The work described in this 
chapter aimed to further understand the production of BAFF and APRIL during RSV 
infection by using an animal model of RSV infection. Specific aims were: 
1- To demonstrate RSV infection in BALB/c mice after infection by RT-PCR.  
2- To define the Kinetics of both BAFF and APRIL expression following RSV 
infection by RT-PCR and ELISA. 
3- Investigate what form of BAFF is expressed in murine lungs after RSV 
infection by western blot analysis. 
4- Examine RSV localization in murine lung sections by Immunofluorescence 
staining. 
5- Examine BAFF localization in lung sections following RSV infection by 
Immunofluorescence staining. 
 
4.2. Experimental design  
 
Samples from three groups of mice were kindly provided by Prof Jurgen Schwarze 
and Miss Amanda McFarlane working at Queens Medical Research Institute at the 
University of Edinburgh. All animal work associated with these experiments were 
conducted in Edinburgh. Three independent experiments were carried out and in 
each case comparison made between animals challenged with RSV or UV 
inactivated RSV as a control. Control RSV was inactivated by the UV in order to see 
if the observed response was due to live RSV infection and not due to the cell lysate 
which is a part of the inoculate. Three animals were used at each time point for each 
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treatment. At the start of each experiment, samples were collected from a group 
challenged with PBS only as control. This group is referred to as day 0. In 
experiment 1, samples were collected at day 0, 1, 2, 4 and 7 days after challenge. 
The second experiment included additional groups collected at day 8 consisting of 
(day 0, 1, 2, 4, 6, 7 and 8 days) and the third experiment included day 0, 1, 2, 4, 7, 
10, 14, 21days to extend the time series. After collection, lungs were divided into 3 
parts, left upper lobe for analysis of protein expression, left lower lobe for mRNA 
preparation and quantitative PCR and the whole right lung frozen for 
immunofluorescence (Figure 4.1). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
The first experiment included (day 0, 1, 2, 4, and 7), the second experiment included (day 0, 
1, 2, 4, 7 and 8 and the third experiment included (day 0, 1, 2, 4, 7, 10, 14 and 21). At day 0 
mice were given PBS as control and at each day 3 mice were infected with RSV and 3 mice 
were infected with UV-RSV control as further control. Mice lungs were extracted and 
divided into three parts, left upper lob for study protein expression , left lower lobe for study 
mRNA expression and the whole right lung for study tissue sections staining and western 
blot analysis. 
RSV 
PBS at day 0 Inactivated with UV  
To study protein expression 
(ELISA) 
 
To study mRNA expression (RT-PCR) 
Whole right lung was 
frozen immediately 
upon extraction with 
frozen media 
 
Left upper lobe of lung was 
homogenised in 2mL of PBS+ 
protease inhibitors 
asupernatants were collected 
and sored at -70 
Left lower lobe of lung was 
homogenised in 500 µl of lysis buffer 
RLT (Qiagen), RNA was extracted and 
sored at -70 
To study 
Immunofluorescence 
and Western blot 
analysis 
BALB/c mice 
Figure 4.1. Diagram shows the structure of three independent experiments used to study 
RSV infection in BALB/c mice 
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The results are presented from each of three individual experiments starting from 
measurement of RSV N RNA by RT-PCR as well as BAFF, APRIL, CXCL12, 
CXCL13, CCL19 and CCL21. In addition, measurements of protein for BAFF, 
CXCL12, CXCL13, CCL19 and CCL21 by ELISA and immunofluorescence 
staining of RSV, BAFF and CXCL13 are presented.  
 
4.3. Results 
4.3.1. Experiment- I 
 
To ensure RSV infection of mouse lungs after challenge with RSV (strain A2), 
mouse lungs were homogenised and RNA prepared using Qiagen as described in 
(chapter 2.4). RSV N RNA was measured by RT-PCR. The PCR values obtained for 
experiment 1 and how the data was calculated are shown below (Table 4.1). There 
was no expression of RSV N RNA in non-infected mice at day 0 (Figure 4.2). 
However, after RSV infections RSV N RNA was observed at day 1 (fold expression 
relative to L32 = 0.64, P=0.1), day 2 (0.74, P=0.2), day 4 (0.91) and less in day 7 
(0.08) after RSV infection in comparison to control UV RSV control on day 1 (0), 
day 2 (0), day 4 (0) and day 7 (0). The maximal expression of RSV N RNA was at 
day 4 and at day 7 was substantially reduced, approaching control levels. 
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1) All L32 Ct values of the samples were averaged, 2) all RSV N probe Ct values were 
averaged, 3) the CT value of samples for RSV N probe were corrected to L32. For example: 
The L32 expression – RSV N. This produced a Ct value relative to L32 expression, 4) Fold 
expression relative to L32 and this can be calculated by 2 to the power of n, where n = value 
determined in step 3. This calculation converts the value from a ct number to the fold 
difference. This particular calculation is because every cycle result in an increases the 
amount of product two fold. (ND= not determined, Ct= cycle threshold the number of cycles 
required for the fluorescent signal to cross the threshold).  
 
 
 
 
 
Days after 
RSV infection 
1. Average 
of L32 Ct 
value 
2. Average of 
RSV N Ct value 
3. L32-RSV N 
(n) 
4. Fold expression 
relative to L32 (2 to the 
power of n) 
PBS1 Day0 25.77 ND   
PBS2 Day0 24.20 ND   
PBS3 Day0 30.57 ND   
UV1 Day1 25.43 38.96 -13.53 8.43 
UV2 Day1 28.49 38.07 -9.57 0.0013 
UV3 Day1 29.46 39.03 -9.57 0.0013 
RSV1 Day1 27.007 29.13 -2.12 0.2295 
RSV2 Day1 28.83 28.36 0.47 1.38 
RSV3 Day1 31.49 33.26 -1.76 0.29 
UV1 Day2 26.20 ND   
UV2 Day2 24.91 ND -22.57 1.59 
UV3 Day2 25.85 41.51 -15.66 1.92 
RSV1 Day2 31.46 30.67 0.79 1.73 
RSV2 Day2 24.74 26.576 -1.83 0.28 
RSV3 Day2 30.60 32.918 -2.31 0.20 
UV1 Day4 26.27 ND   
UV2 Day4 27.13 ND   
UV3 Day4 28.47 ND   
RSV1 Day4 25.47 24.85 0.61 1.52 
RSV2 Day4 26.34 26.35 -0.012 0.99 
RSV3 Day4 27.19 29.36 -2.16 0.22 
UV1 Day7 26.08 ND   
UV2 Day7 24.59 ND   
UV3 day7 26.30 ND   
RSV1 Day7 24.69 29.24 -4.55 0.042 
RSV2 Day7 23.67 31.49 -7.82 0.004 
RSV3 Day7 24.89 27.41 -2.52 0.174 
Table 4.1. Summary of steps used to analyze RT-PCR data and calculate fold expression 
of RSV N RNA relative to housekeeping gene control L32 
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RSV N RNA was measured by RT-PCR. RSV N RNA was detected in day 1, 2, 4 and less in 
day 7 after RSV infection in comparison to RSV UV control at the same time points and non-
infected at day 0. Values are shown as fold expression relative to L32. Result shown is the 
average of three animals in the first experiment. Mean and SD are shown (two way ANOVA 
with Bonferroni post-hoc test, n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Expression of RSV N RNA after RSV infection or challenge 
with UV-RSV control  
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4.3.1.1. Expression of BAFF mRNA after RSV infection in mice  
 
BAFF mRNA was firstly measured by RT-PCR (Figure 4.3). Non-infected mice at 
day 0 expressed BAFF mRNA (fold increase relative to control = 0.83). After RSV 
infection BAFF mRNA expression was increased significantly at day 1 (fold 
increase = 1.18, P=0.03) and day 7 (1.7, P=0.02) in comparison to UV RSV control 
at day 1 (0.7) and day 7 (0.9). BAFF mRNA was expressed consistently in non-
infected mice at day 0 and UV RSV control. BAFF mRNA reached high levels at 
day 1 and 7 and declined at day 4 after RSV infection relative to UV RSV control. 
 
 
 
 
 
 
 
 
 
 
BAFF mRNA expression was measured by RT-PCR. BAFF mRNA expression was increased 
significantly after RSV infection on day 1 and 7 in comparison to UV RSV control at the 
same time points. Values are shown as fold expression relative to control. Result shown is 
the average of three animals in the first experiment. Mean and SD are shown (two way 
ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
Figure 4.3. Expression of BAFF mRNA after RSV infection or challenge 
with UV-RSV control  
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4.3.1.2. Expression of BAFF protein RSV infection in mice 
 
To confirm production of BAFF protein and not only mRNA after RSV infection, 
BAFF protein concentration was measured in homogenised lung using a murine 
BAFF ELISA (Chapter 2.5). BAFF protein was present in lung homogenate prepared 
from non-infected mice at day 0, mean= 402 pg/ml (Figure 4.4). However, after RSV 
infection significantly increased levels of soluble BAFF were detected. BAFF 
protein was elevated significantly on day 2 (1157 pg/ml, P=0.01) and day 7 (2941 
pg/ml, P=0.0001) in comparison to UV RSV control at day 2 (370 pg/ml) and day 7 
(393pg/ml). BAFF protein reached high levels at day 2 and 7 and declined at day 4 
after RSV infection relative to UV RSV control. 
 
 
 
 
 
 
 
 
 
 
 
BAFF protein was measured by use specific murine BAFF ELISA. BAFF protein was 
increased significantly after RSV infection at day 2 and 7 in comparison to UV RSV control 
at the same time points. Result shown is the average of three animals in the first experiment. 
Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
Figure 4.4. Expression of BAFF protein after RSV infection or challenge 
with UV-RSV control  
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4.3.1.3. BAFF protein expression in comparison to total protein concentration 
after RSV infection  
 
Although standardised procedures were used to prepare lung homogenates, changes 
in protein concentration or yield could result in apparent changes in BAFF 
concentration, BAFF protein concentrations (pg/ml) were Normalization of to total 
protein (pg/ng) as measured by total protein assay BCA (Chapter 2.3.2; Figure 4.5). 
BAFF protein was elevated significantly after RSV infection at day 1 (mean 755 
pg/ng, P=0.02), day 2 (1042 pg/ng, P=0.02) and day 7 (1720 pg/ng, P=0.008) in 
comparison to UV RSV control at day 1 (428 pg/ng), day 2 (342 pg/ng) and day 7 
(353 pg/ng). BAFF protein reached high levels at day 2, 7 and declined at day 4. 
 
 
 
 
 
 
 
 
 
 
 
BAFF protein levels were normalized to total protein (pg/ng) by BCA assay. BAFF protein 
was increased significantly after RSV infection on day 1, 2 and 7 in comparison to UV RSV 
control at the same time points. Result shown is the average of three animals in the first 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
 
 
 
 
Figure 4.5. Normalized BAFF protein to total protein after RSV infection or 
challenge with UV-RSV control  
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4.3.1. 4. RSV infection did not significantly up regulate APRIL mRNA 
expression  
To determine if RSV infection of mice resulted in increased APRIL mRNA 
expression, mouse lungs were homogenised and RNA prepared using Qiagen, as 
described in the (chapter 2, section 2.4). APRIL mRNA was expressed in non-
infected mice at day 0 (fold expression relative to control =1.47) (Figure 4.6). 
However, after RSV infection there was no significant increase of APRIL mRNA 
observed at day 1 (2.06, P=0.8), day 2 (5.02, P=0.5), day 4 (3.15, P=0.4) and day 7 
(1.3, P=0.7) in comparison to the RSV UV control on day 1 (2.45), day 2 (3.14), day 
4 (6.5) and day 7 (1.7). There was no significant increased expression of APRIL 
mRNA after RSV infection relative to UV RSV controls.  
 
 
 
 
 
 
 
 
 
APRIL mRNA was measured by RT-PCR. RSV infection of mice did not significantly up 
regulated APRIL mRNA expression at day 1, 2, 4 and 7 in comparison to UV RSV control at 
the same time points. Values are shown as fold expression relative to control. Result shown 
is the average of three animals in the first experiment. Mean and SD are shown (two way 
ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
Figure 4.6. Expression of APRIL mRNA after RSV infection or challenge with 
UV-RSV control  
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4.3.2. Experiment- II 
 
4.3.2.1. RSV N RNA is expressed after RSV infection in mice 
 
To determine if RSV infection of mouse lungs expressed RSV N RNA after 
challenge with RSV (A2), mouse lungs were homogenised and RNA prepared using 
Qiagen as described in the (chapter 2, 2.4) and RSV N RNA measured and analysed 
by RT-PCR. There was no expression of RSV N RNA in non-infected mice at day 0 
(Figure 4.7). However, RSV N RNA was observed at day 1 (fold expression relative 
to L32= 2.5, P=0.1), day 2 (0.66, P=0.1) and day 4 (2.83, P=0.1) after RSV infection 
in comparison to the UV RSV control on day 1 (0), day 2 (0) and day 4 (0).  
 
  
 
 
 
 
 
 
 
RSV N RNA was measured by RT-PCR. RSV N RNA was detected in day 1, 2 and 4 after 
RSV infection in comparison to RSV UV control at the same time points and non-infected 
control at day 0. Values are shown as fold expression relative to L32. Result shown is the 
average of three animals in the second experiment. Mean and SD are shown (two way 
ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Expression of RSV N RNA after RSV infection or challenge 
with UV-RSV control  
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4.3.2.2. Expression of BAFF mRNA after RSV infection in mice 
 
To determine the influence of RSV on expression of BAFF mRNA in vivo, murine 
were infected with RSV (A2 strain) at different time points, including day 0 (non-
infected), 1, 2, 4 7 and 8. At the time points indicated after RSV infection mouse 
lung tissue were homogenized and RNA was isolated and prepared using Qiagen as 
described (chapter 2, 2.4). After RSV infection BAFF mRNA was measured and 
analyzed by RT-PCR. Non-infected mice at day 0 expressed BAFF mRNA (fold 
increase=0.67) (Figure 4.8). However, BAFF mRNA expression was increased 
significantly after RSV infection on day 7 (fold increase relative to control = 1.2, 
P=0.04) and day 8 (1.09, P=0.01) in comparison to UV RSV control on day 7 (0.8), 
day 8 (0.5). BAFF mRNA reached highest levels at day 7 and 8 after RSV infection 
relative to UV RSV control. 
 
 
 
 
 
 
 
 
 
 
 
BAFF mRNA expression was measured by RTPCR. BAFF mRNA expression was increased 
significantly after RSV infection on day 7 and 8 in comparison to UV RSV control at the 
same time points. Values are shown as fold expression relative to control. Result shown is 
the average of three animals in the second experiment. Mean and SD are shown (two way 
ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
Figure 4.8. Expression of BAFF mRNA after RSV infection or challenge 
with UV-RSV control  
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4.3.3.3. Expression of BAFF protein after RSV infection in mice  
 
To confirm production of BAFF protein and not only mRNA after RSV infection, 
BAFF protein concentrations were measured in homogenized lung tissues using 
murine BAFF ELISA (chapter 2, 2.5). BAFF protein was expressed in non-infected 
mice at day 0 (mean = 484 pg/ml) (FFigure 4.9). However, BAFF protein levels 
were elevated significantly after RSV infection at day 1 (1832 pg/ml, P= 0.0007), 
day 2 (1737 pg/ml, P= 0.0001), day 4 (925 pg /ml, P= 0.003), day 7 (3203 pg /ml, P= 
0.0007) and day 8 (2355 pg /ml, P=0.004) in comparison to UV treated RSV control 
on day 1 (497 pg/ml), day 2 (498 pg/ml), day 4 (481 pg/ml ), day 7 (401 pg/ml) and 
day 8 (473 pg/ml). BAFF protein reached high levels at day 2 and 7 and declined at 
day 4 after RSV infection relative to UV RSV controls. 
 
 
 
 
 
 
 
 
 
 
 
 
BAFF protein was measured by specific murine BAFF ELISA. BAFF protein was increased 
significantly after RSV infection at day 1, 2, 4, 7 and 8 in comparison to UV RSV control at 
the same time points. Result shown is the average of three animals in the second experiment. 
Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
Figure 4.9. Expression of BAFF protein after RSV infection or challenge 
with UV-RSV control  
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4.3.3.4. BAFF protein expression in compression to total protein concentration 
after RSV infection in mice  
 
BAFF protein concentrations (pg/ml) were normalized to total protein (pg/ng) 
(Figure 4.10). BAFF protein was elevated significantly after RSV infection at day 1 
(mean=269 pg/ng, P=0.0004), day 2 (197 pg/ng, P=0.04), day 4 (129 pg/ng, 
P=0.003), day 7 (455 pg/ng, P=0.0008) and day 8 (344 pg/ng, P=0.001) in 
comparison to UV RSV control on day 1 (74 pg/ng), day 2 (71 pg/ng), day 4 (67 
pg/ng), day 7 (59 pg/ng) and day 8 (67 pg/ng). BAFF protein reached high levels at 
day 1, 7 and 8 and declined at day 4. 
 
 
 
 
 
 
 
 
 
 
 
 
BAFF protein levels were normalized to total protein (pg/ng) by BCA assay. BAFF protein 
was increased significantly after RSV infection on day 1, 2, 4, 7 and 8 in comparison to UV 
treated RSV control at the same time points. Result shown is the average of three animals in 
the second experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc 
test, *P <0.05, n=3). 
 
 
 
 
Figure 4.10. Normalization of BAFF protein to total protein after RSV infection or 
challenge with UV-RSV control  
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4.3.3.5. RSV infection did not significantly up regulate APRIL mRNA 
expression  
To determine whether RSV infection induced APRIL mRNA expression, mouse 
lungs were homogenised and RNA prepared using Qiagen as described in the 
(chapter 2, 2.4). APRIL mRNA was expressed in non-infected mice at day 0 (fold 
expression relative to control=1.47) (Figure 4.11). However, after RSV infection 
there was no significant increase of APRIL mRNA at day 1 (4.02, P=0.6) day 2 (2.57 
, P=0.5) , day 4 (2.82, P=0.2) , day 7 (0.918, P=0.1) and day 8 (2.963, P=0.6) in 
comparison to the RSV UV treated  on day 1 (5.99), day 2 (3.96), day 4 (5.27),day 7 
(4.25) and day 8 (4.007).  
 
 
 
 
 
 
 
 
 
 
APRIL mRNA expression was measured by RT-PCR. RSV infection of mouse lungs did not 
significantly increase APRIL mRNA expression at day 1, 2, 4,7 and 8 in comparison to RSV 
UV control at the same time points. Values are shown as fold expression relative to control. 
Result shown is the average of three animals in the second experiment. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
Figure 4.11. Expression of APRIL mRNA after RSV infection or challenge with 
UV-RSV control  
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4.3.3. Experiment- III  
 
4.3.3.1. RSV N RNA is expressed after RSV infection in mice 
 
In order to achieve better understanding of the kinetics of BAFF and APRIL 
expression following RSV infection, RSV N RNA has been examined at various 
time points, including day 10, 14 and 21. RSV N RNA (Figure 4.12.) was detected at 
day 1 (fold expression relative to L32= 0.58, P= ns), day 2 (0.06, P= ns), day 4 (8.35, 
P= ns) and day 7 (0.0263, P= ns) after RSV infection in comparison to the UV RSV 
control on day 1 (0), day 2 (0) day 4 and day 7 (0). RSV N RNA was detected at day 
1 and day 2 but not at day 4. These results suggested that mice did not have 
appropriate infection as the first and second experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
RSV N RNA was measured by RT-PCR. RSV N RNA. There was weak expression of RSV N 
RNA on day1, 2, and 4 after RSV infections in comparison to RSV UV control. Values are 
shown as fold expression relative to L32. Result shown is the average of three animals in the 
third experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, 
*P <0.05, n=3). 
 
 
 
Figure 4.12. Expression of RSV N RNA after RSV infection or challenge 
with UV-RSV control  
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4.3.3.2. Expression of BAFF protein after RSV infection 
 
BAFF protein was expressed in non-infected mice PBS at day 0 (mean= 42 pg/ml) 
(Figure 4.13). However, after RSV infection BAFF protein was increased 
significantly at day 21 (69 pg/ml, P=0.001) in comparison to RSV UV control at day 
21 (48 pg/ml). BAFF protein concentrations were lower than first and second 
experiments (Figures 4.4 and Figure4.9) as a result of the weak RSV infection 
(Figure 4.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAFF protein was measured by specific murine BAFF ELISA. BAFF protein was increased 
significantly after RSV infection at day 21 in comparison to UV RSV control at day 21. 
Result shown is the average of three animals in the third experiment. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
Figure 4.13. Expression of BAFF protein after RSV infection or challenge 
with UV-RSV control  
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4.3.3.3. BAFF protein expression in comparison to total protein after RSV 
infection in mice  
 
BAFF protein concentrations (pg/ml) were Normalization of to total protein (pg/ng) 
(Figure 4.14). BAFF protein was increased significantly after RSV infection at day 
14 (53 pg/ng, P=0.001) and day 21 (55 pg/ng, P=0.002) in comparison to UV RSV 
control at day 14 (40 pg/ng) and day 21 (34 pg/ng). BAFF protein concentrations 
were lower compared with previous experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAFF protein levels were Normalization of to total protein (pg/ng) by BCA assay. BAFF 
protein was increased significantly after RSV infection at day 14 and 21 in comparison to 
UV RSV control at the same time point. Result shown is the average of three animals in the 
third experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, 
*P <0.05, n=3). 
 
 
 
 
 
Figure 4.14. Normalized levels of BAFF protein to total protein after RSV infection or 
challenge with UV-RSV control  
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4.3.4. An average of experiment-I and experiment- II 
 
4.3.4.1. Average of RSV N RNA after RSV infection in mice 
 
There was no expression of RSV N RNA in non -infected mice at day 0 (Figure 
4.15). However, after RSV infection RSV N RNA was elevated significantly at day 
1 (fold expression relative to L32= 1.60, P=0.05), day 2 (0.70, P=0.02) and day 4 
(1.87, P=0.12) in comparison to the UV RSV control at day 1 (0), day 2 (0) and day 
4 (0). This is the overall average of experiments one and two, experiment three is not 
included in this analysis. Moreover, two peaks of RSV N RNA were detected. The 
maximal expression of RSV N RNA was at day 1 and 4 and substantially reduced at 
day 7 and undetectable at day 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RSV N RNA was measured by RT-PCR. RSV N RNA was expressed significantly after RSV 
infection at day 1, 2 and 4 in comparison to UV RSV control at the same time points. Result 
shown is the average of six animals from the first and second experiments .Values are shown 
as fold expression relative to L32. Mean and SD are shown (two way ANOVA with 
Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
Figure 4.15. Average of RSV N RNA expression after RSV infection or challenge 
with UV-RSV control  
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4.3.4.2. Average of BAFF mRNA after RSV infection in mice 
 
BAFF mRNA was expressed in non-infected mice PBS at day 0 (fold increase 
relative to control= 0.75; Figure 4.16). However, after RSV infection BAFF mRNA 
expression was increased significantly on day 1 (fold increase relative to control= 
1.09, P=0.008), day 7 (1.5, P=0.004) and day 8 (1.09, P=0.01) in comparison to UV 
treated RSV control on day 1 (0.7), day 7 (0.8) and day 8 (0.5). This is the overall 
average of experiments one and two and three is not included in this analysis. BAFF 
mRNA reached high levels at day 7 declined at day 8 after RSV infection relative to 
UV RSV control. 
 
 
 
 
 
 
 
 
 
 
 
BAFF mRNA was measured by RT-PCR. BAFF mRNA expression was increased 
significantly after RSV infection on days 1, 7 and 8 in comparison to UV RSV control on 
days 1, 7 and 8. Result shown is the average of six animals from the first and second 
experiments. Values are shown as fold expression in comparison to control. Mean and SD 
are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=6). 
 
 
 
Figure 4.16. Average of BAFF mRNA expression after RSV infection or challenge with 
UV-RSV control  
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4.3.4.3. Average of BAFF protein after RSV infection in mice 
BAFF protein was expressed in non-infected mice at day 0 (mean = 478 pg/ml) 
(Figure 4.17). However, after RSV infection BAFF protein was elevated 
significantly at day 1 (1379 pg/ml, P=0.002), day 2 (1447 pg/ml, P=0.0001), day 7 
(3272 pg/ml, P=0.0001) and day 8 (2355 pg /ml, P=0.004) in comparison to UV 
RSV control at day 1 (460 pg/ml), day 2 (434 pg/ml), day 7 (398 pg/ml) and day 8 
(473 pg/ml). This is the overall average of experiments one and two. Experiment 
three is not included in this analysis. Two kinetics of BAFF were noticed at day 2 
and 7, and BAFF declined at day 4.  
  
 
 
 
 
 
 
 
 
 
 
BAFF protein was measured by specific murine BAFF ELISA. BAFF protein was increased 
significantly after RSV infection at days 1, 2, 7 and 8 in comparison to UV RSV control at 
the same time points. Result shown is the average of six animals from the first and second 
experiments. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=6). 
 
 
 
 
Figure 4.17: Average of BAFF protein expression after RSV infection or challenge 
with UV-RSV control 
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4.3.4.4. Average of APRIL mRNA after RSV infection in mice 
APRIL mRNA was expressed in non-infected mice at day 0 (fold expression relative 
to control=2.06) (Figure 4.18). However, after RSV infection, there was no 
significant increase of APRIL mRNA at day 1 (3.04, P=0.5) day 2 (3.79 ,P=0.8), day 
4 (2.98, P=0.1), day 7 (1.13 , P=0.1) or day 8 (2.96, P=0.6) in comparison to the 
RSV UV control on day 1 (4.22), day 2 (3.55), day 4 (5.9), day 7 (3.17) and day 8 
(4.007). RSV infection of mice did not significantly increase APRIL expression 
relative to UV RSV control at the same time points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APRIL mRNA was measured by RT-PCR. There was no significantly increase of APRIL 
mRNA after RSV infection at days 1, 2, 4, 7 and 8 in comparison to UV RSV control at the 
same time points.Values are shown as fold expression relative to control. Result shown is the 
average of six animals from the first and second experiment. Mean and SD are shown (two 
way ANOVA with Bonferroni post-hoc test, *P <0.05, n=6). 
 
 
 
 
 
Figure 4.18. Average of APRIL mRNA expression after RSV infection or challenge 
with UV-RSV control  
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4.3.5. Examination of the form of BAFF in murine lung after RSV infection  
 
To determine what form of BAFF is expressed after RSV infection, mice lung 
tissues were homogenized and analysed by western blot (Figure 4.19). The non-
infected BEAS-2B cells used as the positive control expressed a 31kD molecular 
weight form consistent with membrane BAFF (31kD). Membrane BAFF was 
expressed slightly on non-infected mice PBS at day 0, day 2 and day 4. However, 
after RSV infection a lower molecular weight form at around 20kD consistent with 
soluble BAFF (20kD) was detected on day 1, 2, 4 and 7.  
 
 
 
 
 
 
                                    
 
 
 
 
The non-infected BEAS-2B cells expressed membrane BAFF (31kD). Murine membrane 
BAFF was expressed slightly on non-infected mice PBS at day 0 (34 kD). After RSV 
infection soluble BAFF (20 kD) was expressed at day 1, 2, 4 and 7. β-Actin was used as a 
control to show any differences in amount of sample loaded on the gel. Human recombinant 
BAFF (17kD) was used as positive control for soluble BAFF.  
 
 
 
 
 
                                                  Days after RSV infection 
    rBAFF   BEAS-2B   PBS     1         2          4          7 
Membrane BAFF 31kd 
Soluble BAFF 17kd 
Soluble BAFF 20 kd 
β actin 
Figure 4.19. Western blot of analysis of BAFF expression by murine lungs 
after RSV infection 
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4.3.6. Immunofluorescence staining 
 
Immunofluorescence staining was used to confirm RSV infection and to examine the 
location of virus within the lung and to identify  RSV-infected cells and study the 
histological structure after RSV infection comparing control non-infected mice at 
day 0 and UV RSV control. Mouse lung section was prepared and stained with anti-
RSV (red) and anti-BAFF (green) as described in (chapter 2, section 2.8). 
4.3.6. 1. Detection of RSV in mice lung tissue after RSV infection  
 
4.3.6.2. Detection of RSV in mice lung tissue at day 0  
 
Murine at day 0 were given PBS as negative control of RSV infection. No positive 
staining for RSV was detected at day 0 and there was no comparable staining 
observed with the isotype control. No clear damage of airways and no obvious 
epithelial damage was seen (Figure 4.20). 
                                                   10x                                           40x 
 
                      Isotype  
 
 
 
 
                   DAPI/RSV 
 
 
 
No RSV (red) was detected. DAPI (Blue) staining was used to stain cell nucleus. Isotype 
control was applied. Images were originally obtained at 10 x and 40x magnifications.  
 
 
Figure: 4.20. RSV staining of lung sections taken from mice treated with PBS at day 0 
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4.3.6. 3. Detection of RSV in mice lung tissue after RSV infection at day 1 
 
Immunofluorescent staining of mouse lung tissue showed strong positive staining of 
RSV (red) at day 1 after RSV infection (Figure 4.21) indicated as white arrow and 
there was no comparable staining observed with the isotype control. RSV was 
localized in the cytoplasm of infected cells and appeared near to the airway 
epithelium. However, it has been shown that the predominant infected cell is the 
Type I alveolar pneumocyte (Openshaw 2013). Furthermore, it is likely that other 
cells may be infected with RSV such as alveolar macrophages and DCs. In addition, 
the structure of some RSV infected cells appeared to be affected possibly due to the 
cytopathic effect of RSV. In addition, some inflammatory cells were noticed in the 
lung sections as indicated (green arrow). 
 
                                  10x                                         40x                      400x                     
 
 
Isotype  
 
 
 
 
 
DAPI/RSV 
 
 
 
 
RSV (red) was detected around alveolar and airways as well as some inflammatory cells 
(green arrow). Cell nuclei shown in blue (DAPI). Isotype control was applied. Images were 
originally obtained using confocal microscopy at 10 x, 40x and 400x magnifications.  
Figure: 4.21. Immunohistochemical localization of RSV A2 proteins in lung sections 
prepared from mice at day 1 after RSV infection 
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4.3.6. 4. UV treated RSV in mouse lung after challenge at day 1  
 
 
As expected to observe, no RSV was detected from mouse lung tissue at day 1 after 
challenge with RSV UV treated (Figure 4.22) and no comparable staining was 
observed with the isotype control. In addition, no visible histological changes were 
seen after challenge, airways were clear with no obvious epithelial damage and the 
tissue structures appeared similar to non-infected mice at day 0 (Figure 4.20). 
However, some inflammatory cells were observed (green arrow). 
 
 
                                        10x                                  40x                                        400x 
 
 
 
Isotype  
 
 
 
 
DAPI/RSV 
 
 
 
RSV (red) was not detected in the airways. Cell nuclei shown in blue (DAPI). 
Isotype control was applied. Images were originally obtained using confocal 
microscopy at 10x, 40x and 400x magnifications.  
 
 
 
 
 
 
Figure: 4.22. RSV is absent from mice challenged with RSV UV treated at day 1 
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4.3.6.5. Detection of RSV in mice lung tissue after RSV infection at day 2 
 
Strong positive staining of RSV (red) was observed at day 2 after RSV infection 
(Figure 4.23) as indicated (white arrow), and no comparable staining was noticed 
with the isotype control. RSV was detected in the cytoplasm of infected cells. RSV 
was localized close to airways. In addition, infiltrated inflammatory cells as 
indicated (green arrow) were also observed between epithelium and alveolar spaces. 
RSV induced morphological changes including, epithelial damage that resulted in 
shrinkage and presence of debris, in comparison to non-infected PBS (Figure 4.20). 
 
 
                                   10x                                       40x                                     400x 
 
 
 
    Isotype  
 
 
 
 
 
 
 
 
RSV (red) was detected around alveolar and airways as indicated by arrow. Cell nuclei 
shown in blue (DAPI). Isotype control was applied. Images were originally obtained 
using confocal microscopy at 10x, 40x and 400x magnifications.  
 
 
 
DAPI/RSV 
Figure: 4.23. Immunohistochemical localization of RSV A2 proteins in lung sections 
prepared from mice day 2 
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4.1.3.6. UV treated RSV in mice lung after challenge at day 2 
 
No RSV (red) was detected in mouse lung tissue at day 2 after challenge with UV 
treated RSV (Figure 4.24), and no comparable staining was noticed with the isotype 
control. Furthermore, no histological damage caused after challenge and the tissue 
structures were comparable to non-infected mice at day 0 (Figure 4.20) although 
there was some inflammatory cell infiltration (green arrow). 
 
  10x                                       40x                                     400x 
 
   
  Isotype  
 
 
 
 
 
 
 
 
RSV (red) was not in the airways. Cell nuclei shown in blue (DAPI). Isotype control was 
applied. Images were originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications. 
 
 
 
 
 
 
DAPI/RSV 
Figure 4.24. RSV is absent from mice challenged with RSV UV treated on day 2 
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4.3.6.7. Detection of RSV in mice lung tissue after RSV infection at day 4 
 
 
Strong positive staining of RSV (red) was observed at day 4 after RSV infection 
(Figure 4.25) as indicated by arrow, and no comparable staining was noticed with the 
isotype control. In addition, RSV was detected into the cytoplasm of infected cells. 
RSV was localized near to airways epithelium and alveolar. RSV induced 
morphological changes including, epithelial damage that resulted in shrinkage of 
infected cells and infiltration of inflammatory cells (green arrow). 
 
                               10x                                          40x                                      400x 
 
 
Isotype  
 
 
 
 
DAPI/RSV 
 
 
 
 
RSV (red) was detected around alveolar and airways as indicated by arrow. Cell nuclei 
shown in blue (DAPI). Isotype control was applied. Images were originally obtained using 
confocal microscopy at 10x, 40x and 400x magnifications. 
 
 
 
 
 
Figure: 4.25 Immunohistochemical localization of RSV proteins in lung sections prepared 
from mice day 4 after infection with RSV 
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4.3.6.8. UV treated RSV in mice lung tissue after challenge at day 4 
 
No RSV staining was observed after challenge with RSV UV treated (Figure 4.26) at 
day 4, and no comparable staining was noticed with the isotype control. In addition, 
no histological damage was observed and the tissue structures were quite similar to 
non-infected mice PBS (Figure 4.20) and there were some inflammatory cells 
noticed (green arrow). 
    
                             10x                                           40x                                      400x 
  
 
Isotype  
 
 
 
 
 
 
 
No RSV (red) was detected in the airways. Cell nuclei shown in blue (DAPI). Isotype 
control was applied. Images were originally obtained using confocal microscopy at 10x, 
40x and 400x magnifications. 
 
 
 
 
 
 
 
DAPI/RSV 
Figure 4.26. RSV is absent from mice infected with RSV UV treated on day 4 
147 
 
4.3.6.9. Detection of RSV in mice lung tissue after RSV infection at day 7 
 
RSV (red) was detected at day 7 after RSV infection (FFigure 4.27) as indicated by 
arrow, and no comparable staining was noticed with the isotype control. RSV was 
detected in the cytoplasm of infected cells. RSV induced morphological changes 
including, shrinkage of infected cells, and spread of debris and obstruction of 
airways as well as infiltration of inflammatory cells (green arrow) in comparison to 
non-infected at day 0 (Figure 4.20). 
 
                                         10x                                        40x                                 400x  
 
    Isotype  
 
 
 
 
    DAPI/RSV 
 
 
 
 
There was positive staining of RSV (red) detected around alveolar and airways as 
indicated by arrow. Cell nuclei shown in blue (DAPI). Isotype control was applied. 
Images were originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications. 
 
 
 
 
 
Figure 4.27. Immunohistochemical localization of RSV proteins in lung 
sections prepared from mice day 7 after infection with RSV 
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4.3.6.10. UV treated RSV in mice lung tissue after challenge at day 7 
 
 
No RSV staining was observed after challenge with RSV UV treated (FFigure 4.28) 
at day 7, and no comparable staining was noticed with the isotype control. In 
addition, limited histological damage observed and the tissue structures were quite 
similar to non-infected mice PBS (Figure 4.20) and there some inflammatory cells 
were noticed (green arrow). 
                                                10x                                         40x                               
 
            Isotype  
 
 
 
 
           DAPI/RSV 
 
 
 
RSV (red) was not in the airways. Cell nuclei shown in blue (DAPI). Isotype control was 
applied. Images were originally obtained using confocal microscopy at 10x and 40x 
magnifications. 
 
 
 
 
 
 
 
Figure 4.28. RSV was not detected in mice challenged with RSV UV treated at day 7 
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4.3.6.11. Detection of RSV in mice lung tissue after RSV infection at day 8 
 
 
No RSV was detected from mouse lung tissue at day 8 after RSV infection (Figure 
4.29), and no comparable staining was noticed with the isotype control. In addition, 
there was limited histological damage and some infiltration of inflammatory cells 
was observed (green arrow).  
                                        10x                                         40x                                  400x 
 
    Isotype 
 
 
 
 
    DAPI/RSV 
 
 
 
No RSV (red) was detected in the airways. Cell nuclei shown in blue (DAPI). Isotype 
control was applied. Images were originally obtained using confocal microscopy at 10x, 
40x and 400x magnifications. 
 
 
 
 
 
 
 
 
 
Figure 4.29. RSV is absent from mice infected with RSV at day 8 
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4.3.6.12. UV treated RSV in mice lung tissue after challenge at day 8 
 
No RSV was detected from mouse lung tissue at day 8 after RSV UV treated 
challenge (Figure 4.30), and no comparable staining was noticed with the isotype 
control. There was limited histological damage and some inflammatory cells were 
observed (green arrow). 
                                        10x                                    40x                            400x  
 
 
    Isotype  
 
 
 
    DAPI/RSV 
 
 
RSV (red) was not in the airways. Cell nuclei shown in blue (DAPI). Isotype control was 
applied. Images were originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications. 
 
 
 
 
 
 
 
 
 
Figure 4.30. RSV is absent from mice challenged with RSV UV treated at day 8 
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4.3.6.2. Detection of BAFF in lung tissue after RSV infection 
 
4.3.6.2.1. Mouse spleen positive control sections 
 
BAFF is normally expressed in secondary lymphoid tissue such as spleen (Mackay 
& Browning 2002). Thus, BAFF (green) has been stained in mouse spleen sections 
as positive control (Figure 4.31).  
 
                                     
                                    10x                                    40x                                 400x 
 
 
DAPI/BAFF 
 
 
 
 
 
BAFF (green) was detected around cells as indicated by arrow. Cell nuclei 
shown in blue (DAPI). Isotype control was applied. Images were originally 
obtained using confocal microscopy at 10x, 40x and 400x magnifications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isotype BAFF 
Figure 4.31. BAFF is normally expressed in mouse spleen section 
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4.3.6.2. 2. BAFF is expressed in non-infected mice at day 0 
 
Mouse lung sections at day 0 showed positive staining of BAFF (green) in the lungs 
(Figure 4.32), and no comparable staining was noticed with the isotype control. 
BAFF was expressed around the epithelium.  
                                           10x                               40x                            400x  
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   DAPI/BAFF 
 
 
BAFF (green) was detected around epithelium and airways as indicated by 
arrow. Cell nuclei shown in blue (DAPI). Isotype control was applied. Images 
were originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32. Expression of BAFF in non-infected mice at day 0 
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4.3.6.2.3. RSV infection of mice lungs induced BAFF expression at day 1 
 
Immunofluorescent staining of a lung section from mouse infected with RSV at day 
1 showed strong positive staining BAFF (green), and no comparable staining was 
noticed with the isotype control. Moreover, BAFF was localized around epithelium 
and alveoli (Figure 4.33), as indicated by arrow. In addition, there were 
morphological changes of lungs’ structure, including epithelial damage, and 
obstruction of airways with fragmented and mixed inflammatory cells (brown 
arrow), that may also express BAFF. 
 
 
                                         10x                                40x                                    400x 
 
   Isotype  
 
 
 
 
  DAPI/BAFF 
 
 
There was strong positive staining of BAFF (green) detected around epithelium, alveoli 
and some inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). 
Isotype control was applied. Images were originally obtained using confocal microscopy 
at 10x, 40x and 400x magnifications. 
  
 
 
 
 
Figure 4.33. Expression of BAFF in mouse lung section after RSV infection at day 1 
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4.3.6.2.4. UV treated RSV challenge of mouse lungs expressed BAFF at day 1 
 
Lung sections from mice challenge with UV treated RSV at day 1 showed positive 
staining of BAFF (green) (Figure 4.34), and no comparable staining was noticed 
with the isotype control. BAFF was localized around airway and some infiltrated 
inflammatory cells (brown arrow) also expressed BAFF.  
                              10x                                         40x                               400x 
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DAPI/BAFF 
 
 
There was positive staining of BAFF (green) detected around epithelium and airways 
as indicated by arrow. Cell nuclei shown in blue (DAPI). Isotype control was applied. 
Images were originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34. Expression of BAFF in RSV UV treated mouse at day 1 
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4.3.6.2.5. RSV infection of mice lungs induced BAFF expression at day 2 
 
Lung sections from mice infected with RSV at day 2 showed strong positive staining 
of BAFF (green), and no comparable staining was noticed with the isotype control. 
BAFF is expressed around epithelium (Figure 4.35) and some infiltrating 
inflammatory cells (brown arrow) also expressed BAFF. 
 
                                  10x                                    40x                                    400x 
 
Isotype  
 
 
 
 
DAPI/BAFF 
 
 
 
There was strong positive staining of BAFF (green) detected around epithelium, airways 
and some inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). 
Isotype control was applied. Images were originally obtained using confocal microscopy at 
10x, 40x and 400x magnifications. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35. Expression of BAFF in mouse lung section after RSV infection at day 2 
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4.3.6.2.6. UV treated RSV of mice lungs challenge expressed BAFF at day 2 
 
Lung sections from mice challenge with UV treated RSV at day 2 showed positive 
staining of BAFF (green) (Figure 4.36), and no comparable staining was noticed 
with the isotype control. BAFF was localized around airway and some infiltrating 
inflammatory cells also expressed BAFF (brown arrow).  
 
                                         10x                                  40x                           400x  
 
            Isotype 
 
 
 
        DAPI/BAFF 
 
 
 
There was positive staining of BAFF (green) detected around epithelium, airways 
and inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). 
Isotype control was applied. Images were originally obtained using confocal 
microscopy at 10x, 40x and 400x magnifications. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36. Expression of BAFF after RSV UV treated challenged at day 2 
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4.3.6.2.7. RSV infection of mice lungs induced BAFF expression at day 4  
 
Lung sections from mice infected with RSV at day 4 showed positive staining of 
BAFF (green) (Figure 4.37), and no comparable staining was noticed with the 
isotype control. BAFF is expressed around epithelium and some infiltrating 
inflammatory cells. 
                                        10x                                40x                           400x  
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     DAPI/BAFF 
 
 
There was positive staining of BAFF (green) detected around epithelium, airways and 
inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). Isotype control 
was applied. Images were originally obtained using confocal microscopy at 10x, 40x and 
400x magnifications. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.37. Expression of BAFF after RSV infection at day 4 
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4.3.6.2.8. UV treated RSV mice lungs challenge expressed BAFF at day 4 
 
Lung sections from mice challenge with UV treated RSV at day 4 showed positive 
staining of BAFF (Figure 4.38), and no comparable staining was noticed with the 
isotype control. BAFF (green) was localized around epithelium and some infiltrating 
inflammatory cells (brown arrow).  
 
 
                                       10x                              40x                               400x 
 
 
Isotype 
 
 
DAPI/BAFF 
 
 
 
There was positive staining of BAFF (green) detected around epithelium, airways and 
inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). Isotype control 
was applied. Images were originally obtained using confocal microscopy at 10x, 40x and 
400x magnifications. 
 
 
 
 
 
 
 
Figure 4.38. Expression of BAFF after RSV UV treated challenged at day 4 
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4.3.6.2.9. RSV infection of mice lungs induced BAFF expression at day 7 
 
Lung sections from mice infected with RSV at day 7 showed strong positive staining 
of BAFF (green) ,and no comparable staining was noticed with the isotype control 
(Figure 4.39). BAFF was localized around epithelium and some inflammatory cells 
(brown arrow) have also expressed BAFF. 
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    DAPI/BAFF 
 
 
There was strong positive staining of BAFF (green) detected around 
epithelium, airways and some inflammatory cells as indicated by arrow. 
Cell nuclei shown in blue (DAPI). Isotype control was applied. Images were 
originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications.  
 
 
 
 
 
 
 
 
Figure 4.39. Expression of BAFF after RSV infection at day 7 
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4.3.6.2.10 .UV treated RSV mice lungs challenge expressed BAFF at day 7 
 
Lung sections from mice challenge with UV treated RSV at day 7 showed positive 
staining of BAFF (green), and no comparable staining was noticed with the isotype 
control (Figure 4.40). BAFF was localized around epithelium and some infiltrated 
inflammatory cells (brown arrow).  
 
                                             10x                            40x                                   400x 
 
      Isotype 
 
 
 
     DAPI/BAFF 
 
 
 
There was positive staining of BAFF (green) detected around epithelium, airways 
and inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). 
Isotype control was applied. Images were originally obtained using confocal 
microscopy at 10x, 40x and 400x magnifications 
 
 
 
 
 
 
 
 
Figure 4.40. Expression of BAFF after RSV UV challenged at day 7 
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4.3.6.2.11. RSV infection of mice lungs induced BAFF expression at day 8 
 
Lung sections from mice infected with RSV at day 8 showed strong positive staining 
of BAFF (green), and no comparable staining was noticed with the isotype control 
(Figure 4.41). BAFF was localized around epithelium and some inflammatory cells 
(brown arrow) that also expressed BAFF. 
                                             10x                                40x                                      400x 
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     DAPI/BAFF 
 
 
 
 
There was strong positive staining of BAFF (green) detected around 
epithelium, airways and some inflammatory cells as indicated by arrow. 
Cell nuclei shown in blue (DAPI). Isotype control was applied. Images were 
originally obtained using confocal microscopy at 10x, 40x and 400x 
magnifications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.41. Expression of BAFF after RSV infection at day 8 
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4.3.6.2.12. UV treated RSV mice lungs challenge expressed BAFF at day 8 
 
Lung sections from mice challenge with UV treated RSV at day 8 showed positive 
staining of BAFF (green), and no comparable staining was noticed with the isotype 
control (Figure 4.42). BAFF was localized around epithelium and some infiltrated 
inflammatory cells (brown arrow).  
                                           10x                                   40x                                   400x 
 
 
               Isotype 
 
 
 
          DAPI/BAFF 
 
 
 
There was positive staining of BAFF (green) detected around epithelium, airways and 
inflammatory cells as indicated by arrow. Cell nuclei shown in blue (DAPI). Isotype 
control was applied. Images were originally obtained using confocal microscopy at 
10x, 40x and 400x magnifications. 
 
 
 
 
 
 
 
Figure 4.42. BAFF Expression after UV RSV challenged at day 8 
163 
 
4.3.7. Discussion 
 
4.3.7.1. Detection of RSV infection in BALB/c mice after infection 
 
To demonstrate that intranasal RSV A2 challenge of mice resulted in RSV infection 
within the lower airway, RSV N RNA expression was measured by RT-PCR. These 
experiments were carried out using homogenized lung tissue from RSV infected and 
UV treated RSV control and non-infected mice challenge with PBS at day 0. 
Increasing levels of RSV were significantly detected at day 1, 2 and day 4 (1.87, 
P=0.12) after RSV infection in comparison to the UV RSV controls at the same time 
points. RSV N RNA was significantly higher 4 days after infection and began to 
decline by 7 days after infection (F). RSV infection was undetectable 8 days after 
infection. Overall, there were two peaks of RSV, at day1 and 4. This is the overall 
average of experiments one and two, experiment three is not included in this analysis 
as result of weak infection (Figure 4.12). Overall, these findings are in agreement 
with other study that found at day 4 after infection viral load peaks at days 4–5 and 
after which the viral load declined (Openshaw 2013; Taylor et al. 1984) . 
Moreover, RSV infection was further confirmed by immunofluorescence staining. 
As expected, RSV (red) was detected at day 1 (Figure 4.21), day 2 (Figure 4.23), and 
day 4 (Figure 4.25). There was strong positive staining of RSV at day 4, weak at day 
7 (Figure 4.27) and undetectable on day 8 (Figure 4.29) in comparison to non-
infected PBS and RSV-UV treated at the same time points. The results obtained 
using immunofluorescence staining of lung sections are correlated with the RT-PCR 
results measuring RSV N RNA (Figure 4.15). 
Furthermore, immunofluorescence staining of RSV infected mice on day 1 (Figure 
4.21), day 2 (Figure 4.23), day 4 (Figure 4.25) and day 7 (Figure 4.27) showed that 
RSV infection induced pathological changes including bronchiolar epithelial 
damage, and obstruction of some bronchioles with fragmented epithelium mixed 
with infiltrated inflammatory cells. However, these changes were less evident in 
non-infected at day 0 (Figure 4.20) and UV treated RSV animals at day 1 (Figure 
4.22), day 2 (Figure 4.24), day 4 (Figure 4.26) and day 7 (Figure 4.28). 
Furthermore, immunofluorescence staining indicated that the RSV was both 
localized around airway epithelium and in other alveolar cells, possibly macrophages 
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(Figures 4-21, 4-23, 4-25 and 4-27). However, it has been shown that the 
predominant infected cell is the Type I alveolar pneumocyte that line the alveolar 
surfaces of the lungs (Openshaw 2013). To ensure these cells were epithelium and 
that RSV infects murine epithelium, the epithelium could be labeled with a specific 
marker such as cytokeratin-19, and dual stained for RSV.  
 
4.3.7.2. BAFF mRNA and protein, but not APRIL mRNA, were increased 
significantly during RSV infection, compared to UV treated RSV and non-
infected animals 
 
BAFF mRNA was expressed in non-infected mice at day 0 (fold increase 0.75). 
However, after RSV infection BAFF mRNA expression was increased significantly 
on day 1 (fold increase relative to control= 1.09, P=0.008), day 7 (1.5, P=0.004) and 
day 8 (1.09, P=0.01) in comparison to UV treated RSV control on day 1 (0.7), day 7 
(0.8) and day 8 (0.5) (Figure 4.16). 
BAFF protein was expressed in non-infected mice at day 0 (mean = 478 pg/ml). This 
could be released during preparation of samples or also it is possible that lung 
normally contains BAFF protein. However, after RSV infection BAFF protein was 
elevated significantly at day 1, 2, 4, 7 and day 8 in comparison to UV treated RSV 
control at the same time points (Figure 4.17). 
Overall, there appear to be two peaks of both BAFF mRNA (Figure 4.16) and 
protein (Figure 4.17) expressions after RSV infection. BAFF was increased on day 1 
and 2 and then declined on day 4. This increase could be as results of production of 
BAFF by the infected lung epithelial cells. On day 7 BAFF protein reached the peak 
level of expression. This could be due to further secretion by the infiltrated 
leukocytes and DC where B cells respond and differentiate (chapter 5).  
Although BAFF expression after RSV infection has been reported to depend on 
production of IFN-β by the infected cells (McNamara et al. 2013), it is difficult to 
confirm whether this is the case in this model. Thus, to determine whether BAFF 
expression in this model was depending on IFN-β or not, we could inhibit IFN-β in 
mice prior to RSV infection and observe if production of BAFF depends on IFN-β at 
day 7 and 8 after RSV challenge. Furthermore, measuring IFN-β after infection 
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would also be useful to determine an increase production of IFN-β following RSV 
infection. Taken together, the kinetics of BAFF expressions were associated with 
RSV kinetics expression at day 1 and 2, although RSV reached highest levels at day 
4, BAFF protein was significantly declined. Furthermore, the kinetics of BAFF 
protein expression initially parallel RSV kinetics suggesting that RSV is directy or 
indirectly inducing BAFF expression. At day 7 and 8 there was no evidence by PCR 
of the presence of RSV, which suggested that BAFF can be further released by 
inflammatory cells. 
Expression of BAFF was further confirmed by immunofluorescence staining of 
mouse lung sections. It has been reported that BAFF is expressed normally in 
secondary lymphoid tissue such as spleen (Bossen & Schneider 2006), thus, mouse 
spleen was stained for BAFF as apositive control for lung sections (Figure 4.31).  
Immunofluorescence staining of mouse lung on day 0 (Figure 4.32) and non-infected 
BEAS-2B cells (chapter 3, Figure 3.13.2.A) showed that BAFF was normally 
expressed.  
Furthermore, western blot analysis of homogenized lung tissue showed membrane 
BAFF (34kD) was expressed by non-infected mice and resting BEAS-2B cells 
(31kD) (Figure 4.19). However, soluble BAFF was (20 kD) expressed at day 1, 2, 4 
and 7 after RSV infection. This suggests that at later time points soluble BAFF (20 
kD) was cleaved from the membrane bound form (34 kD) and soluble BAFF 
released by RSV infected epithelial cells may enhance the adaptive immune response 
by inducing infiltration of cells. In addition, the absence of a clear band of membrane 
BAFF expected in non-infected mice at day 0 could be as result of low protein 
loading as shown by beta actin. 
Furthermore, there was strong positive staining of BAFF (green) detected at day 1 
(Figure 4.33), 2 (Figure 35), 7 (Figure 4.39) and 8 (Figure 4.41) in comparison to 
UV treated RSV control where BAFF was expressed weaker than RSV infected at 
day 1 (Figure 4.34), day 2 (Figure 4.36), day 7 (Figure 4.40) and day 8 (Figure 4.42). 
BAFF was expressed around epithelium and some infiltrated inflammatory cells that 
could also induce BAFF expression such as neutrophils, monocytes and 
macrophages.  
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Expression of APRIL was studied by RT-PCR. Non-infected mice at day 0 
expressed APRIL mRNA but there was no significant increase expression of APRIL 
mRNA after RSV infection relative UV RSV control at day 1, 2, 4, 7 and 8 (Figure 
4.18). 
In the absence of evidence from these PCR experiments that the level of APRIL 
mRNA expression increased as a result of RSV infection and the low sensitivity of 
commercial APRIL ELISA’s assays, APRIL protein expression was not measured.  
APRIL is known to be expressed at the cell surface or complexed to proteoglycans, 
which would also make detection difficult (Reijmers et al. 2011). It could also be 
possible that APRIL is expressed as a protein at later time points or it requires 
further signals to be released. In addition, this result correlates with our recent 
finding where there was no significant up regulation of APRIL observed during 
natural RSV infection in humans (McNamara et al. 2013), at least not in epithelial 
cells. Although here the study is limited to showing that there was no significant 
increased expression of APRIL mRNA, absence of APRIL protein could lead to 
decreased B cell maturation and memory cell responses (Xiao et al. 2011). 
Human respiratory syncytial virus can re-infect symptomatically throughout life 
without significant antigenic change, suggestive of incomplete or short-lived 
immunity. In contrast, re-infection by influenza A virus largely depends on antigenic 
change, suggestive of more complete immunity (Le Nouen et al. 2011). 
It has been suggested that BAFF has an important role at the early stages of B cell 
development, while APRIL is more essential at later stages of B cell responses when 
plasma cells are produced (Treml et al. 2009). Thus, it could be possible that 
influenza infection induces APRIL expression and therefore increases survival of 
long lived plasma cells, whereas RSV does not induce APRIL and for this reason no 
strong adaptive immune response is induced against RSV, allowing later re-
infection. 
In vivo, it has been shown that mice infected with influenza virus for 35 days and 
later treated for 2 weeks with TACI-Fc that neutralizes both BAFF and APRIL have 
a reduced percentage and total number of Ab-secreting cells, including virus-specific 
Ab-secreting cells, in lungs and BM. This was associated with a significant reduction 
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in antiviral serum IgG, as well as virus-specific IgG and IgA in the BAL (Wolf et al. 
2011). However, mice treated with anti-BAFF after 36 days of influenza infection 
had no effect on antiviral antibody protection measured by virus specific IgG and 
IgA titre in serum and BAL although CD19
+
 B cells were significantly reduced in 
spleen, lung-draining medLN, and lungs. These observations suggested that 
blockade of BAFF and APRIL, but not BAFF alone, regulates ASC survival in 
response to influenza virus infection (Wolf et al. 2011). To further understand this 
process behind this mechanism of local antibody production in RSV infection, 
APRIL alone could be blocked to see if the survival of B cells will be affected since 
the study above targeted BAFF and APRIL or BAFF alone. 
 
4.3.8. Summary 
A mouse model of human RSV infection was successfully established and used to 
examine BAFF expression in response to RSV infection. Immunofluorescence 
staining indicated that the RSV was localized to the airway epithelium. However, it 
has been shown that the predominant infected cell is the Type I alveolar pneumocyte. 
RSV infection of mice induced significantly expression of BAFF mRNA and 
protein, but not APRIL relative to non-infected and UV-RSV challenge control. Two 
peaks of BAFF expression were observed. Immunofluorescence staining of mouse 
lung sections further confirmed expression of BAFF around epithelium and some 
inflammatory cells after RSV infection. Western blot analysis of homogenized lung 
tissue showed that non infected mice expressed membrane BAFF (34 kD) and after 
RSV infection soluble BAFF (20 kD) was noticed. These results suggest the 
importance of epithelium in supporting the adaptive immune response by production 
of BAFF in the lungs during RSV infection, and do not exclude production of BAFF 
by other inflammatory cells. 
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CHAPTER 5. EXPRESSION OF CXCL12, CXCL13, CCL19 AND CCL21 IN 
A MURINE MODEL OF HUMAN RESPIRATORY SYNCYTIAL VIRUS 
INFECTION 
5.1. Aims 
Experiments described in chapter 4 demonstrate increased expression of BAFF, a B 
cell growth and differentiation factor in the airway in response to RSV infection, 
raising the possibility that BAFF may act locally to enhance the adaptive immune 
response within the airway. For this to occur, lymphocytes would also need to be 
recruited to the lungs. The work described in this chapter aimed to use the murine 
model of human RSV infection described in chapter 4 to further understand how 
recruitment of B and T cells in response to RSV infection may be regulated. To 
better understand this process, the local expression of the lymphoid chemokines, 
including CXCL12, CXCL13, CCL19, and CCL21 (chapter 1, 1.4) were measured in 
homogenised mouse lung tissue after RSV infection. Specific aims were: 
1 -To determine if the homeostatic chemokines CXCL12, CXCL13, CCL19 and 
CCL21 (chapter 1, 1.4) are expressed following RSV infection by RT-PCR and 
ELISA. 
2- To examine localization of CXCL13 expression in lung murine sections following 
RSV infection. 
3 -To determine if B (anti-CD20) and T cells (anti-CD3) were recruited into the 
lungs after RSV infection and examine their localization in lung sections following 
RSV infection. 
5.2. Experimental design  
 
The same samples as used in the previous chapter (chapter 4) were further used to 
analyse local expression of CXCL12, CXCL13, CCL19 and CCL21 by RT-PCR and 
ELISA. In addition, mouse lung sections were examined by immunofluorescence 
staining to study localization of CXCL13, B cells and T cells (Chapter 4, Figure 4.1). 
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5.3. Results 
5. 3.1. Experiment 1 
5. 3.1.1. Expression of CXCL13 mRNA and protein after RSV infection   
 
To study CXCL13 mRNA expression in vivo, mice were infected with RSV (A2 
strain) and samples collected at different time points, time day 0 (non-infected), 1, 2, 
4 and 7 days. RNA was isolated and prepared using Qiagen as described (chapter 2, 
2.4). CXCL13 mRNA was measured and analyzed by RT-PCR. Non-infected mice 
day 0 expressed CXCL13 mRNA (fold expression relative to control=0.07). 
However, after RSV infection CXCL13 mRNA expression was increased 
significantly at day 1 (1.36, P=0.04), day 2 (1.08, P=0.04) and day 7 (0.97, P=0.02) 7 
in comparison to UV RSV control on day 1 (0.29), day 2 (0.08) and day 7 (0.08) 
(Figure 5.1.A). Furthermore, CXCL13 protein (Figure 5.1.B) was measured in 
homogenised lung tissue. CXCL13 protein was expressed in non-infected mice at 
day 0 (mean=296 pg/ml). However, after RSV infection CXCL13 protein was 
increased significantly at day 1 (762 pg/ml, P=0.01), day 2 (612 pg/ml, P=0.02), and 
day 7 (388 pg/ml, P=0.007) in comparison to UV RSV control at day 1 (374 pg/ml), 
day 2 (278 pg/ml) and day 7 (249 pg/ml). Overall, there were two peaks formed of 
both CXCL13 mRNA and protein at day 1 and 7 and declined at day 4. 
 
 
  
 
 
 
CXCL13 mRNA was measured by RT-PCR. CXCL13 mRNA expression was increased 
significantly after RSV infection on day 1, 2 and 7 in comparison to UV RSV control at the 
same time points. Values are shown as fold expression relative to control. CXCL13 protein 
was measured by use of specific murine CXCL13 ELISA. CXCL13 protein was increased 
significantly after RSV infection at day 1, 2, and 7 in comparison to UV RSV control at the 
same time points. Result shown is the average of three animals in the first experiment. Mean 
and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
A B 
Figure 5. 1. Expression of CXCL13 mRNA (A) and protein (B) after RSV infection or 
challenge with UV-RSV control 
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5.3.1.2. CXCL13 protein expression in comparision to total ptotein 
concentration after RSV infection 
 
CXCL13 protein (pg/ml) levels were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). CXCL13 protein was expressed in non-infected mice at day 0 (mean=256 
pg/ng). After RSV infection there was no significant increase of CXCL13 protein 
(Figure 5.2) at day 1 (617 pg/ng, P=0.1), day 2 (567 pg/ng, P=0.1), day 4 (205 pg/ng, 
P=0.1) and day7 (222 pg/ng, P=0.9) in comparison to UV RSV control on day 1 (460 
pg/ng), day 2 (258 pg/ng), day 4 (253 pg/ng) and day 7 (223 pg/ng).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL13 protein was expressed in non- infected mice at day 0 and after RSV infection there 
was no significant increase in comparison to UV RSV control on day 1, 2, 4 and 7. Result 
shown is the average of three animals in the first experiment. Mean and SD are shown (two 
way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Normalized CXCL13 protein to total protein after RSV infection or 
challenge with UV-RSV control 
                  CXCL13 pg/mg of total protein (n=3)
0 1 2 4 7
0
200
400
600
800
1000
RSV
UV-RSV
Days after  RSV  infection
P
g
 /
m
g
 o
f 
to
ta
l 
p
ro
te
in
171 
 
5. 3.1.3. RSV infection did not significantly up regulate CCL19 mRNA and 
protein expression  
 
To determine if CCL19 mRNA is expressed after RSV infection, mice were infected 
with RSV (A2 strain) at time points, including time day 0 (non-infected), 1, 2, 4 and 
7. At the time points indicated after RSV infection mouse lung tissues were 
homogenized and RNA was isolated and prepared using Qiagen as described 
(Chapter 2.4). There was significant increase of CCL19 mRNA (Figure 5.3.A) after 
RSV infection on day 4 (0.01, P=0.0005) in comparison to UV RSV control on day 4 
(0.005). CCL19 protein (Figure 5.3.B) was measured in homogenized mouse lung 
tissue. Non - infected mice at day 0 expressed CCL19 protein (mean = 298 pg/ml). 
However, after RSV infection there was significant decrease of CCL119 protein at 
day 7 (200 pg/ml, P=0.03) in comparison to UV RSV control on day 7 (290 pg/ml).  
 
 
 
 
 
 
 
 
CCL19 mRNA was measured by RT-PCR. CCl19 was expressed at day 1, 2 and 7. However, 
on day 4 CCL19 mRNA was decreased significantly in comparison to UV treated RSV 
control at the same time point. Values are shown as fold expression relative to control. 
CCL19 protein was measured by using specific murine CCL19 ELISA. CCL19 protein was 
expressed in non-infected mice at day 0 and there was significant decrease after RSV 
infection at day 7 in comparison to UV RSV control at the same time point. Result shown is 
the average of three animals in the first experiment. Mean and SD are shown (two way 
ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
A B 
Figure 5.3. Expression of CCL19 mRNA (A) and protein (B) after RSV infection or 
challenge with UV-RSV control 
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5. 3.1.4. CCL19 protein expression in comparison to total protein concentration 
after RSV infection  
 
CCL19 protein (pg/ml) levels were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). CCL19 protein (Figure 5.4) was expressed in samples collected at day 0 
(mean =266 pg/ng). However, after RSV infection, CCL19 protein was decreased 
significantly at day 7 (115 pg/ng, P=0.003) in comparison to UV RSV control on day 
7 (260 pg/ng). 
 
 
 
 
 
 
 
 
 
 
 
 
CCL19 protein was expressed in non-infected mice at day 0 and there was significant 
decrease of CCL19 protein at day 7 after RSV infection in comparison to UV RSV control at 
day 7. Result shown is the average of three animals in the first experiment. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3).  
 
 
 
 
 
 
 
 
 
Figure 5.4. Normalized CCL19 protein to total protein after RSV infection or challenge 
with UV-RSV control 
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5. 3.1.5. RSV infection did not significantly up regulate CCL21 mRNA and 
protein  
 
To determine if CCL21 mRNA is expressed after RSV infection, mice were infected 
with RSV (A2 strain) at various time points, including time day 0 (non-infected), 1, 
2, 4 and day 7. At the time points indicated after RSV infection mouse lungs tissue 
were homogenized and RNA was isolated and prepared using Qiagen as described 
(chapter 2, 2.4). CCL21 mRNA was expressed in non-infected mice at day 0 (fold 
expression relative to control= 3.64). After RSV infection, there was no significant 
increase of CCL21 mRNA expression at day 1 (2.9, P=0.9), day 2 (5, P=0.6), day 4 
(4.31, P=0.1) and day 7 (2.62, P=0.8) in comparison to UV RSV control on day 1 
(2.86), day 2 (3.81), day 4 (9.07) and day 7 (2.95) (Figure 5.5.A). 
Furthermore, CCL21 protein (Figure 5.5.B) was measured in homogenised lung 
tissue. CCL21 protein was expressed in non-infected mice at day 0 (mean 
=571pg/ml). After RSV infection, CCL21 protein was decreased significantly at day 
1 (408 pg/ml, P=0.04) in comparison to UV RSV control at day 1 (499 pg/ml). 
 
 
 
 
 
 
 
 
CCL21 mRNA was measured by RT-PCR. CCL21 mRNA was expressed in non-infected mice 
at day 0 and there was no significant increase after RSV infection on day 1, 2, 4 and 7 in 
comparison to UV RSV control at the same time points. Values are shown as fold expression 
relative to control. CCL21 protein was measured by use a specific murine CCL21 ELISA. 
CCL21 protein was expressed in non-infected mice at day 0 and after RSV infection CCL21 
protein decreased significantly at day 1 relative to UV RSV control on day 1. Result shown 
is the average of three animals in the first experiment. Mean and SD are shown (two way 
ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
A B 
Figure 5.5. Expression of CCL21 mRNA (A) and protein (B) after RSV infection or 
challenge with UV-RSV control 
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5. 3.1.6. Normalised CCL21 protein to total protein after RSV infection  
 
CCL21 protein levels (pg/ml) were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). Non-infected mice expressed CCL21 protein at day 0 (mean= 500 pg/ng) 
(Figure 5.6). RSV infection did not significantly increase expression of CCL21 
protein at day 1 (343 pg/ng, P=0.1), day 2 (427 pg/ng, P=0.9), day 4 (319 pg/ng, 
P=0.1) and day 7 (215 pg/ng, P=0.059) in comparison to UV RSV control on day 1 
(633 pg/ng), day 2 (437 pg/ng), day 4 (391 pg/ng) and day 7 (354 pg/ng).  
 
 
 
 
 
 
 
 
 
 
 
 
CCL21 protein was expressed in non-infected mice at day 0 and there was no significant 
increase of CCl21 protein after RSV infection in comparison to UV RSV control on day 1, 2, 
4 and 7. Result shown is the average of three animals in the first experiment. Mean and SD 
are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Normalized CCL21 protein to total protein content after RSV infection or 
challenge with UV-RSV control 
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5. 3.1.7. RSV infection did not significantly up regulate CXCL12 protein  
 
To determine if CXCL12 protein is expressed after RSV infection, mice were 
infected with RSV (A2 strain) at different time points, including time day 0 (non-
infected), 1, 2, 4 and 7. At the time points indicated after RSV infection mouse lung 
tissues were homogenized and CXCL12 protein was measured. Non-infected mice 
expressed CXCL12 protein (Figure 5.7) at day 0 (mean= 879 pg/ml). However, after 
RSV infection there was no significant increased expression of CXCL12 protein at 
day 1 (781, P=0.2), day 2 (790, P=0.5), day 4 (918, P= 0.9) and day 7 (669 pg/ml, 
P=0.2) in comparison to UV RSV control on day 1 (967 pg/ml), day 2 (847 pg/ml), 
day 4 (925 pg/ml) and day 7 (932 pg/ml).  
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was measured by use of specific murine CXCL12 ELISA. CXCL12 protein 
was expressed in non-infected mice at day 0 and there was no significant increased after 
RSV infection at day 1, 2, 4 and 7 in comparison to UV RSV control at the same time points. 
Result shown is the average of three animals in the first experiment. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
Figure 5.7. Expression of CXCL12 protein after RSV infection or challenge with UV-
RSV control 
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5. 3.1.8. Normalised CXCL12 protein to total protein  
 
CXCL12 protein (pg/ml) was normalised to total protein (pg/ng) (chapter 2, 2.3.2). 
Non-infected mice expressed CXCL12 protein (Figure 5.8) at day 0 (mean=764 
pg/ng). RSV infection did not significantly increase expression of CXCL12 protein 
at day 1 (634 pg/ng, P=0.1), day 2 (739 pg/ng, P=0.8) and day 4 (675 pg/ng, P=0.8) 
and day 7 in comparison to UV RSV control on day 1 (1246 pg/ng), day 2 (793 
pg/ng) and day 4 (701 pg/ng). In addition, at day 7, CXCL12 protein was decreased 
significantly after RSV infection (368 pg/ng, P=0.007) relative to UV RSV control at 
day 7 (833 pg/ng).  
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was expressed in non-infected mice at day 0 and there was no significant 
increase after RSV infection in comparison to UV RSV control on day 1, 2and 4. In addition, 
at day 7, there was sifniccant decrease of CXCL12 protein relative to UV RSV control at day 
7. Result shown is the average of three animals in the first experiment. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
  
Figure 5.8. Normalised CXCL12 protein to total protein content after RSV infection or 
challenge with UV-RSV control 
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5. 3.2. Experiment II 
 
5. 3.2.1. Expression of CXCL13 mRNA and protein after RSV infection  
 
Mice were infected with RSV (A2 strain) at various time points, including day 0 
(non-infected), 1, 2, 4, 7 and 8. At the time points indicated after RSV infection 
mouse lungs tissue was homogenized and RNA was isolated and prepared using 
Qiagen as described (chapter 2, 2.4). CXCL13 mRNA was measured and analysed 
by RT-PCR. Non-infected mice (Figure 5.9.A) at day 0 expressed CXCL13 mRNA 
(fold expression relative to control=0.09). However, after RSV infection, CXCL13 
mRNA expression was increased significantly at day 1 (1.76, P=0.03) in comparison 
to UV RSV control on day 1 (0.12). 
CXCL13 protein was measured in homogenised tissue (Figure 5.9.B). CXCL13 
protein was expressed in non-infected mice at day 0 (mean=246 pg/ml). However, 
after RSV infection CXCL13 protein was increased significantly at day 1 (787 
pg/ml, P=0.006), day 2 (421 pg/ml, P=0.04), day 7 (331 pg/ml, P=0.009) in 
comparison to control day 1 (293.4 pg/ml), day 2 (302 pg/ml) and day 7 (235 pg/ml). 
CXCL13 mRNA and protein peaked at day 1, 7 and declined at day 4. 
 
 
 
 
 
 
CXCL13 mRNA was measured by RT-PCR. CXCL13 mRNA expression was increased 
significantly after RSV infection at day 1 in comparison to UV RSV control at the same time 
point. Values are shown as fold expression relative to control. CXCL13 protein was 
measured by use specific CXCL13 ELISA.CXCL13 protein was increased significantly after 
RSV infection at day 1, 2, and 7 in comparison to UV RSV control at the same time points. 
Result shown is the average of three animals in the second experiment. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
A B 
Figure 5.9. Expression of CXCL13 mRNA (A) and protein (B) after RSV 
infection or challenge with UV-RSV control 
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5. 3.2.2. CXCL13 protein expression in comparison to total protein 
concentration after RSV infection  
 
CXCL13 protein (pg/ml) levels were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). CXCL13 protein was expressed in non-infected mice at day 0 (mean= 36 
pg/ng). CXCL13 protein (Figure 5.10) was elevated significantly after RSV infection 
at day 1 (116 pg/ng, P=0.0008), and day 7 (47 pg/ng, P=0.01) in comparison to UV 
RSV control at day 1 (45 pg/ng) and day 7 (35 pg/ng).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL13 protein was expressed significantly after RSV infection on day 1 and 7 in 
comparison to RSV UV control at the same time points. Result shown is the average of three 
animals in the second experiment. Mean and SD are shown (two way ANOVA with 
Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Normalized CXCL13 protein to total protein after RSV infection or 
challenge with UV-RSV control 
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5. 3.2.4. RSV infection did not significantly up regulate CCL19 protein 
expression  
 
Mouse lung tissue was homogenised and CCL19 protein was measured using 
specific mouse CCL19 ELISA. CCL19 protein (Figure 5.11) was expressed in non-
infected mice at day 0 (mean= 605 pg/ml). RSV infection of mice did not 
significantly increase expression of CCL19 protein at day 1 (589 pg/ml, P=0.4), day 
2 (574 pg/ml, P=0.8), day 4 (325 pg/ml, P=0.1), day 7 (384 pg/ml ,P=0.9) and day 8 
(323 pg/ml, P=0.1) in comparison to UV RSV control on day 1 (504 pg /ml), day 2 
(583 pg/ml ), day 4 (446 pg/ml), day 7 (388 pg/ml) and day 8 (488 pg/ml). 
 
 
 
 
 
 
 
 
 
 
CCL19 protein was measured by ELISA. CCL19 protein was expressed in non-infected mice 
at day 0 and there was no significant up regulation after RSV infection at day 1, 2, 4, 7and 8 
in comparison to UV RSV control at the same time points. Result shown is the average of 
three animals in the second experiment. Mean and SD are shown (two way ANOVA with 
Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
Figure 5.11. Expression of CCL19 protein after RSV infection or challenge with UV 
treated RSV control 
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5. 3.2.5. CCL19 protein expression in comparison to total protein concentration 
after RSV infection  
 
CCL19 protein (pg/ml) levels were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). CCL19 protein (Figure 5.12) was expressed in non-infected mice (mean=90 
pg/ng). However, after RSV infection there was no significant up regulation of 
CCL19 protein at day 1 (87 pg/ng, P=0.4), day 2 (68 pg/ng, P=0.4), day 4 (46 pg/ng, 
P=0.4), day 7 (55 pg/ng, P= 0.9) and day 8 ( 48 pg/ng, P= 0.9) in comparison to UV 
RSV control on day 1 (77 pg /ng), day 2 (85 pg/ng), day 4 (63 pg/ng), day 7 ( 58 
pg/ng) and day 8 (70 pg/ng).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL19 protein was expressed in non-infected mice at day 0 and RSV infection did not 
significantly increase CCL19 protein expression in comparison to UV RSV control on day 1, 
2, 4 and 7. Result shown is the average of three animals in the second experiment. Mean and 
SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
Figure 5.12. Normalized CCL19 protein to total protein after RSV infection or challenge 
with UV treated RSV control 
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5. 3.2.6. RSV infection did not significantly up regulate CCL21 protein 
expression 
 
Mouse lung tissues were homogenised and CCL21 protein was measured. CCL21 
protein (Figure 5.13) was expressed in non-infected mice at day 0 (mean= 800 
pg/ml). However, after RSV infection there was no significant expression on day 1 
(703 pg/ml, P=0.1), day 2 (764 pg/ml, P=0.2), day 4 (496 pg/ml, P=0.2) , day 7 (560 
pg/ml ,P=0.3) and day 8 (537 pg/ml, P=0.1) in comparison to UV RSV control on 
day 1 (860 pg /ml), day 2 (870 pg/ml), day 4 (555 pg/ml), day 7 (609 pg/ml) and day 
8 (629 pg/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
CCL21 protein was measured by use of specific murine CCL21 ELISA. CCL21 protein was 
expressed in non-infected mice at day 0 and there was no significant increased expression 
after RSV infection at day 1, 2, 4, 7 and 8 in comparison to UV RSV control at the same time 
points. Result shown is the average of three animals in the second experiment. Mean and SD 
are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
 
Figure 5.13. Expression of CCL21 protein after RSV infection or challenge with UV 
treated RSV control 
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5. 3.2.7. CCL21 protein expression in comparison to total protein concentration 
after RSV infection  
 
CCL21 protein (pg/ml) levels were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). CCL21 protein (Figure 5.14) was expressed in non-infected mice (mean= 119 
pg/ng). However, after RSV infection there was no significant increase of CCL21 
protein at day 1 (103 pg/ng, P=0.1), day 2 (87 pg/ng, P=0.1), day 4 (69 pg/ng, 
P=0.1), day 7 (79 pg/ng ,P= 0.1) and day 8 (79 pg/ng, P= 0.2) in comparison to UV 
RSV control on day 1 (130 pg /ng), day 2 (125 pg/ng), day 4 (77 pg/ng), day 7 (89 
pg/ng) and day 8 (89 pg/ng) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL21 protein was expressed in non-infected mice at day 0 and there was no significant 
increased expression after RSV infection in comparison to UV RSV control on day 1, 2, 4 
and 7. Result shown is the average of three animals in the second experiment. Mean and SD 
are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
Figure 5.14. Normalized CCL21 protein to total protein after RSV infection or 
challenge with UV treated RSV control 
         CCL21 pg/mg of total prptein
0 1 2 4 7 8
0
50
100
150
200
RSV
UV-RSV
Days after RSV infection
P
g
 /
m
g
 o
f 
to
ta
l 
p
ro
te
in
183 
 
 
5. 3.2.8. RSV infection did not significantly up regulate CXCL12 protein 
expression  
 
Mouse lung tissue was homogenised and CXCL12 protein measured. CCL21 protein 
(Figure 5.15) was expressed in non-infected mice at day 0 (mean= 1895 pg/ml). 
However, after RSV infection there was no significant increase of CXCL12 at day 1 
(pg/ml, P=0.3), day 2 (2033 pg/ml, P=0.5), day 4 (1333 pg/ml, P=0.1), day 7 (1626 
pg/ml ,P=0.2) and day 8 (1477 pg/ml, P=0.5) in comparison to UV RSV control at 
day 1 (1780 pg /ml), day 2 (2114 Pg/ml ), day 4 (1692 pg/ml), day 7 (1416 pg/ml) 
and day 8 (1692 pg /ml). 
 
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was measured by use of specific murine CXCL12 ELISA. CXCL12 protein 
was expressed in non-infected mice at day 0 and there was no significant increase 
expression after RSV infection at day 1, 2, 4, 7 and 8 in comparison to UV RSV control at 
the same time points. Result shown is the average of three animals in the second experiment. 
Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
Figure 5.15. Expression of CXCL12 protein after RSV infection or challenge with 
UV treated RSV control 
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5. 3.2.9. CXCL12 protein expression in comparison to total protein 
concentration after RSV infection  
 
CXCL12 protein (pg/ml) levels were normalised to total protein (pg/ng) (chapter 2, 
2.3.2). CXCL12 protein (Figure 5.16) was expressed in non-infected mice 
(mean=281 pg/ng). However, after RSV infection there was no significant up 
regulation of CXCL12 protein at day 1 (312 pg/ng, P=0.4), day 2 (233 pg/ng, P=0.2), 
day 4 (186 pg/ng, P=0.1) , day 7 (231 pg/ng ,P= 0.4) and day 8 (217pg/ng, P= 0.6) in 
comparison to UV RSV control on day 1 (268 pg /ng), day 2 ( 305 pg/ng), day 4 
(237 pg/ng), day 7 (210 pg/ng) and day 8 (243 pg/ng).  
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was expressed in non-infected mice at day 0 and there was no significant 
increased expression of CXCL12 protein after RSV infection in comparison to UV RSV 
control on day 1, 2, 4 and 7. Result shown is the average of three animals in the second 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
 
 
 
 
 
Figure 5.16. Normalized CXCL12 protein to total protein after RSV infection or 
challenge with UV treated RSV control 
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5. 3.3. Experiment -III 
 
5. 3.3.1. Expression of CXCL13 protein after RSV infection  
 
Mouse lungs tissues were homogenised and CXCL13 protein was measured (Figure 
5.17). CXCL13 was expressed in non-infected mice PBS at day 0 (mean= 372 
pg/ml). However, after RSV infection there was no significant increased expression 
of CXCL13 protein at day 1 (504 pg/ml, P=0.7), day 2 (389 pg/ml, P=0.3), day 4 
(302 pg/ml, P=0.07), day 7 (306 pg/ml ,P=0.06) and day 10 (339 pg/ml, P=0.08) in 
comparison to UV RSV control at day 1 (467 pg/ml), day 2 (316 pg/ml), day 4 (380 
pg/ml), day 7 (363 pg/ml) and day 10 (452 pg/ml). In addition, CXCL13 protein was 
significantly decreased after RSV infection at day 14 (375 pg/ml, P=0.002) and day 
21 (315pg/ml, P=0.002) relative to UV RSV control at day 14 (590 pg/ml) and day 
21(518 pg/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL13 protein was measured by use of specific murine CXCL13 ELISA.CXCL13 protein 
was expressed in non-infected mice at day 0 and there was no significant increased 
expression of CXCL13 protein at day 1,2,4,7 and 10 after RSV infection. However, CXCL13 
protein was decreased at day 14 and 21 after RSV infection in comparison to UV RSV 
control at the same time points. Result shown is the average of three animals in the third 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
Figure 5.17. Expression of CXCL13 protein after RSV infection or challenge with UV 
treated RSV control 
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5.3.3.2. CXCL13 protein expression in comparison to total protein 
concentration after RSV infection  
 
CXCL13 protein (pg/ml) was normalised to total protein (pg/ng) (chapter 2, 2.3.2). 
CXCL13 protein (Figure 5.18) was expressed in non-infected mice (mean = 287 
pg/ng). However, after RSV infection CXCL13 protein was decreased significantly 
at day 4 (161pg/ng, P=0.04), day 7 (133 pg/ng, P=0.004), day 10 (189 pg/ng, 
P=0.004), day 14 (286 pg/ng ,P= 0.02) and day 21 (219 pg/ng ,P= 0.01) in 
comparison to UV RSV control at day 4 (223 pg /ng), day 7 (233pg/ng ), day 10 
(334 pg/ng), day 14 (392 pg/ng) and day 21 (393 pg/ng). 
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL13 protein was expressed in non-infected mice at day 0 and there was significant 
decreased expression after RSV infection at day 4, 7, 10, 14 and 21 in comparison to UV 
RSV control at the same time points. Result shown is the average of three animals in the 
third experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, 
*P <0.05, n=3). 
 
 
 
 
Figure 5.18. Normalized CXCL13 protein to total protein after RSV infection or 
challenge with UV treated RSV control 
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5. 3.3.3. Expression of CCL19 protein after RSV infection  
 
Mouse lungs were homogenised and CCL19 protein was measured. CCL19 protein 
(Figure 5.19) was expressed in non-infected mice at day 0 (mean=705 pg/ml). 
However, after RSV infection CCL19 protein decreased significantly at day 4 (456 
pg/ml, P=0.03), day 7 (460 pg/ml, P=0.04) and day 10 (569 pg/ml, P=0.02) in 
comparison to UV RSV control day 4 (674 pg/ml), day 7 (595 pg/ml) and day 10 
(817 pg/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL19 protein was measured by use of specific murine CCL19 ELISA. CCL19 protein was 
expressed in non-infected mice at day 0 and after RSV infection. CCL19 protein expression 
was significantly decreased at day 4, 7 and 10 in comparison to UV RSV control at the same 
time points. Result shown is the average of three animals in the third experiment. Mean and 
SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
Figure 5.19. Expression of CCL19 protein after RSV infection or challenge with UV 
treated RSV control 
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5. 3.3.4. CCL19 protein expression in comparison to total protein concentration 
after RSV infection  
  
 
CCL19 protein (pg/ml) was normalised to total protein (pg/ng) (chapter 2, 2.3.2). 
CCL19 protein (Figure 5.20) was expressed in non-infected mice at day 0 (mean= 
543 pg/ng). However, after RSV infection CCL19 protein decreased significantly at 
day 4 (241 pg/mg, P=0.009), day 7 (198 pg/ng, P=0.0002) and day 10 (318 pg/ng, 
P=0.02) in comparison to UV RSV control at day 4 (396 pg/ng), day 7 (381 pg/mg) 
and day 10 (601 pg/ng). 
 
 
 
 
 
 
 
 
 
 
 
CCL19 protein was expressed in non-infected mice at day 0. CCL19 protein was 
significantly decreased after RSV infection at day 4, 7, 10 in comparison to UV RSV control 
at the same time points. Result shown is the average of three animals in the third 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
 
 
 
 
 
 
Figure 5.20. Normalized CCL19 protein to total protein after RSV infection or 
challenge with UV treated RSV control 
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5. 3.3.5. Expression of CCL21 protein after RSV infection  
 
Mouse lung tissues were homogenised and CCL21 protein was measured. CCL21 
protein (Figure 5.21) was expressed in non-infected mice at day 0 (mean= 5103 
pg/ml). However, after RSV infection CCL21 protein was decreased significantly at 
day 4 (3647 pg/ml), day 10 (4885 pg/ml), day 14 (3256 pg/ml), day 21 (2948 pg/ml) 
in comparison to UV RSV control at day 4 (4868 pg/ml), day 10 (6840 pg/ml), day 
14 (4685 pg/ml) and day 21 (4123 pg/ml). 
 
 
 
 
 
 
 
 
 
 
 
CCL21 protein was measured by use of specific murine CCL21 ELISA. CCL21 protein was 
expressed in non-infected mice at day 0 and after RSV infection. CCL21 protein expression 
was significantly decreased at day 4, 10, 14 and 21 in comparison to UV RSV control at the 
same time points. Result shown is the average of three animals in the third experiment. 
Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
Figure 5.21. Expression of CCL21 protein after RSV infection or challenge with 
UV treated RSV control 
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5. 3.3.6. CCL21 protein expression in comparison to total protein concentration 
after RSV infection  
 
CCL21 protein (pg/ml) was normalised to total protein (pg/ng) (chapter 2, 2.3.2). 
CCL21 protein (Figure 5.22) was expressed in non-infected mice (mean=3913 
pg/ng). However, after RSV infection CCL19 protein was decreased significantly at 
day 4 (1937 pg/ng, P=0.009), day 10 (2732 pg/ng, P=0.02) and day 21 (2026 pg/ml, 
P=0.02) in comparison to UV RSV control on day 4 (2872 pg/ng), day 10 (5018 
pg/mg) and day 21 (3114 pg/ng). 
 
  
 
 
 
 
 
 
 
 
 
CCL21 protein was expressed in non-infected mice at day 0 and there was significantly 
decreased expression after RSV infection at day 4, 10 and 21 in comparison to UV RSV 
control at the same time points. Result shown is the average of three animals in the third 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
 
 
 
 
 
 
Figure 5.22. Normalized CCL21 protein to total protein after RSV infection or 
challenge with UV treated RSV control 
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5. 3.3.7. Expression of CXCL12 protein after RSV infection  
 
CXCL12 protein was measured from lungs homogenised tissue. CXCL12 protein 
(Figure 5.23) was expressed in non-infected mice at day 0 (mean= 4280 pg/ml). 
However, after RSV infection CXCL12 protein was decreased significantly at day 4 
(2798 pg/ml, P=0.01), day 10 (3838 pg/ml, P=0.03) and day 21 (1562 pg/ml, 
P=0.02) in comparison to UV RSV control at day 4 (4276 pg/ml), day 10 (4810 
pg/ml) and day 21 (2534 pg/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was measured by use of specific murine CXCL12 ELISA. CXCL12 protein 
was expressed in non-infected mice at day 0 and after RSV infection. CXCL12 protein 
expression was significantly decreased at day 4, 10 and 21 in comparison to UV RSV 
control at the same time points. Result shown is the average of three animals in the third 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
 
 
 
 
Figure 5.23. Expression of CXCL12 protein after RSV infection or challenge with 
UV treated RSV control 
           CXCL12 protein (n=3)
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5.3.3.8. CXCL12 protein expression in comparison to total protein 
concentration after RSV infection  
 
CXCL12 protein (pg/ml) was normalised to total protein (pg/ng) (chapter 2, 2.3.2). 
CXCL12 protein (Figure 5.24) was expressed in non-infected mice at day 0 (mean = 
3283 pg/ng). However, after RSV infection CXCL12 protein was significantly 
decreased at day 4 (1486 pg/mg, P=0.003), day 7 (1439 pg/ng, P=0.004), day 10 
(2154 pg/ng, P=0.02) and day 21 (1089 pg/ng, P=0.02) in comparison to UV RSV 
control on day 4 (2510 pg /mg), day 7 (3000 pg/ml), day 10 (3527 pg/ng) and day 21 
(1896 pg/ng).  
 
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was expressed in non-infected mice at day 0 and there was significantly 
decreased expression after RSV infection at day 4, 7, 10 and 21 in comparison to UV RSV 
control at the same time points. Result shown is the average of three animals in the third 
experiment. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P 
<0.05, n=3). 
 
 
 
 
Figure 5.24. Normalized CXCL12 protein to total protein after RSV infection 
or challenge with UV treated RSV control 
             CXCL12 pg/mg of total protein (n=3)
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5. 3.4. An average of first and second experiments  
 
5. 3.4.1. Average of CXCL13 mRNA and protein after RSV infection  
 
Mice were infected with RSV (A2 strain) at various time points, day 0 (non-
infected), 1, 2, 4, 7 and 8. At the time points indicated after RSV infection mouse 
lungs tissues were homogenized and RNA was isolated and prepared using Qiagen 
as described (chapter 2, 2.4). CXCL13 mRNA was measured and analysed by RT-
PCR. Non-infected mice at day 0 expressed CXCL13 mRNA (fold expression 
relative to control= 0.08). However, after RSV infection CXCL13 mRNA expression 
(Figure 5.25.A) was increased significantly on day 1 (1.56, P=0.001) and day 7 
(0.92, P=0.001) in comparison to UV RSV control on day 1 (0.20) and day 7 (0.18). 
Furthermore, CXCL13 protein (Figure 5.25.B) was expressed in non-infected mice 
at day 0 (mean =271 pg/ml). However, after RSV infection CXCL13 protein was 
significantly increased at day 1 (775 pg/ml, P=0.0001), day 2 (517 pg/ml, P=0.005), 
and day 7 (360 pg/ml, P=0.0002) in comparison to UV RSV control at day 1 (334 
pg/ml), day 2 (290pg/ml) and day 7 (243 pg/ml). Overall, there were two peaks 
formed of CXCL13 mRNA and protein at day 1, 7 and declined at day 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL13 mRNA was measured by RT-PCR. CXCL13 mRNA was increased significantly 
after RSV infection on day 1 and 7 in comparison to UV RSV control at the same time points. 
Values are shown as fold expression relative to control. In (B) CXCL13 was measured by 
use of specific murine CXCL13 ELISA. CXCL13 protein was increased significantly after 
RSV infection at day 1, 2, and 7 in comparison to UV RSV control at the same time points. 
Result shown is the average of six animals from the first and second experiments. Mean and 
SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n= 6). 
A B 
Figure 5.25. Expression of CXCL13 mRNA (A) and protein (B) after RSV infection or 
challenge with UV treated RSV control 
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5. 3.4.2. Average of CXCL12 protein after RSV infection  
 
 
CXCL12 protein was expressed in non-infected mice at day 0 (mean= 1387 pg/ml). 
However, after RSV infection there was no significant increase of CXCL12 protein 
(Figure 5.26) at day 1 (1452 pg/ml, P=0.8), day 2 (1411 pg/ml, P=0.8), day 4 (1126 
pg/ml, P=0.4), day 7 (1148 pg/ml ,P=0.9) and day 8 (1477 pg/ml, P=0.5) in 
comparison to UV RSV control on day 1 (1374 pg /ml), day 2 (1481 Pg/ml), day 4 
(1309 pg/ml), day 7 (1174 pg/ml) and day 8 (1692 pg /ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CXCL12 protein was measured by use of specific murine CXCL12 ELISA. CXCL12 was 
expressed in non-infected mice PBS at day 0 and after RSV infection there was no significant 
increase expression of CXCL12 protein at day 1, 2, 4, 7 and 8 in comparison to UV RSV 
control at the same time points. Result shown is the average of six animals from the first and 
second experiments. Mean and SD are shown (two way ANOVA with Bonferroni post-hoc 
test, *P <0.05, n= 6). 
 
 
 
 
 
 
 
 
Figure 5.26. Expression of CXCL12 protein after RSV infection or challenge 
with UV treated RSV control 
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5. 3.4.3. Average of CCL19 protein after RSV infection  
 
CCL19 protein (Figure 5.27) was expressed in non-infected mice at day 0 (mean= 
452 pg/ml). However, after RSV infection there was no significant increase of 
CCL19 protein at day 1 (448 pg/ml, P=0.8), day 2 (435 pg/ml, P=0.8), day 4 (318 
pg/ml, P=0.3), day 7 (292 pg/ml, P=0.3) and day 8 (323 pg/ml, P=0.1) in comparison 
to UV RSV control at day 1 (427 pg /ml) , day 2 (448 Pg/ml), day 4 (364.7 pg/ml) , 
day 7 (339.2 pg/ml) and day 8 (488 pg /ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL19 protein was measured by use of specific murine CCL19 ELISA. CCL19 was 
expressed in non-infected mice PBS at day 0 and after RSV infection there was no significant 
up regulation of CCL19 in comparison to UV RSV control at the same time points. Result 
shown is the average of six animals from the first and second experiments. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n= 6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.27. Expression of CCL19 protein after RSV infection or 
challenge with UV treated RSV control 
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5. 3.4.4. Average of CCL21 protein after RSV infection  
 
CCL21 protein (Figure 5.28) was expressed in non-infected mice PBA at day 0 
(mean= 684 pg/ml). However, after RSV infection there was no significant increase 
of CCL21 protein at day 1 (556 pg/ml, P=0.2), day 2 (611 pg/ml, P=0.6), day 4 (467 
pg/ml, P=0.2), day 7 (463 pg/ml ,P=0.6) and day 8 (537 pg/ml, P=0.1) in comparison 
to UV RSV control on day 1 (680 pg /ml), day 2 (670 Pg/ml), day 4 (558pg/ml) , day 
7 (502 pg/ml) and day 8 (537 pg /ml). 
 
 
 
 
 
 
 
 
 
 
CCL21 protein was measured by use of specific murine CCL21 ELISA. CCL21 was 
expressed in non-infected mice PBS at day 0 and after RSV infection there was no significant 
increase of CCL21 in comparison to UV RSV control at the same time points. Result shown 
is the average of six animals from the first and second experiments. Mean and SD are shown 
(two way ANOVA with Bonferroni post-hoc test, *P <0.05, n= 6). 
 
 
 
 
 
 
Figure 5.28. Expression of CCL21 protein after RSV infection or 
challenge with UV treated RSV control 
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5. 3.5. Immunofluorescence staining 
 
To further prove expression of CXCL13 and to understand how recruitment of B and 
T cells occurs and to determine where they are expressed in the lung in response to 
RSV infection, mouse lung sections were prepared stained with anti-CXCL13, anti-
CD20 (B cells) and anti-CD3 (T cells) antibodies (chapter 2, section 2.8).  
5. 3.5.1.1. Expression of CXCL13 in mouse spleen sections 
 
CXCL13 (chapter 1, 1.4) is normally expressed in secondary lymphoid tissue such as 
spleen (Rangel-Moreno et al. 2007). Therefore, mouse spleen sections were used as 
positive control to optimize the staining (Figure 5.29), and no comparable staining 
was noticed with the isotype control. CXCL13 (red) was secreted around some cells 
that could be B cells-rich follicles as indicated below (arrow). 
 
 
 
 
 
 
 
 
 
 
 
CXCL13 (red) was detected around some cells that could be B cells-rich follicles and some 
other cells as indicated below (arrow). Isotype control was applied in each test. Cell nuclei 
shown in blue (DAPI). Images were originally obtained at 40x and 400x magnifications 
using confocal microscopy. 
 
 
 
 
 
    Isotype control                            40x                                  400x 
DAPI/CXCL13 
Figure 5.29. CXCL13 is normally expressed in mouse spleen section 
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5.3.5.1.2. Expression of CXCL13 in non–infected mouse lung sections at day 0 
 
 
Non-infected mice were given PBS as negative control. Positive staining of CXCL13 
protein (red) was observed in non–infected mice at day 0 (Figure 5.30) as indicated 
(white arrow), and no comparable staining was noticed with the isotype control. 
CXCL13 was distributed around epithelium and other cells that might induce its 
expression such as DCs indicated below (brown arrow). 
 
 
 
   
 
 
 
 
 
  
 
 
 
CXCL13 (red) was expressed around epithelium and some other cells as 
indicated by arrow. Isotype control was applied. Cell nuclei shown in blue 
(DAPI). Images were originally obtained at 10x, 40x and 400x magnifications 
using confocal microscopy. 
 
 
 
 
 
 
                   40x                                    400x 10x 
DAPI/CXCL13 
Isotype 
Figure 5.30. CXCL13 is normally expressed in non-
infected mice at day 0 
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5.3.5.1.3. Expression of CXCL13 in mouse lung sections after RSV infection at 
day 1  
 
Strong positive staining of CXCL13 (red) was observed after RSV infection at day 1 
(Figure 5.31) as indicated (white arrow), and no comparable staining was noticed 
with the isotype control. CXCL13 was accumulated in some areas and distributed 
between the cells as indicated below (arrow). 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
There was strong positive staining of CXCL13 (red) that accumulated in 
some aggregates as indicated above (arrow). Isotype control was applied. 
Cell nuclei shown in blue (DAPI). Images were originally obtained at 10x, 
40x and 400x magnifications using confocal microscopy. 
 
 
 
 
 
10x                  40x                                     400x 
  DAPI/CXCL13 
Isotype 
Figure 5.31. Expression of CXCL13 in mouse lung section after RSV 
infection at day1 
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5. 3.5.1.4. Expression of CXCL13 in mouse lung sections after UV RSV 
challenge at day 1  
 
Positive staining of CXCL13 (red) was detected after mice challenge with UV RSV 
at day 1 (Figure 5.32), and no comparable staining was noticed with the isotype 
control. In addition, CXCL13 was distributed around epithelium and other cells that 
might also induce its expression as indicated below (arrow).  
 
 
 
 
 
 
 
   
 
 
 
 
 
There was positive staining for CXCL13 around epithelium and some cells. 
Isotype control was applied. Cell nuclei shown in blue (DAPI). Images were 
originally obtained at 10x, 40x and 400x magnifications using confocal 
microscopy.  
 
 
 
 
 
 
                         40x                                  400x 10x 
DAPI/CXCL13 
Isotype 
Figure 5.32. Expression of CXCL13 in mouse lung section after UV RSV 
challenged at day 1 
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5. 3.5.1.5. Expression of CXCL13 in mouse lung sections after RSV infection at 
day 2  
 
Strong positive staining of CXCL13 (red) was observed after RSV infection at day 2 
(Figure 5.33), and no comparable staining was noticed with the isotype control. In 
addition, CXCL13 was accumulated in aggregates nearby airways as indicated below 
(white arrow). 
 
 
 
   
 
 
 
 
 
 
 
 
There was strong positive staining of CXCL13 (red) that accumulated in some 
aggregates that close to airways, as indicated above (arrow). Isotype control 
was applied. Cell nuclei shown in blue (DAPI). Images were originally 
obtained at 10x, 40x and 400x magnifications using confocal microscopy. 
 
 
 
 
 
 
                    40x                               400x 10x 
DAPI/CXCL13 
Isotype  
 
Figure 5.33. Expression of CXCL13 in mouse lung section after RSV 
infection at day 2 
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5.3.5.1.6. Expression of CXCL13 in mouse lung sections after UV RSV 
challenge at day 2 
  
Positive staining of CXCL13 (red) was detected after challenge with UV RSV at day 
2 (Figure 5.34), and no comparable staining was noticed with the isotype control. 
CXCL13 was distributed around epithelium and other cells that might also induce its 
expression, as indicated below (arrow). 
 
 
 
    
 
 
 
 
 
 
 
 
 
There was positive staining for CXCL13 around epithelium as indicated by 
arrow. Isotype control was applied. Cell nuclei shown in blue (DAPI). Images 
were originally obtained at 10x, 40x and 400x magnifications using confocal 
microscopy. 
 
 
 
 
 
 
                  40x                                     400x 10x 
    
DAPI/CXCL13 
Isotype 
Figure 5.34. Expression of CXCL13 in mouse lung section after UV RSV 
challenged at day2 
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5. 3.5.1.7. Expression of CXCL13 in mouse lung sections after RSV infection at 
day 4  
 
Positive staining of CXCL13 (red) was detected after RSV infection at day 4 (Figure 
5.35), as indicated (white arrow), but not as strong as at day 1 and 2 and no 
comparable staining was noticed with the isotype control. CXCL 13 was distributed 
around epithelium and some infiltrated cells as indicated below (brown arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was positive staining for CXCL13 (red) distributed around epithelium 
and some infiltrated cells as indicated (arrow). Isotype control was applied. 
Cell nuclei shown in blue (DAPI). Images were originally obtained at 10x, 40x 
and 400x magnifications using confocal microscopy. 
  
 
 
 
 
                           40x                                 400x 10x 
DAPI/CXCL13 
Isotype 
 
Figure 5.35. Expression of CXCL13 in mouse lung section after RSV 
infection at day 4 
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5.3.5.1.8. Expression of CXCL13 in mouse lung sections after UV RSV 
challenge at day 4  
 
Positive staining of CXCL13 (red) was detected in mouse lung sections after 
challenge with UV RSV at day 4 (Figure 5.36), and no comparable staining was 
noticed with the isotype control. CXCL13 was distributed around epithelium and 
other cells that might also induce its expression as indicated below (brown arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was positive staining for CXCL13 around epithelium as indicated 
(arrow). Isotype control was applied. Cell nuclei shown in blue (DAPI). 
Images were originally obtained at 10x, 40x and 400x magnifications using 
confocal microscopy. 
 
 
 
 
 
 
                     40x                                  400x 10x 
DAPI/CXCL13 
Isotype 
 
Figure 5.36. Expression of CXCL13 in mouse lung section after UV RSV 
challenged at day 4 
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5. 3.5.1.9. Expression of CXCL13 in mouse lung sections after RSV infection at 
day 7  
 
Strong positive staining of CXCL13 (red) was detected after RSV infection at day 7 
(Figure 5.37), and no comparable staining was noticed with the isotype control. In 
addition, CXCL 13 accumulated nearby airways and was distributed around some 
cells as indicated below (white arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
There was strong positive staining of CXCL13 (red) that accumulated in some 
aggregates that close to airway as indicated by (arrow). Isotype control was 
applied. Cell nuclei shown in blue (DAPI). Images were originally obtained at 
10x, 40x and 400x magnifications using confocal microscopy. 
 
 
 
 
 
 
 
          40x                               400x 10x 
DAPI/CXCL13 
Isotype 
 
Figure 5.37. Expression of CXCL13 in mouse lung section after RSV 
infection at day 7 
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5.3.5.1.10. Expression of CXCL13 in mouse lung sections after UV RSV 
challenge at day 7 
 
Positive staining of CXCL13 (red) was detected in mice lung challenge with UV 
RSV at day 7 (Figure 5.38), and no comparable staining was noticed with the isotype 
control. CXCL13 was distributed around epithelium and other cells that might also 
induce its expression as indicated below (arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
There was positive staining for CXCL13 (red) distributed around epithelium 
and some infiltrated cells as indicated (arrow). Isotype control was applied. 
Cell nuclei shown in blue (DAPI). Images were originally obtained at 10x, 
40x and 400x magnifications using confocal microscopy.  
 
 
 
 
 
 
 
        40x                              400x 10x 
DAPI/CXCL13 
Isotype 
 
Figure 5.38. Expression of CXCL13 in mouse lung section after UV RSV 
challenged at day7 
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5. 3.5.1.11. Expression of CXCL13 in mouse lung sections after RSV infection at 
day 8 
 
Positive staining of CXCL13 (red) was detected after RSV infection at day 8 (Figure 
5.39), and no comparable staining was noticed with the isotype control. CXCL 13 
was distributed nearby airways and some areas of infiltrating cells as indicated below 
(white arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was positive staining for CXCL13 (red) around epithelium as 
indicated (arrow). Isotype control was applied. Cell nuclei shown in blue 
(DAPI). Images were originally obtained at 10x, 40x and 400x 
magnifications using confocal microscopy.  
 
 
 
 
 
      40x                                   400x 10x 
DAPI/CXCL13 
Isotype 
 
Figure 5.39. Expression of CXCL13 in mouse lung section after RSV 
infection at day 8 
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5.3.5.1.12. Expression of CXCL13 in mouse lung sections after UV RSV 
challenge at day 8  
 
Positive staining of CXCL13 (red) was detected after challenge with UV RSV at day 
8 (Figure 5.40), and no comparable staining was noticed with the isotype control. 
CXCL13 was distributed around epithelium and other cells that might also induce its 
expression as indicated below (white arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was positive staining for CXCL13 (red) distributed around epithelium 
and some infiltrated cells as indicated (arrow). Isotype control was applied. 
Cell nuclei shown in blue (DAPI). Images were originally obtained at 10x, 40x 
and 400x magnifications using confocal microscopy. 
 
 
 
 
                40x                                    400x 10x 
DAPI/CXCL13 
Isotype 
 
Figure 5.40. Expression of CXCL13 in mouse lung section after UV RSV 
challenged at day 8 
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5. 3.5.2. Expression of B cells in mouse spleen section 
 
B cells are normally found in secondary lymphoid tissue such as spleen (Klein & 
Dalla-Favera 2008). Therefore, mouse spleen sections were used as positive control 
to optimize the staining (Figure 5.41). Mouse spleen sections showed strong staining 
of B cells as indicated below (arrow) and no comparable staining was noticed with 
the isotype control.  
 
 
 
 
 
 
 
 
B cells (anti-CD20, red) were accumulated in some areas, could be B cells -
rich follicles and distributed in spleen. Isotype control was applied. Cell 
nuclei shown in blue (DAPI). Images were originally obtained at 40x and 
400x magnifications using confocal microscopy. 
 
 
 
 
 
 
 
 
 
        40x                                    400x Isotype 
DAPI/CD20 
Figure 5.41. B cells are normally expressed in mouse spleen section 
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5. 3.5.2.1. Expression of B cells in non-infected mice at day 0 
 
 
There was positive staining for B cells (red) in non-infected mice at day 0 (Figure 
5.42), and no comparable staining was noticed with the isotype control. B cells were 
accumulated in aggregates and some are distributed around epithelium as indicated 
below (arrow).  
 
 
                                                                      
 
 
 
 
 
 
 
 
 
 
B cells (anti-CD20, red) were accumulated in aggregates, distributed around 
epithelium and airway as indicated below (arrow). Isotype control was applied. 
Cell nuclei shown in blue (DAPI). Images were originally obtained at 10x, 40x 
and 400x magnifications using confocal microscopy. 
 
 
 
 
10x             40x                                 400x 
DAPI/CD20 
Isotype 
 
Figure 5.42. B cells are normally expressed in non-infected mice at day 0 
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5.3.5.2.2. Detection of B cells in mouse lung after RSV infection at day 1  
 
Strong positive staining of B cells (red) was detected after RSV infection at day 1 
(Figure 5.43), and no comparable staining was noticed with the isotype control. B 
cells were accumulated in aggregates and distributed around airway and epithelium 
as indicated below (arrow).  
      
 
 
  
           
           
           
           
           
           
     
           
           
           
    
 
           
           
           
          
B cells (anti-CD20, red) were accumulated in aggregates and distributed around 
airway and epithelium as indicated (arrow). Isotype control was applied. Cell nuclei 
shown in blue (DAPI). Images were originally obtained at 10x, 40x and 400x 
magnifications using confocal microscopy. 
 
 
          40x                             400x 10x 
DAPI/CD20 
Isotype 
Figure 5.43. Expression of B cells in mouse lung section after RSV infection at day1 
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5.3.5.2.3. Detection of B cells in mouse lung after UV RSV challenge at day 1  
 
Positive staining of B cells (red) was detected after UV RSV challenge at day 1 
(Figure 5.44), but not as strong as at day 1 after RSV infection (Figure 5.43). In 
addition, no comparable staining was noticed with the isotype control. B cells were 
located near the airway as indicated (arrow). 
 
           
           
       
 
               
 
           
           
           
           
           
           
           
           
           
     
   
There was positive staining of B cells (anti-CD20, red) that were expressed 
nearby airway as indicated (arrow). Isotype control was applied. Cell 
nuclei shown in blue (DAPI). Images were originally obtained at 10x, 40x 
and 400x magnifications using confocal microscopy. 
 
 
 
 
 
   40x                               400x 10x 
DAPI/CD20 
Isotype 
Figure 5.44. Expression of B cells in mouse lung section after UV RSV 
challenged at day 1 
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5.3.5.2.4. Detection of B cells in mouse lung after RSV infection at day 2  
 
Strong positive staining of B cells were detected after RSV infection at day 2 (Figure 
5.45), and no comparable staining was noticed with the isotype control. B cells were 
accumulated in aggregates close to airway and distributed around epithelium as 
indicated (arrow).  
 
  
 
 
 
    
 
 
  
 
 
 
 
 
 
B cells (anti-CD20, red) were accumulated in aggregates close to airway 
and distributed around epithelium as indicated (arrow). Isotype control was 
applied. Cell nuclei shown in blue (DAPI). Images were originally obtained 
at 10x, 40x and 400x magnifications using confocal microscopy. 
 
 
 
 
 
 
                40x                                    400x 10x 
DAPI/CD20 
Isotype 
Figure 5.45. Expression of B cells in mouse lung section after RSV 
infection at day 2 
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5.3.5.2.5. Detection of B cells in mouse lung after UV RSV challenge at day 2 
 
Positive staining of B cells (red) was detected after UV RSV challenge at day 2 
(Figure 5.46), but not as strong as at day 2 after RSV infection (Figure 5.45). B cells 
were expressed nearby airway and distributed around cells as indicated (arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
B cells (anti-CD20, red) were detected around airway as indicated (arrow). 
Isotype control was applied. Cell nuclei shown in blue (DAPI). Images were 
originally obtained at 10x, 40x and 400x magnifications using confocal 
microscopy. 
 
 
 
 
 
 
 
                40x                           400x 10x 
DAPI/CD20 
 Isotype 
Figure 5.46. Expression of B cells in mouse lung section after UV RSV 
challenged at day 2 
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5.3.5.2.6. Detection of B cells in mouse lung after RSV infection at day 4  
 
Strong positive staining of B cells (red) were detected after RSV infection at day 4 
(Figure 5.47), and no comparable staining was noticed with the isotype control. B 
cells were accumulated in aggregates close to the airway and distributed around 
epithelium as indicated (arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was strong staining of B cells (anti-CD20, red) accumulated in aggregates 
close to airway and distributed around epithelium as indicated (arrow). Isotype 
control was applied. Cell nuclei shown in blue (DAPI). Images were originally 
obtained at 10x, 40x and 400x magnifications using confocal microscopy. 
 
 
 
 
                  40x                              400x 10x 
    Isotype 
DAPI/CD20 
Figure 5.47. Expression of B cells in mouse lung section after RSV 
infection at day 4 
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5.3.5.2.7. Detection of B cells in mouse lung after UV RSV challenge at day 4  
 
Positive staining of B cells (red) were detected after UV RSV challenge at day 4 
(Figure 5.48), but not as strong as day 4 after RSV infection (Figure 5.47). In 
addition, no comparable staining was noticed with the isotype control. B cells were 
expressed near the airways and alveolar as indicated (arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was positive staining of B cells (anti-CD20, red) that expressed nearby 
airway and alveolar as indicated (arrow). Isotype control was applied. Cell nuclei 
shown in blue (DAPI). Images were originally obtained at 10x, 40x and 400x 
magnifications using confocal microscopy. 
 
 
 
 
 
 
 
                40x                            400x 10x 
DAPI/CD20 
Isotype 
 
Figure 5.48. Expression of B cells in mouse lung section after UV-treated 
RSV challenge at day 4 
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5.3.5.2.8. Detection of B cells in mouse lung after RSV infection at day7  
 
Strong positive staining of B cells (red) was detected after RSV infection at day 7 
(Figure 5.49) and no comparable staining was noticed with the isotype control. B 
cells were accumulated in aggregates close to airway and distributed around 
epithelium as indicates (arrow).  
 
 
 
    
 
 
 
 
 
 
There was strong positive staining of B cells that accumulated in aggregates 
close to airway and distributed around epithelium as indicates (arrow). 
Isotype control was applied. Cell nuclei shown in blue (DAPI). Images were 
originally obtained at 10x, 40x and 400x magnifications using confocal 
microscopy. 
 
 
 
 
 
 
 
 
                40x                             400x 10x 
 DAPI/CD20 
     Isotype 
 
Figure 5.49. Expression of B cells in mouse lung section after RSV 
infection at day 7 
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5.3.5.2.9. Detection of B cells in mouse lung after UV RSV challenge at day 7 
 
Positive staining of B cells (red) was detected after UV RSV challenge at day 7 
(Figure 5.50) and no comparable staining was noticed with the isotype control. 
Moreover, staining of B cells was not as strong as day 7 after RSV infection (Figure 
5.49). B cells were expressed nearby airway and alveolar as indicated (arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B cells (red) were expressed around airway as indicated (arrow). Isotype 
control was applied. Cell nuclei shown in blue (DAPI). Images were 
originally obtained at 10x, 40x and 400x magnifications using confocal 
microscopy. 
 
 
 
 
 
 
 
 
                40x                              400x 10x 
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Figure 5.50. Expression of B cells in mouse lung section after UV-treated 
RSV challenge at day 7 
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5.3.5.2.10. Detection of B cells in mouse lung after RSV infection at day 8 
 
 
Strong positive staining of B cells (red) was detected after RSV infection at day 8 
(Figure 5.51) and no comparable staining was noticed with the isotype control. B 
cells were accumulated in aggregates close to the airway and distributed around 
epithelium as indicated (arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
B cells (red) were accumulated in aggregates close to airway and distributed 
around epithelium as indicated (arrow). Isotype control was applied. Cell nuclei 
shown in blue (DAPI). Images were originally obtained at 10x, 40x and 400x 
magnifications using confocal microscopy. 
 
 
 
 
 
 
 
 
 
       40x                                          400x 10x 
DAPI/CD20 
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Figure 5.51. Expression of B cells in mouse lung section after RSV 
infection at day 8 
220 
 
5.3.5.2.11. Detection of B cells in mouse lung after UV RSV challenge at day 8 
 
There was positive staining of B cells after UV RSV challenge at day 8 (Figure 5.52) 
but not strong as day 8 after RSV infection (Figure 5.1.6.2.10). Moreover, no 
comparable staining was noticed with the isotype control. B cells were noticed 
nearby airway and distributed around cells as indicated (arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B cells (red) were expressed around airway as indicated (arrow). Isotype 
control was applied. Cell nuclei shown in blue (DAPI). Images were 
originally obtained at 10x, 40x and 400x magnifications using confocal 
microscopy. 
 
 
 
 
 
 
                     40x                                     400x 10x 
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Figure 5.52. Expression of B cells in mouse lung section after UV-treated 
RSV challenge at day 8 
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5. 3.5.2.12. B cells numbers increased significantly after RSV infection 
 
From the immunofluorescence staining results of mouse lung sections, there was 
strong positive staining of B cells after RSV infection at days 1, 2, 4, 7 and 8 relative 
to UV RSV challenge at the same time points. To further confirm these results, B 
cells numbers (Figure 5.53) were measured by Amanda McFarlane at Queens 
Medical Research Institute at the University of Edinburgh by using FACS analysis. 
B cells numbers were increased significantly after RSV infection at day 6 and 8 
(10×10
5
) and (8.5 ×10
5
) respectively in comparison to UV RSV control at day 6 
(4.3×10
5
) and day 8 (4.8×10
5
). 
 
 
 
 
 
 
 
 
 
Mice were infected with RSV or challenged with UV RSV for 2, 4, 6, 8 and 10 days. Mouse 
lungs (right lobes) were homogenised and B cells numbers were counted. B cells numbers 
increased significantly on day 6 and 8 relative to UV-RSV control at the same time points. 
Mean and SD are shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
 
 
 
 
 
 
Figure 5.53. FACS analysis of B cells numbers from after RSV infection and 
UV RSV challenged 
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5.3.5.3. Expression of CD3 in mouse spleen section 
 
T cells are normally expressed in secondary lymphoid tissues, such as spleen (Klein 
& Dalla-Favera 2008). Thus, mouse spleen sections were used as positive control to 
optimize the staining (Figure 5.54). Mouse spleen sections showed strong staining 
for T cells, as indicated below (arrow). 
 
 
 
 
 
 
There was positive staining of T cells (anti-CD3, green) detected in spleen 
that are placed around spleen. Isotype control was applied. Cell nuclei 
shown in blue (DAPI). Images were originally obtained at 40x and 400x 
magnifications using confocal microscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
             40x                                400x Isotype 
DAPI/CD3 
Figure 5.54. T cells are normally expressed in mouse spleen section 
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5.3.5.3.1. T cells are absent from mouse lung after RSV infection at day 2 
 
 
No positive staining for T cells (CD 3, green) was observed after RSV infection at day 2 
(Figure 5.55).  
 
 
 
 
 
 
        
 
 
 
       
 
 
 
There was negative staining of T cells (anti-CD3, green) in mouse lung section after RSV 
infection at day 2. Isotype control was applied. Cell nuclei shown in blue (DAPI). Images 
were originally obtained at 10x and 40x magnifications using confocal microscopy. 
 
 
 
 
 
 
 
 
 
                   40x                            10x 
DAPI/CD3 
Isotype 
 
Figure 5.55. Absence of T cells in mouse lung section after RSV 
infection at day 2 
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5.3.5.3.2. T cells are absent from mouse lung after UV RSV challenge at day 2 
 
No positive staining for T cells (CD 3, green) was observed after UV RSV challenge at day 
2 (Figure 5.56). 
 
 
  
 
 
 
 
 
 
 
 
 
 
There was negative staining of T cells (anti-CD3, green) in mouse lung section after RSV 
infection at day 2. Isotype control was applied. Cell nuclei shown in blue (DAPI). Images 
were originally obtained at 10x and 40x magnifications using confocal microscopy. 
 
 
 
 
 
 
 
                   40x                            10x 
Isotype 
 
DAPI/CD3 
Figure 5.56. Absence of T cells in mouse lung section 
after UV-RSV challenged at day 2 
225 
 
5.3.6. Summary of expression CXCL13 protein at various time points following 
RSV infection and recruitment of B cells into mice lung   
 
CXCL13 protein (Figure 5.57 A) was expressed in non-infected mice at day 0 (mean 
271 pg/ml). However, after RSV infection CXCL13 protein was significantly 
increased at day 1 (mean 775 pg/ml, P=0.0001), day2 (517 pg/ml, P=0.005), and day 
7 (360 pg/ml, P=0.0002) in comparison to UV RSV control at day 1 (334 pg/ml), 
day 2 (290pg/ml) and day 7 (243 pg/ml). In addition, CXCL13 protein was further 
confirmed by immunofluorescence staining of mouse lung sections that also showed 
association of CXCL13 expression after RSV infection relative to UV RSV 
challenge at the same time points (Figure 5.57 B). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CXCL13 protein was measured by using specific murine CXCL13 ELISA (A). CXCL13 
protein was increased significantly after RSV infection at day 1, 2 and 7 in comparison to 
UV RSV control at the same time points. Immunofluorescence staining of mouse lung 
sections (B) showed association expression of CXCL13 (red) as indicated (arrow) after RSV 
infection and UV RSV challenge at the same time points.  
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Figure 5.57. Expression of CXCL13 protein after RSV infection and UV RSV control 
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The immunofluorescent results shown below (Figure 5.58.C) that there was strong 
positive staining of B cells after RSV infection at day 1, 2, 4, 7 and 8 relative to UV 
RSV challenge at the same time points. Equally, B cells numbers (Figure 5.58 D) 
measured with FACS increased significantly after RSV infection at day 6 and 8 
(10×10
5
) and (8.5 ×10
5
) respectively in comparison to UV RSV control at day 6 
(4.3×10
5
) and day 8 (4.8×10
5
). Both suggest that RSV infection in mice leads to 
significantly increased B cells number in the lungs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was strong positive staining of B cells (anti-CD20, red) at day 1, 2, 4, 7 and 8 after 
RSV infection relative to UV RSV control at the same time points (C). B cells numbers of 
mouse right lobes were measure by FACS (D); B cells numbers were increased significantly 
at day 6 and 8 relative to UVRSV challenge at the same time points. Mean and SD are 
shown (two way ANOVA with Bonferroni post-hoc test, *P <0.05, n=3). 
 
PBS Day 0 RSV Day1 RSV Day2 RSV Day4 RSV Day7 RSV Day8 
UV RSV Day8 UV RSV Day7 UV RSV Day4 UV RSV Day1 UV RSV Day2 
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Figure 5.58. Expression of B cells after RSV infection and UV RSV control in 
mouse lung sections 
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5.3.7. Discussion  
 
5.3.7.1. RSV infection of BALB/c mice significantly induced CXCL13 mRNA 
and protein expression  
 
To further understand the B and T cell responses to RSV infection in the lung, local 
expression of the homeostatic chemokines CXCL12, CXCL13, CCL19 and CCL21 
(chapter 1, section 1.4) were studied. These chemokines are normally expressed in 
secondary lymphoid organs such as spleen, where they control placement of 
lymphocytes (Cyster 1999). However, recent studies have shown that expression of 
homeostatic chemokines can be induced in non-lymphoid tissue such as lungs upon 
viral infection like Influenza and to be involved in formation of inducible bronchus-
associated lymphoid tissue (iBALT), where its formation is essential for initiating 
local  B and T cell responses to influenza (Rangel-Moreno et al. 2007).  
To investigate if CXCL13 expression is induced after RSV infection, mice were 
infected with RSV (A2 strain) at various time points, including time day 0 (non-
infected), 1, 2, 4, 7 and 8 (chapter 2, section 2.3). Firstly, CXCL13 mRNA was 
measured by RT-PCR. Non-infected mice expressed CXCL13 mRNA at day 0 (fold 
expression relative to control= 0.086) indicating that CXCL13 expression occurs in 
the lung in the absence of visible infection. However, after RSV infection CXCL13 
mRNA expression was increased significantly on day 1 (1.56, P=0.001) and day 7 
(0.92, P=0.001) in comparison to UV RSV control at day 1 (0.20) and day 7 (0.18) 
(Figure 5. 25 A). 
To confirm not only CXCL13 mRNA expression was increased following RSV 
infection, CXCL13 protein (Figure 5.25.B) was measured by ELISA. CXCL13 
protein was expressed in control mice at day 0 (mean 271 pg/ml). However, after 
RSV infection CXCL13 protein was significantly increased at day 1 (mean 774 
pg/ml, P=0.0001), day 2 (516 pg/ml, P=0.005) and day 7 (359 pg/ml, P=0.0002) in 
comparison to UV RSV control on day 1 (334 pg/ml), day 2 (290 pg/ml) and day 7 
(242 pg/ml). There was a correlation between the CXCL13 mRNA and protein 
expressions, both were increased significantly at day 1, 2 and 7 after RSV infection 
(Figure 5.25.A-B).  
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Moreover, expression of the CXCL13 protein was further confirmed by 
immunofluorescence staining of mice lung sections, which has also showed strong 
positive staining for CXCL13 at day 1 (Figure 5.31), day 2 (Figure 5.33) and day 7 
(Figure 5.37) after RSV infection relative to non-infected mice at day 0 (Figure 5.30) 
and RSV UV control at the same time points, at day 1 (Figure 5.32), day 2 (Figure 
5.34) and day 7 (Figure 5.38). The CXCL13 protein was accumulated near airway 
and epithelium at day 1 (Figure 5.31), day 2 (Figure 5.33) and day 7 (Figure 5.37). 
Furthermore, increased expression of CXCL13 mRNA and protein was associated 
with RSV infection at day 1, 2 but not at day 4, where RSV has reached the highest 
levels and CXCL13 mRNA and protein declined. In addition, there was no evidence 
of RSV by RT-PCR at day 7 (Figure 4.16), although CXCL13 mRNA and protein 
were increased significantly after RSV infection.  
5.3.7.2. RSV infection of BALB/c mice significantly induced infliltration or 
recruitment of B cells  
 
CXCL13 is known to act as B lymphocyte chemoattractant (Gunn et al. 1998) and to 
determine if B cells were recruited into mouse lungs following RSV infection lung 
sections were stained with the B cell specific marker anti-CD20, which has already 
been tested in mouse spleen tissue as positive control (Figure 5.41).  
Control mice day 0 (Figure 5.42) showed positive staining of B cells accumulated in 
aggregates. In addition, precence of B cells (CD19) was detected in the lungs of 
normal mice and their numbers were decreased after depetion of CXCL13 (Rangel-
Moreno et al. 2007) . However, it could be possible that those mice were exposed to 
some pathogens before treatment in the animal house. In addition, mouse lung 
sections showed strong positive staining of B cells (anti-CD20) after RSV infection 
at day 1 (Figure 5.43), day 2 (Figure 5.45), day 4 (5.47), day 7 (5.49) and day 8 
(5.51) relative to UV RSV control at the same time points on day 1 (5.44), day 2 
(Figure 5.46), day 4 (Figure 5.48), day 7 (Figure 5.50) and day 8 (Figure 5.52). 
To further confirm increased numbers of B cells, they (Figure 5.53) were measured 
quantitatively using FACS analysis. B cells numbers increased significantly after 
RSV infection at day 6 and 8 (10×10
5
 and 8.5 ×10
5
 respectively) in comparison to 
UV RSV control at day 6 (4.3×10
5
) and day 8 (4.8×10
5
). 
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Taken together, increased expression of the CXCL13 protein is associated with 
increased presence of B-cell aggregates at day 1, day 2 and day 7 after RSV infection 
relative to UV RSV control at the same time points, which suggested that CXCL13 
recruited B cells into the lung. Although CXCL13 increased significantly on day 1, 2 
and 7 but not on day 4, B cells were observed in mouse lung sections at day 4 
following RSV infection and increased in day 6 and 8 after RSV infection. Thus, it 
could be possible that these B cells were recruited into the lung at the early stage of 
RSV infection by CXCL13 at day 1 and 2. However, to ensure that CXCL13 was 
responsible for the recruitment of B cells into the lung, mice should be targeted with 
anti-CXCL13 prior to RSV infection, and we could stain for CXCL13 expressed by 
B cells in the lung (Chapter 6.3). 
5.3.7.3. RSV infection of BALB/c mice did not significantly increase expression 
of CXCL12, CCL19 and CCL21 mRNA or protein  
 
 
It has been reported that CXCL12 (Chapter 1.4) can act as a chemoattractant for 
memory B cells that express CXCR4 (Fleige et al. 2014; Okada et al. 2002). To 
determine if CXCL12 is induced following RSV infection, mice were infected with 
RSV (A2 strain) at different time points, including day 0 (non-infected), 1, 2, 4, 7 
and 8. CXCL12 protein (Figure 5.26) was expressed in non-infected mice at day 0 
(mean= 1387 pg/ml) indicating that CXCL12 expression occurs in the lung in the 
absence of visible infection. However, after RSV infection there was no significant 
increase of CXCL12 protein at day 1, day 2, day 4, day 7 and day 8 in comparison to 
UV RSV control at the same time points. Thus, it could be possible that expression 
of CXCL12 protein was normally intracellular and released during inflammation. 
However, this could also be irrelevant. In addition, it has been shown that epithelium  
and alveolar macrophages  may be the primary source of CXCL12 in the lungs of 
LPS- injured mice (Petty et al. 2007). 
Thus, to test if CXCL12 was responsible or not for the recruitment of B cells after 
RSV infection, we could treat mice with anti-CXCL12 prior to RSV infection and 
monitor the kinetics of CXCL12 following RSV infection and observe if B cells 
migrated to the lungs after RSV infection. 
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Furthermore, CCL19 protein (Figure 5.27) was also expressed in non-infected mice 
at day 0 (mean 1387 pg/ml) and there was no was no significant increase after RSV 
infection at day 1, 2, 4, 7 and 8 compared to UV RSV control. Similarly, CCL21 
protein was expressed in non-infected mice at day 0 (mean 684 pg/ml) and there was 
no significant increase flowing RSV infection at day 1, 2, 4, 7 and 8 compared to UV 
RSV control (Figure 5.28). 
Although CCL19 and CCL21 were expressed normally in the lung and there was no 
significant increase after RSV infection; this could indicate that they are not active in 
recruiting cells to the airway in RSV disease. To fully understand their role in RSV 
infection, we should do further studies to determine if CCL19 or CCL21 are released 
from intracellular stores during infection and are active in the recruitment of 
lymphocytes. In this regard, it has been shown that RSV infection of DCs resulted in 
decreased expression of CCR7 and inefficient migration of DC to the lymphatic 
tissue, which then may contribute to reduce adaptive responses to RSV (Le Nouen et 
al. 2011). CCL19 is secreted by fibroblastic reticular cells present in the lymph node 
and CCL21 is secreted from fibroblastic reticular cells and high endothelial venules 
(HEVs), and both are constitutively expressed by stromal cells within the T-cell 
zones in the secondary lymphoid tissue (Brühl et al. 2008; Link et al. 2007) (chapter 
1, section 1.4) 
In contrast to RSV, influenza infection has been reported to induce increased 
expression of CCL19 and CCL21 (Moyron-Quiroz et al. 2004). Taken together, 
these findings suggest that RSV infection may not be fully responsible for 
recruitment of T cell response during infection. Furthermore, it could be possible that 
these chemokines may be induced at later time points after RSV infection. 
5.3.7.4. T cells response is absent following RSV infection 
Immunofluorescence staining of mouse lung tissue sections showed near absence of 
T cells (anti-CD3) following RSV infection in comparison to RSV UV control 
(Figure 5.55 and Figure 5.56). However, it could be possible that the antibody used 
(anti-CD3) was not good enough to stain T cells in the airways and further work is 
required, by use of other antibodies to confirm these preliminary results. This could 
be achieved by staining for CD8 or CD4 in the lung, as well as counting T cells by 
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FACS. From the work of other studies discussed (Chapter 1.1.5.2.1) presence of T 
cells would have been expected in the airway. Presence of T cells in the human lung 
following RSV infection is however controversial. Histological analysis of infants 
with fatal cases of RSV showed few CD4 and CD8 T cells in the lung (Welliver et 
al. 2007). Moreover, histological tissue of infants who died due to severe RSV 
infection showed prominent presence of B cells and near absence of CD3+ T cells, 
which suggests that B cell activation in the lungs during severe infection could be T 
cell-independent (Borchers et al. 2013; Reed et al. 2009). However, it could be 
possible that these children died because they did not develop a proper T cells 
response and in contrast, another study detected virus-specific CD8 T cells in the 
bronchial alveolar lavage and peripheral blood of infants after RSV infection 
(Heidema et al. 2007). 
 
5.3.8. Summary 
Homeostatic chemokines, including CXCL12, CXCL13, CCL19 and CCL21 were 
expressed normally in mouse lungs, which indicated that their expression occurs in 
the lung in the absence of visible infection. However, after RSV infection only 
CXCL13 mRNA and protein were significantly increased at day 1, 2 and 7 compared 
to UV RSV control. Expression of CXCL13 was further confirmed by the 
immunofluorescence staining of mouse lung sections that showed positive staining 
for CXCL13 after RSV infection at day 1, 2 and 7. In addition, CXCL13 was 
accumulated in aggregates near the airway at day 1, 2 and 7. 
Lung sections showed strong positive staining of B cells (anti-CD20 positive cells). 
B accumulation also appears to be associated with expression of CXCL13. 
Moreover, from work described in (chapter 4, 4.17) the BAFF protein was also 
significantly expressed at high levels at these time points (Figure 4.1.5.3). These 
findings suggest that CXCL13 may be directly responsible for B cell recruitment 
into the lung and supports the role of BAFF in promoting airway B cell 
differentiation. 
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5.3.9. Summary of the strength of staining of RSV, BAFF, CXCL13, B and T 
cells and possibility of inflammatory cells 
Arbitrary scale such as (-, +, ++, +++, ++++) was used to indicate and evalute the 
strength of staining of RSV, BAFF, CXCL13, B cell (CD19) and Inflammatory cells 
(Table 5.1)  after RSV infection and UV-treaed RSV at day 0,1,2,4,7 and 8. 
Table 5.1. Summary represents the strength of staining of RSV, BAFF, CXCL13 and B cells 
and possibility of inflammatory cells. 
CHAPTER 6. GENERAL DISCUSSION 
 
6.1. RSV infection induced significant expression of BAFF and CXCL13, but 
not APRIL, CXCL12, CCL19 and CCL21 
 
In vitro, BEAS-2B cells were used to mimic RSV infection of human epithelial cells 
and to determine if the airway epithelium can support effective immune response, in 
particular B cell responses through production of B cell growth factors, including 
BAFF and APRIL during RSV infection. Firstly, RSV F protein can be recognized 
through TLR4 expressed at the cell surface of the airway epithelial cells (Kurt-Jones 
et al. 2000). In addition,  RSV products during replication, such as dsRNA can be 
also recognized by intracellular TLR3 by respiratory epithelial cells (Rudd et al. 
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2006). After recognition, this leads to triggering of an innate antiviral response, 
including IFN-β (Chapter 1.1.5.1.2).  
From the in vitro experiments described in chapter 3 RSV infection of BEAS-2B 
cells induced significant increased expression of both BAFF mRNA and protein, but 
not those of APRIL. In addition, increased RSV titre resulted in increased BAFF 
expression. Furthermore, stimulated BEAS-2B cells with IFN-β induced significant 
expression of BAFF mRNA and protein. BAFF mRNA reached highest levels at 12h 
and declined significantly at 48h after either RSV infection or IFN-β stimulation, 
which suggested that BAFF protein is released at this time point where it has been 
measured in the culture supernatant (Figure 3.5). 
Western blot analysis of BEAS-2B cells showed that resting epithelial cells 
expressed membrane BAFF and mRNA whose  expression peaked at 12h after RSV 
infection and decreased at 24h. Taken together, these observations suggest that 
soluble BAFF (17kD) was cleaved from the membrane-bound form (31kD) and 
released into the culture supernatant of BEAS-2B cells. This is then detected by 
ELISA at 48hours after infection (Figure 3.11.A-B). 
In addition, neutralizing of IFN-β has led to reduced significant expression of BAFF 
mRNA and protein, which suggests that BAFF production through RSV infection, is 
dependent on production of IFN-β from the infected cells (Figure 3.10.1-2) and IFN-
β is a potent stimulator of BAFF expression. 
To further understand the production of BAFF and APRIL, in vivo, BALB/c mice 
were infected with RSV (chapter 4). BAFF mRNA and protein but not APRIL were 
significantly increased after RSV infection relative to UV-RSV control and there 
were two peaks of BAFF protein expression, at day 2 and 7 (Figure 4.17). 
Although BAFF expression has been shown to be IFN-β dependent in in vitro 
experiments, it remains to be shown that BAFF induction is interferon dependent in 
vivo. To test this we could inhibit IFN-β in mice prior to RSV infection and observe 
if production of BAFF is dependent on IFN-β at day 2 and 7 after RSV challenge.  
Western blot analysis of homogenised lung tissue showed that resting epithelial cells 
BEAS-2B cells expressed membrane BAFF, and non-infected mice at day 0 
expressed slightly membrane BAFF and soluble BAFF was detected at day 1, 2, 4 
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and 7.These suggested that soluble BAFF (20kD) was cleaved from the membrane-
bound (34kD) and released into the supernatant of cells where it has been measured 
by murine BAFF ELISA (Figure 4.17).  
Human respiratory syncytial virus can re-infect asymptomatically throughout life 
without significant antigenic change, suggestive of incomplete or short-lived 
immunity. In contrast, re-infection by influenza A virus largely depends on antigenic 
change, suggestive of more complete immunity (Le Nouen et al. 2011). 
It has been shown that neutralizing both BAFF and APRIL in Influenza infection 
reduced the percentage and total number of Ab-secreting cells, including virus-
specific Ab-secreting cells, in lungs and bone marrow (BM) and were associated 
with a significant reduction in the antiviral serum IgG, as well as virus-specific IgG 
and IgA in the BAL and targeting BAFF alone did not affect antiviral antibody 
production, which  suggested that APRIL and but not BAFF alone, regulates ASC 
survival in response to influenza virus infection (Wolf et al. 2011). 
It could be possible that APRIL may be induced at later time points after RSV 
infection such as day 14, 25 and 35 day. To further understand this process behind 
this mechanism of antibody regulation it may be possible to block APRIL alone and 
see if the survival of B cells will be affected since the study above targeted BAFF 
and APRIL or BAFF alone, but not APRIL alone. Thus, it could be possible that 
influenza infection induces APRIL expression and therefore increased survival of 
long lived plasma cells since APRIL binds with BCMA expressed on the plasma 
cells (O'Connor et al. 2004), whereas RSV does not induce APRIL and for this 
reason no strong adaptive immune response has been made for the RSV, which then 
is allowing re-infection again.  
Furthermore, to evaluate the potential role of the airway epithelium in supporting the 
adaptive immune response through recruitment of B and T cells, homeostatic 
chemokines CXCL12, CXCL13, CCL19 and CCL21 (chapter 1, section 1.4) were 
investigated both in vitro and in vivo. It has been shown that expression of 
homeostatic chemokines can be induced in non-lymphoid tissue such as lung upon 
viral infection such as influenza and to be involved in formation of iBALT, where its 
formation is essential for initiating local B and T cells responses to influenza 
(Rangel-Moreno et al. 2007).  
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In vitro there was no expression of these chemokines in RSV infected of BEAS-2B 
cells. However, in animal model only CXCL13 mRNA and protein expression were 
increased significantly after RSV infection, not CXCL12, CCL19 or CCL21. This 
indicates that airway epithelium is not the main source of these chemokine and there 
could be other potential sources. 
CXCL12, CCL19 and CCL21 did not increase in expression following RSV 
infection relative to UV RSV control. Whist it is possible that an active form is 
released perhaps from stored cytokines, this could indicate that these were not active 
in the recruitment of lymphocytes during RSV infection and could be active in other 
viral infections such as influenza infection, which has been reported to induce 
increased expression of CXCL12, CCL19 and CCL21 that resulted in induced 
effective immune response (Moyron-Quiroz et al. 2004). To fully understand their 
role in RSV infection, we should do further studies to determine if the CCL19 or 
CCL21 are released from intracellular stores during infection and are active in the 
recruitment of lymphocytes. Considered together, these findings suggest that RSV 
infection may not fully recruit T cells during infection. However, it could be possible 
that these chemokines may be induced at later time points after RSV infection, such 
as day 14, 25 and 35 day.  
CXCL13 is known to act as B lymphocyte chemoattractant (Gunn et al. 1998) and to 
determine if B cells were recruited into mouse lungs following RSV infection, 
mouse lung sections were stained with the B cell specific marker anti-CD20.  
Control mice day 0 (Figure 5.42) showed positive staining of B cells which 
accumulated in aggregates and this could be possible if those mice were exposed to 
some pathogens before use in this study. In addition, mouse lung sections showed 
strong positive staining of B cells relative to UV RSV control in days 1, 2, 4, 7 and 
8. In addition, B cell numbers were also increased significantly after RSV infection 
at day 6 and 8 relative to UV RSV control at the same time points (Figure 5.53). This 
indicates and clearly demonstrates that increased B cell number in the airway at least 
up to day 8 is a feature of this model of RSV infection.  
Taken together, increased expression of the CXCL13 protein is associated with the 
presence and increased number of B-cell aggregates at day, 1 day 2 and day 7 after 
RSV infection relative to the UV RSV control at the same time points, which suggest 
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that CXCL13 could recruit B cells into the lung. To test this, we could then target 
CXCL13 before RSV infection and examine how many B cells are in the lung and 
also determine certain features of these B cells. Furthermore, from chapter 4 (Figure 
4.17) BAFF protein levels were also increased significantly at these time points. 
Considering the findings together, this raises the possibility that CXCL13 may be 
directly responsible for B cell recruitment into the lung and the possible role of the 
local BAFF produced by epithelium in promoting airway B cell differentiation.  
 
6.2. Proposed model of airway immune response to RSV  
 
Based on the work described in this thesis using both the BEAS2B cell line and 
animal model, the following model of how the immune response of the airway 
epithelium to RSV infection may influence the adaptive immunity to RSV and 
possibly other viral infections (Figure 6.1) has been described. 
Firstly, RSV is recognized by the epithelial cells either by TLR4 or TLR3 (Kurt-
Jones et al. 2000; Rudd et al. 2006); this triggers the antiviral response, including 
IFN-β. In turn this induces cleavage of soluble BAFF from the membrane bound 
form expressed on the epithelial cell surface. This is supported by my observation 
that neutralizing IFN-β resulted in reduced BAFF expression by infected BEAS2B 
cells, which indicates that BAFF production in BEAS-2B cells through RSV 
infection is IFN-β dependent (Chapter 3), fact also confirmed by the results of 
western blot analysis shown in Chapters 3 and 4 looking at the molecular weight of 
BAFF present. Consistent with in vitro experiments, the BAFF mRNA and protein 
were also significantly increased after RSV infection in in vivo (chapter 4), but it 
remains to be shown that BAFF induction is interferon dependent in vivo.  
This model proposes that at least one activity of BAFF in the airway is to support B 
cell survival and that B cells are both present and increased in number in the lung 
during RSV infection, as shown in chapter 4 and 5.   
The stimulus for B cell recruitment was suggested to be homeostatic chemokines 
such as CXCL12, CXCL13, CCL19 and CCL21. BEAS-2B cells infected with RSV 
did not express CXCL12, CXCL13, CCL19 and CCL21, which suggested that there 
are other potential sources rather than airway epithelium that express these 
chemokines during RSV infection in vivo. 
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From the animal model, only CXCL13 increased significantly after RSV infection at 
day 1, 2 and 7, whereas CXCL12, CCL19 and CCL21 did not increase after RSV 
infection. It is possible that these chemokines are not active in RSV infection but 
have been shown to be active in other viral infection such as influenza (Rangel-
Moreno et al. 2007).  
CXCL13 is known to act as a B cell chemoattractant. The examination of the mouse 
lung sections showed strong positive staining of B cells that appeared accumulated 
in aggregates at later time points.  
Taken together, these findings suggest that CXCL13 may be directly responsible for 
B cells recruitment into the lung and the possible role of local BAFF expression in 
promoting airway B cell differentiation and survival. Although these suggestions 
must be further confirmed experimentally, from the experiment carried out in chapter 
three BAFF derived from RSV infected BEAS-2B cells increased B cell survival 
(Figure 3.14). 
Moreover, I would expect to observe proper and organised iBALT structure 
localized in the lung following RSV infection and specific B and T cells areas and 
associated follicular dendritic cells. However, only CXCL13 was increased and 
detected in mouse lung sections following RSV infection relative to UV RSV 
control. Examination of later time points might show if fully organised iBALT is 
formed in response to RSV infection or if the lack of increased expression of 
CXCL12, CCL19 and CCL21 at least at these early time points does not facilitate 
formation of typical iBALT. The outcome of iBALT formation is production of 
specific antibodies as it occurs in the response to influenza (Moyron-Quiroz et al. 
2004). 
In contrast to influenza, immunity to RSV is not long lasting. This could be as a 
result of incomplete formation of iBALT or insufficient signals from APRIL that 
could mediate long lived B cell responses through engagement with BCMA 
expressed on the cell surface of plasma cells. 
To test these possibilities fully, extending the time points analysed would be useful 
and to determine if APRIL or CXCL12, CCL19 and CCL21 can be subsequently 
increased. BAFF expression is a common feature in respiratory infection and not 
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specific for RSV (McNamara et al. 2013) and it is likely that the response suggested 
here to RSV is equally likely against other respiratory pathogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resting epithelial cells express membrane BAFF. RSV is recognized by TLR 4 expressed at 
the cell surface of airway epithelial cells or intracellular TLR3 and the outcome of this 
interaction leads to induced antiviral response, such as IFN-β, that induces soluble BAFF 
expression after cleaved from the cells surface. Local soluble BAFF increased B cell 
survival and differentiation. DCs are the main source of CXCL13 that can recruit B cells 
from the peripheral blood into the lung. Stroma cells may also express other chemokines 
such as CCL19, CXCL12 and CCL21 that recruit T-cells or B cells from the peripheral 
blood into the lung. The iBALT formation is dependent on the complex interactions between 
a number of cell types including activated DCs and stromal cells through the release of 
these chemokines, where B and T cells are recruited to the site and often organized into 
distinct zones where the specific antibody is produced. Interaction of APRIL with plasma 
cells express BCMA may increase their long lived survival in the bone marrow. 
Figure 6.1. Proposed model of airway epithelium immune response to RSV infection 
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6.3. Future directions 
 
Building on previous findings the results also suggest a number of further avenues 
for investigation. In Chapter 3 it was demonstrated that RSV infected epithelia cell 
supernatants which contain BAFF support B cell survival. Further work is required 
to investigate whether that was mediated by BAFF or not by neutralizing BAFF or 
blocking its receptors, including BAFF-R, TACI and BCMA.  
From Chapter 4, the animal model of human RSV infection, the BAFF protein 
increased significantly after RSV infection and there were two peaks of BAFF 
response, at day 2 and 7. From in vitro experiments, BAFF production after RSV 
infection is IFN-β dependent. Thus, to determine if this is also IFN-β mediated at 
day 2 or 7 in mice following RSV infection, further work is required either through 
neutralizing IFN-β prior to RSV infection and to measure IFN-β mRNA by RT-CR 
or protein by ELISA.  
In addition, to investigate the role of BAFF in supporting B cells differentiation in 
mouse lungs, we could then inhibit BAFF during RSV infection and determine the B 
cells response. Furthermore, from Chapter 5 it was shown that CXCL13, which is 
known to act as B cell chemoattractant, was the only lymphoid chemokine that 
increased significantly following RSV infection of mice. Further work is required to 
evaluate if CXCL13 was responsible in recruiting B cells from the peripheral blood 
into the mouse lung, then we could target CXCL13 before RSV infection and 
examine how many B cells are in the lung. Moreover, extending the time points of 
RSV infection in mice more than 8 days would also be useful to achieve better 
understanding about kinetics of BAFF and APRIL in addition to CXCL12, CXCL13, 
CCL19 and CCL21 that may be increased at later time points after RSV infection.  
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